Substituted N-aryl heterocycles, process for their preparation and their use as medicaments

Information

  • Patent Grant
  • 7223788
  • Patent Number
    7,223,788
  • Date Filed
    Tuesday, February 17, 2004
    20 years ago
  • Date Issued
    Tuesday, May 29, 2007
    17 years ago
Abstract
The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof.
Description

The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof.


Compounds having a pharmacological effect and similar in their overall structure to the N-aryl heterocycles described herein have already been described in the prior art. Thus, for example, WO 00/35454 describes ureido-substituted phenylpiperidines and -pyrrolidines as agents for the treatment of inflammatory and autoimmune diseases. Acylamido-substituted phenylpyrrolidines are proposed in WO 02/042271 for the treatment of diabetes, obesity and disorders of lipid metabolism.


The invention was based on the object of providing compounds which bring about a weight reduction in mammals and are suitable for preventing and treating obesity and diabetes.


The invention therefore relates to compounds of the formula I




embedded image



wherein

  • R1, R2 are each independently H, (C1-C8)-alkyl, —(CR78R79)o-R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, aryloxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, CO—(C1-C8)-alkyl, —CO—(CH2)o-R12, CO-aryloxy-(C1-C4)-alkyl, CO—(C2-C8)-alkenyl, CO—(C2-C8)-alkynyl, COCH═CH(R13), COCC(R14), CO—(C1-C4) -alkyl-S(O)p-(C1-C4)-alkyl, CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))rCON(R21)(R22) or CO(C(R23)(R24))sO(R25); or
    • R1 and R2, together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered mono-, bi- or spirocyclic ring which, apart from said nitrogen atom of attachment, optionally contains 1, 2, 3 or 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, and is optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R26), CON(R27)(R28), hydroxy, COO(R29), N(R30)CO(C1-C6)-alkyl, N(R31)(R32) or SO2CH3;
    • wherein
      • o is 0, 1, 2, 3, 4, 5 or 6;
      • p is 0, 1 or 2
      • q, r, s are each independently 0, 1, 2, 3 or 4;
      • R13, R14 are each independently a 5-, 6-, 7-, 8-, 9- or 10-membered aromatic ring system optionally containing 1 or 2 heteroatoms selected from the group of nitrogen, oxygen and sulfur, and is optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl or O—(C1-C8)-alkyl;
      • R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32 are each independently H or (C1-C6)-alkyl;
      • R18 is H, (C1-C6)-alkyl, CO(C1-C6)-alkyl or CO(R33); or
      • substituent pairs R17 and R18, R21 and R22, R27 and R28, and R31 and R32, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from said nitrogen atom of attachment, optionally contains one additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur;
      • R33 is a 5-, 6-, 7-, 8-, 9- or 10-membered aromatic ring system which optionally contains 1 or 2 heteroatoms selected from the group of nitrogen, oxygen and sulfur, and is optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl or O—(C1-C8)-alkyl;
      • R12 is OH, O—(C1-C6)-alkyl, O(C0-C8)-alkylene-aryl, CN, S—(C1-C6)-alkyl, COO(R80), CON(R81)(R93), N(R82)(R83) or a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered mono-, bi- or spirocyclic ring which optionally contains one or more heteroatoms selected from the group of N, O and S, and is optionally substituted with F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, O—(C0-C8)-alkylene-aryl, N(R34)(R35), COCH═CH(R36), (C(R37)(R38))t(R39), CO(C(R37)(R38))t(R39), CO(C1-C6)-alkyl, COCOO(C1-C6)-alkyl, COO(R40), S(O)u(R41) or COOH;
      • t is 0, 1, 2, 3, 4, 5 or 6;
      • u is 0, 1 or 2;
    • R34, R35, R37, R38 are each independently H or (C1-C8)-alkyl; or
    • R34 and R35, taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from said nitrogen atom of attachment, optionally contains one additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur, and is optionally substituted by 1 or 2 oxo groups;
    • R36, R39 are each independently (C3-C8)-cycloalkyl or a 5-, 6-, 7-, 8-, 9- or 10-membered aromatic ring system wherein said aromatic ring system optionally contains one or two additional heteroatoms selected from the group of nitrogen, oxygen and sulfur, and is optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl or O—(C1-C8)-alkyl;
    • R40 is H, (C1-C8)-alkyl, (C2-C6)-alkenyl or (C0-C8)-alkylene-aryl;
    • R41 is (C1-C6)-alkyl or a 5-, 6-, 7-, 8-, 9-, or 10-membered aromatic ring system optionally containing one or two heteroatoms from the group of nitrogen, oxygen and sulfur, and optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl or O—(C1-C8)-alkyl;
    • R78, R79 are each independently H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH or (C1-C4)-alkoxy-(C1-C4)-alkyl;
    • R80, R81, R93 are each independently (C1-C8)-alkyl, (C2-C6)-alkenyl or (C0-C8)-alkylene-aryl;
    • R82, R83 are each independently H or (C1-C6)-alkyl; or
    • R82 and R83, taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from said nitrogen atom of attachment, optionally contains one additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur, and is optionally substituted by 1 or 2 oxo groups;
  • R3 is H or (C1-C6)-alkyl;
  • R4, R5 are each independently H, (C1-C6)-alkyl, OH, O—(C1-C6)-alkyl, O—CO(C1-C6)-alkyl or S—(C1-C6)-alkyl;
  • R6, R7, R8, R9 are each independently H or (C1-C8)-alkyl; or
    • substituent pairs R6 and R7, and R8 and R9, optionally form, independently of one another, an oxo group;
  • n, m are each independently 0, 1 or 2;
  • A, B, D, G are each independently N or C(R42); or
    • said radicals A and B, or said radicals D and G are each C(R42) and, taken together, optionally form a 5- or 6 membered carbocyclic or heterocyclic radical resulting in an overall bicyclic ring system;
    • wherein
      • R42 is H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, S-aryl, N(R43)(R44), SO2—CH3, COOH, COO—(C1-C6)-alkyl, CON(R45)(R46), N(R47)CO(R48), N(R49)SO2(R50), CO(R51) or —(CR84R85)x—O(R86);
        • wherein
        • R43, R44, R45, R46, R47, R49 are each independently H or (C1-C8)-alkyl; or
        • substituent pairs R43 and R44, and R45 and R46, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from said nitrogen atom of attachment, optionally contains an additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur;
        • R48, R50, R51 are each independently H, (C1-C8)-alkyl or aryl;
        • R84, R85 are each independently H or (C1-C8)-alkyl;
        • R86 is H, (C1-C6)-alkyl or aryl;
        • x is 1, 2, 3, 4, 5 or 6;
  • R10 is H, (C1-C8)-alkyl, (C3-C6)-alkenyl or (C3-C6)-alkynyl;
  • X is N(R52), O, a bond, C═C, C(R53)(R54), C(R55)(R56)O, CO, C≡C, or a group of the formula —(CR87R88)Y-wherein one or more —(CR87R88)-units contained in said group of formula —(CR87R88)Y— is optionally replaced by Y;
    • wherein
      • Y is O, S or N(R89) wherein R89 is H or (C1-C8)-alkyl;
      • R52, R53, R54, R55, R56 are each independently H or (C1-C8)-alkyl;
      • R87, R88 are each independently H or (C1-C4)-alkyl, and may be defined the same or differently in each of said —(CR87R88)-units contained in said group of formula —(CR87R88)Y-;
      • y is 2, 3, 4, 5 or 6;
  • E is a 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13- or 14-membered bivalent carbo- or heterocyclic ring structure with 0, 1, 2, 3 or 4 heteroatoms selected from the group of N, O and S, and optionally substituted with H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, S-aryl, N(R57)(R58), SO2—CH3, COOH, COO—(C1-C6)-alkyl, CON(R59)(R60), N(R61)CO(R62), N(R63)SO2(R64) or CO(R65), and wherein said bivalent carbo- or heterocyclic ring structure is mono- or bicyclic;
    • wherein
      • R57, R58, R59, R60, R61, R63 are each independently H or (C1-C8)-alkyl; or
      • substituent pairs R57 and R58, and R59 and R60, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from said nitrogen atom of attachment, optionally contains one further heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur;
      • R62, R64, R65 are each independently H, (C1-C8)-alkyl or aryl;
  • K is a bond, O, OCH2, CH2O, S, SO, SO2, N(R66), N(R67)CO, CON(R68), (C(R69)(R70))v, CO, C≡C, C═C or a group of the formula —(CR90R91)Z-in which one or more of the —(CR90R91)-units contained in said group of the formula —(CR90R91)Z-is optionally replaced by Z;
    • wherein
      • v is 1, 2, 3 or 4
      • R66, R67, R68, R69, R70 are each independently H or (C1-C8)-alkyl;
      • Z is O, S, N(R92), CO, SO or SO2;
      • R90, R91 are each independently H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, hydroxy or (C1-C4)-alkoxy-(C1-C4)-alkyl, and wherein R90 and R91 may be defined the same or differently in each of said —(CR90R91)-units contained in said group of formula —(CR90R91)Z-;
      • z is 2, 3, 4, 5 or 6;
      • R92 is H or (C1-C8)-alkyl;
  • R11 is H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl or a 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-membered mono-, bi- or spirocyclic ring, optionally containing 1, 2, 3 or 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, and optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R71), CON(R72)(R73), hydroxy, hydroxy-(C1-C4)-alkyl, COO(R74), N(R75)CO(C1-C6)-alkyl, N(R76)(R77), SO2CH3 or SCF3;
    • wherein
      • R71, R72, R73, R74, R75, R76, R77 are each independently H or (C1-C8)-alkyl; or
      • substituent pairs R72 and R73, and R76 and R77, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from the nitrogen atom, optionally contain one additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur; or
  • E, K and R11 taken together form a tricyclic system where each of the rings in said tricyclic system are, independently of one another, saturated, partially saturated or unsaturated, and wherein each ring is comprised of 3-8 ring atoms;
  • and the N-oxides and pharmaceutically acceptable salts thereof.


In a further embodiment, the invention therefore relates to compounds of the formula I in which the meanings are:




embedded image



wherein

  • R1, R2 are each independently H, (C1-C8)-alkyl, —(CR78R79)o-R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, aryloxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, CO—(C1-C8)-alkyl, —CO—(CH2)o—R12, CO-aryloxy-(C1-C4)-alkyl, CO—(C2-C8)-alkenyl, CO—(C2-C8)-alkynyl, COCH═CH(R13), COCC(R14), CO—(C1-C4)-alkyl-S(O)p—(C1-CCO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))rCON(R21 )(R22) or CO(C(R23)(R24))sO(R25); or
    • R1 and R2, together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered mono-, bi- or spirocyclic ring which, apart from said nitrogen atom of attachment, optionally contains 1, 2, 3 or 4 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, and is optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R26), CON(R27)(R28), hydroxy, COO(R29), N(R30)CO(C1-C6)-alkyl, N(R31 )(R32) or SO2CH3;
    • wherein
      • o is, 0, 1, 2, 3, 4, 5 or 6;
      • p is 0, 1 or 2
      • q, r, s are each independently 0, 1, 2, 3 or 4;
      • R13, R14 are each independently a 5-, 6-, 7-, 8-, 9- or 10-membered aromatic ring system optionally containing 1 or 2 heteroatoms selected from the group of nitrogen, oxygen and sulfur, and is optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl or O—(C1-C8)-alkyl;
      • R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32 are each independently H or (C1-C6)-alkyl;
      • R18 is H, (C1-C6)-alkyl, CO(C1-C6)-alkyl or CO(R33); or
      • substituent pairs R17 and R18, R21 and R22, R27 and R28, and R31 and R32, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from said nitrogen atom of attachment, optionally contains one additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur;
      • R33 is a 5-, 6-, 7-, 8-, 9- or 10-membered aromatic ring system which optionally contains 1 or 2 heteroatoms selected from the group of nitrogen, oxygen and sulfur, and is optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl or O—(C1-C8)-alkyl;
      • R12 is OH or a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered mono-, bi- or spirocyclic ring which optionally contains one or more heteroatoms selected from the group of N, O and S, and is optionally substituted with F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, O—(C0-C8)-alkylene-aryl, N(R34)(R35), COCH═CH(R36), (C(R37)(R38))t(R39), CO(C(R37)(R38))t(R39), CO(C1-C6)-alkyl, COCOO(C1-C6)-alkyl, COO(R40), S(O)u(R41) or COOH;
      • t is 0, 1, 2, 3, 4, 5 or 6;
      • u is 0, 1 or 2;
    • R34, R35, R37, R38 are each independently H or (C1-C8)-alkyl; or
    • R34 and R35, taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from said nitrogen atom of attachment, optionally contains one additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur, and is optionally substituted by 1 or 2 oxo groups;
    • R36, R39 are each independently (C3-C8)-cycloalkyl or a 5-, 6-, 7-, 8-, 9- or 10-membered aromatic ring system wherein said aromatic ring system optionally contains one or two additional heteroatoms selected from the group of nitrogen, oxygen and sulfur, and is optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl or O—(C1-C8)-alkyl;
    • R40 is H, (C1-C8)-alkyl, (C2-C6)-alkenyl or (C0-C8)-alkylene-aryl;
    • R41 is (C1-C6)-alkyl or a 5-, 6-, 7-, 8-, 9-, or 10-membered aromatic ring system optionally containing one or two heteroatoms from the group of nitrogen, oxygen and sulfur, and optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl or O—(C1-C8)-alkyl;
  • R3 is H or (C1-C6)-alkyl;
  • R4, R5 are each independently H, (C1-C6)-alkyl, OH, O—(C1-C6)-alkyl, O—CO(C1-C6)-alkyl or S—(C1-C6)-alkyl;
  • R6, R7, R8, R9 are each independently H or (C1-C8)-alkyl; or
    • substituent pairs R6 and R7, and R8 and R9, optionally form, independently of one another, an oxo group;
  • n, m are each independently 0, 1 or 2;
  • A, B, D, G are each independently N or C(R42);
    • wherein
    • R42 is H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, S-aryl, N(R43)(R44), SO2—CH3, COOH, COO—(C1-C6)-alkyl, CON(R45)(R46), N(R47)CO(R48), N(R49)SO2(R50) or CO(R51);
      • wherein
      • R43, R44, R45, R46, R47, R49 are each independently H or (C1-C8)-alkyl; or
      • substituent pairs R43 and R44, and R45 and R46, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from said nitrogen atom of attachment, optionally contains an additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur;
      • R48, R50, R51 are each independently H, (C1-C8)-alkyl or aryl;
  • R10 is H, (C1-C8)-alkyl, (C3-C6)-alkenyl or (C3-C6)-alkynyl;
  • X is N(R52), O, a bond, C═C, C(R53)(R54) or C(R55)(R56)O;
    • wherein
      • R52, R53, R54, R55, R56 are each independently H or (C1-C8)-alkyl;
  • E is a 3, 4, 5, 6, 7 or 8-membered bivalent carbo- or heterocyclic ring structure with 0, 1, 2, 3 or 4 heteroatoms selected from the group of N, O and S, and optionally substituted with H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C8)-cycloalkyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, O—(C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, S-aryl, N(R57)(R58), SO2—CH3, COOH, COO—(C1-C6)-alkyl, CON(R59)(R60), N(R61)CO(R62), N(R63)SO2(R64) or CO(R65), and wherein said bivalent carbo- or heterocyclic ring structure is mono- or bicyclic;
    • wherein
      • R57, R58, R59, R60, R61, R63 are each independently H or (C1-C8)-alkyl; or
      • substituent pairs R57 and R58, and R59 and R60, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from said nitrogen atom of attachment, optionally contains one further heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur;
      • R62, R64, R65 are each independently H, (C1-C8)-alkyl or aryl;
  • K is a bond, O, OCH2, CH2O, S, SO, SO2, N(R66), N(R67)CO, CON(R68), (C(R69)(R70))v, CO or C≡C;
    • wherein
      • v is 1, 2, 3 or 4
      • R66, R67, R68, R69, R70 are each independently H or (C1-C8)-alkyl;
  • R11 is H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl or a 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-membered mono-, bi- or spirocyclic ring, optionally containing 1, 2, 3 or 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, and optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R71), CON(R72)(R73), hydroxy, COO(R74), N(R75)CO(C1-C6)-alkyl, N(R76)(R77) or SO2CH3;
    • wherein
      • R71, R72, R73, R74, R75, R76, R77 are each independently H or (C1-C8)-alkyl; or
      • substituent pairs R72 and R73, and R76 and R77, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from the nitrogen atom, optionally contain one additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur; or
  • E, K and R11 taken together form a tricyclic system where each of the rings in said tricyclic system are, independently of one another, saturated, partially saturated or unsaturated, and wherein each ring is comprised of 3-8 ring atoms;


    and the N-oxides and pharmaceutically acceptable salts thereof.


The invention relates to compounds of the formula I in the form of their racemates, enantiomer-enriched mixtures and pure enantiomers, and to their diastereomers and mixtures thereof.


The alkyl, alkenyl and alkynyl radicals in the substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R85, R86, R87, R88, R89, R90, R91, R92 and R93 may be either straight-chain, branched or optionally halogenated.


The term “aryl” means in particular a phenyl or naphthyl group.


A “tricyclic system” means structures having 3 rings which are connected together by more than one bond. Examples of such systems are fused systems with 3 rings and spirocycles with a ring system fused on.


In the case where R1 and R2 form together with the nitrogen atom to which they are bonded a ring, this ring may be substituted by one or more of the substituents mentioned.


The bivalent carbo- or heterocyclic ring structure E includes structures which are linked by one and the same atom to the two adjacent groups K and X.


Pharmaceutically acceptable salts are, because their solubility in water is greater than that of the initial or basic compounds, particularly suitable for medical applications. These salts must have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric, sulfonic and sulfuric acid, and of organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic, tartaric and trifluoroacetic acid. For medical purposes the chlorine salt is particularly preferably used. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts), alkaline earth metal salts (such as magnesium and calcium salts).


Salts with a pharmaceutically unacceptable anion likewise belong within the framework of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications.


The term “physiologically functional derivative” used herein refers to any physiologically tolerated derivative of a compound of the formula I of the invention, for example an ester, which on administration to a mammal such as, for example, a human is able to form (directly or indirectly) a compound of the formula I or an active metabolite thereof.


Physiologically functional derivatives include prodrugs of the compounds of the invention. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may themselves be active or not.


The compounds of the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds of the invention belong within the framework of the invention and are a further aspect of the invention.


All references to “compound(s) of formula (I)” hereinafter refer to compound(s) of the formula (I) as described above, and their salts, solvates and physiologically functional derivatives as described herein.


If radicals or substituents can occur more than once in the compounds of the formula I, they may all have independently of one another the stated meanings and be identical or different.


In a particularly preferred embodiment, the present invention relates to compounds of the formula I in which the meanings are:

  • R1, R2 are each independently H, (C1-C8)-alkyl, —(CH2)o—R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, CO—(C1-C8)-alkyl, —CO—(CH2)o—R12, COCH═CH(R13), COCC(R14), CO—(C1-C4)-alkyl-S(O)p—(C1-C4)-alkyl, CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))rCON(R21)(R22) or CO(C(R23)(R24))sO(R25); or R1 and R2 together with the nitrogen atom to which they are attached, optionally form a 4-, 5-, 6-, 7, 8-, 9- or 10-membered mono-, bi- or spirocyclic ring which, apart from he nitrogen atom, may comprise 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R26), CON(R27)(R28), hydroxy, COO(R29), N(R30)CO(C1-C6)-alkyl, N(R31)(R32) or SO2CH3, where R1 and R2 are preferably not both H, and R1 and R2 together with the nitrogen atom are preferably not a morpholino radical;
  • o 0, 1, 2, 3, 4;
  • p 0, 1, 2;
  • q, r, s independently of one another 0, 1, 2, 3, preferably q, s are independently of one another 1, 2, 3 and r is 0, 1, 2, 3;
  • R13, R14 independently of one another a 5-10 membered aromatic ring system which may comprise a further heteroatom from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;
    • R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32
    • independently of one another H, (C1-C6)-alkyl;
  • R18 H, (C1-C6)-alkyl, CO(C1-C6)-alkyl, CO(R33);
  • R17 and R18, R21 and R22, R27 and R28, R31 and R32 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur;
  • R33 a 5-10 membered aromatic ring system which may comprise a further heteroatom from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;
  • R12 OH, 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, CF3, CN, oxo, O—(C1-C6)-alkyl, (C1-C6)-alkyl, O—(C0-C8)-alkylene-aryl, N(R34)(R35), COCH═CH(R36), (C(R37)(R38))t(R39), CO(C(R37)(R38))t (R39), CO(C1-C6)-alkyl, COCOO(C1-C6)-alkyl, COO(R40) and S(O)u (R41), where in a preferred embodiment the substituent O—(C1-C6)-alkyl is excluded when the 3-12 membered ring is phenyl;
  • t 0, 1, 2, 3, 4;
  • u 0, 1, 2;
  • R34, R35, R37, R38
    • independently of one another H, (C1-C8)-alkyl;
  • R34 and R35
    • optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur and may optionally be substituted by 1-2 oxo groups;
  • R36, R39 independently of one another (C3-C8)-cycloalkyl, 5-10 membered aromatic ring system which may comprise a further heteroatom from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;
  • R40 H, (C1-C8)-alkyl, (C2-C6)-alkenyl, (C0-C8)-alkylene-aryl;
  • R41 (C1-C6)-alkyl, 5-10 membered aromatic ring system which may comprise 0-2 further heteroatoms from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;
  • R3 H, (C1-C6)-alkyl;
  • R4, R5 independently of one another H, (C1-C6)-alkyl, OH, O—(C1-C6)-alkyl, O—CO(C1-C6)-alkyl;
  • R6, R7, R8, R9
    • independently of one another H, (C1-C8)-Alkyl;
  • R6 and R7, R8 and R9
    • independently of one another optionally oxo;
  • n, m independently of one another 0, 1, 2, preferably m is 0, 1, 2 and n is 1;
  • A, B, D, G independently of one another N, C(R42);
  • R42 is H, F, Cl, Br, CF3, CN, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, (C0-C2)-alkylene-aryl, O—(C0-C2)-alkylene-aryl, N(R43)(R44), SO2—CH3, COO—(C1-C6)-alkyl, CON(R45)(R46), N(R47)CO(R48), N(R49)SO2(R50), CO(R51)
  • R43, R44, R45, R46, R47, R49
    • independently of one another H, (C1-C8)-alkyl;
  • R43 and R44, R45 and R46
    • independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur;
  • R48, R50, R51
    • independently of one another H, (C1-C8)-alkyl, aryl;
  • R10 H, (C1-C8)-alkyl;
  • X N(R52), O, a bond, C═C, C(R53)(R54), C(R55)(R56)O;
  • R52, R53, R54, R55, R56
    • independently of one another H, (C1-C8)-alkyl
  • E 3-8 membered bivalent carbo- or heterocyclic ring structure with 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, CF3, NO2, OH, CN, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, N(R57)(R58), SO2—CH3, COO—(C1-C6)-alkyl, CON(R59)(R60), N(R61)CO(R62), N(R63)SO2(R64), CO(R65) and may be mono- or bicyclic, preferably the group E has no substituents from the group of (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl and N(R57)(R58), in which R57 and R58 form together with the nitrogen atom a 5-6 membered ring, in the position ortho to the point of attachment of X; particularly preferably E is monocyclic;
  • R57, R58, R59, R60, R61, R63
    • independently of one another H, (C1-C8)-alkyl;
  • R57 and R58, R59 and R60
    • independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur, where R59 and R60 are preferably not both H;
  • R62, R64, R65
    • independently of one another H, (C1-C8)-alkyl, aryl;
  • K a bond, O, CH2O, N(R66), (C(R69)(R70))v, C≡C, OCH2, CON(R68), preferably a bond, O, CH2O, ((CR69)(R70))v, C≡C, N(R66);
  • v 1, 2;
  • R66, R68, R69, R70
    • independently of one another H, (C1-C8)-alkyl;
  • R11 H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, a 3 to 10-membered mono-, bi- or spirocyclic ring which may comprise 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R71), CON(R72)(R73), hydroxy, COO(R74), N(R75)CO(C1-C6)-alkyl, N(R76)(R77) or SO2CH3, preferably R11 is not COO(R74);
  • R71, R72, R73, R74, R75, R76, R77
    • independently of one another H, (C1-C8)-alkyl;
  • R72 and R73, R76 and R77
    • independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur.


Particularly preferred compounds of the formula I are those in which

  • A, B, D, G are independently of one another N or C(R42), and the total number of nitrogen atoms in this ring is 0-2, preferably 0 or 1.


Very particularly preferred compounds of the formula I are those in which

  • n is 1 and
  • m is 1 or 2.


Especially preferred compounds of the formula I are those in which

  • A, B, D, G are independently of one another N or C(R42) and the total number of nitrogen atoms in this ring is 0-2, preferably 0 or 1;
  • n is 1 and
  • m is 1 or 2.


In a further preferred embodiment, the present invention relates to compounds of the formula I in which the meanings are:

  • R1, R2 independently of one another are H, (C1-C8)-alkyl, —(CR78R79)o—R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, CO—(C1-C8)-alkyl, —CO—(CH2)o—R12, CO-aryloxy-(C1-C4)-alkyl, COCH═CH(R13), COCC(R14), CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))rCON(R21 )(R22), CO(C(R23)(R24))sO(R25); or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may comprise 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C1-C6)-alkyl, O—(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R26), CON(R27)(R28), hydroxy, COO(R29), N(R30)CO(C1-C6)-alkyl, N(R31)(R32) or SO2CH3;
    • preferably independently of one another H, (C1-C8)-alkyl, —(CR78R79)o—R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, CO—(C1-C8)-alkyl, —CO—(CH2)o—R12, COCH═CH(R13), COCC(R14), CO(C(R15)(R16))qN(R17)(R18), CO(C(R23)(R24))sO(R25);
    • or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono- or bicyclic ring which, apart from the nitrogen atom, may comprise 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C1-C6)-alkyl, O—(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R26), hydroxy, N(R31)(R32) or SO2CH3;
    • particularly preferably independently of one another H, (C1-C8)-alkyl, —(CR78R79)o—R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, CO—(C1-C8)-alkyl, —CO—(CH2)o—R12, CO(C(R15)(R16))qN(R17)(R18), or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono- or bicyclic ring which, apart from the nitrogen atom, may comprise 0 to 2 additional heteroatoms selected from the group of oxygen and nitrogen, where the heterocyclic ring system may be additionally substituted by F, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, oxo, CO(R26), hydroxy, N(R31)(R32);
  • o 0, 1, 2, 3, 4, 5, 6; preferably 0, 1, 2, 3, 4; particularly preferably 0, 1, 2, 3;
  • q, r independently of one another 1, 2, 3; preferably q is 1 or 2;
  • s 0, 1, 2, 3, 4; preferably 0, 1, 2, 3; particularly preferably 0, 1, 2;
  • R13, R14 independently of one another are a phenyl ring which may comprise 0-1 nitrogen atoms;
  • R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32
    • independently of one another H, (C1-C6)-alkyl;
  • R18 H, (C1-C6)-alkyl, CO(C1-C6)-alkyl, CO(R33); preferably H, (C1-C6)-alkyl, CO(C1-C6)-alkyl; particularly preferably H, (C1-C6)-alkyl;


    or
  • R17 and R18, R21 and R22, R27 and R28, R31 and R32
    • independently of one another optionally form together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur; preferably the ring is pyrrolidine, piperidine, N-methylpiperazine, morpholine;
  • R33 a 5-10 membered aromatic ring system which may comprise a further heteroatom from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;
  • R12 OH, O—(C1-C6)-alkyl, O—(C0-C8)-alkylene-aryl, CN, S—(C1-C6)-alkyl, COO(R80), CON(R81)(R82), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, O—(C0-C8)-alkylene-aryl, (C0-C8)-alkylene-aryl, N(R34)(R35), COCH═CH(R36), (C(R37)(R38))t (R39), CO(C(R37)(R38))t (R39), CO(C1-C6)-alkyl, COCOO(C1-C6)-alkyl, COO(R40), S(O)u (R41);
    • preferably OH, O—(C1-C6)-alkyl, O—(C0-C8)-alkylene-aryl, CN, 3-10 membered mono- or bicyclic ring which may comprise 1-3 heteroatoms from the group of N, O and S, and the 3-10 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C0-C2)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl;
    • particularly preferably OH, O—(C1-C6)-alkyl, 3-10 membered mono- or bicyclic ring which may comprise 1-2 heteroatoms from the group of N, O and S, and the 3-10 membered ring may comprise further substituents such as F, OH, oxo, (C1-C6)-alkyl, CO(C1-C6)-alkyl;
  • t 0, 1, 2, 3, 4, 5, 6;
  • u 0, 1, 2; preferably 0 or 2; particularly preferably 2;
  • R34, R35, R37, R38
    • independently of one another H, (C1-C8)-alkyl;


      or
  • R34 and R35
    • optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur and may optionally be substituted by 1-2 oxo groups;
  • R36, R39 independently of one another (C3-C8)-cycloalkyl, 5-10 membered aromatic ring system which may comprise 0-2 further heteroatoms from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;
  • R40 H, (C1-C8)-alkyl, (C2-C6)-alkenyl, (C0-C8)-alkylene-aryl;
  • R41 (C1-C6)-alkyl, 5-10 membered aromatic ring system which may comprise 0-2 further heteroatoms from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;
  • R78, R79 independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl;
  • R80, R81 independently of one another H, (C1-C8)-alkyl;
  • R3 H, (C1-C6)-alkyl; preferably H;
  • R4, R5 independently of one another H, (C1-C6)-alkyl, OH, O—(C1-C6)-alkyl, O—CO—(C1-C6)-alkyl, S—(C1-C6)-alkyl;
    • preferably independently of one another H, (C1-C6)-alkyl, OH, O—(C1-C6)-alkyl, O—CO—(C1-C6)-alkyl; particularly preferably independently of one another H, OH, O—(C1-C6)-alkyl;
  • R6, R7, R8, R9
    • H;


      or
  • R6 and R7, R8 and R9
    • independently of one another optionally oxo;
  • preferably R6, R7, R8, R9 are H;
  • n 1
  • m 1 or 2; preferably 1;
  • A, B, D, G independently of one another N, C(R42);
    • or
    • the groups A and B or D and G are each C(R42) and together form an ortho-phenylene unit to result overall in a 1,4-bisubstituted naphthalene system;
    • preferably
    • B is N, C(R42); and A, D, G C(R42);
    • particularly preferably
    • A, B, D, G are C(R42);
  • R42 H, F, Cl, Br, CF3, CN, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, N(R43)(R44), SO2—CH3, CON(R45)(R46), N(R47)CO(R48), CO(R51), —(CR84R85)x—O(R86);
    • preferably H, F, Cl, Br, CF3, CN, O—(C1-C6)-alkyl, (C1-C6)-alkyl, SO2—CH3, CON(R45)(R46), N(R47)CO(R48), CO(R51), —(CR84R85)x—O(R86);
    • particularly preferably H, F, Cl, CF3, CN, (C1-C6)-alkyl, —(CR84R85)x—O(R86);
  • R43, R44, R45, R46, R47
    • independently of one another H, (C1-C8)-alkyl;


      or
  • R43 and R44, R45 and R46
    • independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur;
  • R48, R50, R51
    • independently of one another H, (C1-C8)-alkyl, aryl; preferably independently of one another H, (C1-C8)-alkyl;
  • R84, R85 H;
  • R86 H, (C1-C6)-alkyl;
  • x 0, 1, 2; preferably 0, 1; particularly preferably 1;
  • R10 H, (C1-C8)-alkyl;
  • x N(R52), a bond, C═C, C(R53)(R54), C(R55)(R56)O, C≡C, CH2—CH2, YCH2; preferably N(R52), a bond, C═C, C(R53)(R54), CH2—CH2; particularly preferably a bond, C═C, C(R53)(R54), CH2—CH2;
  • y O, S, N(R89);
  • R89 H, (C1-C8)-alkyl;
  • R52, R53, R54, R55, R56
    • independently of one another H, (C1-C8)-alkyl;
  • E 3-8 membered bivalent carbo- or heterocyclic ring structure with 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, S-aryl, N(R57)(R58), SO2—CH3, N(R61)CO(R62), N(R63)SO2(R64), CO(R65) and may be mono- or bicyclic;
    • preferably 5-7 membered bivalent carbo- or heterocyclic ring structure with 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, O—(C0-C8)-alkylene-aryl, S-aryl, N(R57)(R58), SO2—CH3,
    • N(R61)CO(R62), CO(R65) and may be mono- or bicyclic; particularly preferably 5-7 membered bivalent carbo- or heterocyclic ring structure with 0-2 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, N(R57)(R58), SO2—CH3, CO(R65)
    • e.g. E is selected from the group consisting of




embedded image



which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, N(R57)(R58), SO2—CH3, CO(R65);


preferably




embedded image



which may optionally have the aforementioned substituents;

  • R57, R58, R61, R63
    • independently of one another H, (C1-C8)-alkyl;
  • R62, R64, R65
    • independently of one another H, (C1-C8)-alkyl, aryl; preferably independently of one another H, (C1-C8)-alkyl;
  • K a bond, O, OCH2, CH2O, S, SO, SO2, N(R66), N(R67)CO, CON(R68), (C(R69)(R70))v, CO, C═C, C≡C, SCH2, SO2CH2; preferably a bond, O, OCH2, CH2O, N(R66), CON(R68), (C(R69)(R70))v, CO, C≡C, SCH2; particularly preferably a bond, O, OCH2, CH2O, CON(R68), (C(R69)(R70))v, CO, C≡C;
  • v 1, 2, 3, 4; preferably 1, 2, 3; particularly preferably 1, 2;
  • R66, R67, R68, R69, R70
    • independently of one another H, (C1-C8)-alkyl;
  • R11 H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring, which may comprise 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl hydroxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R71), CON(R72)(R73), hydroxy, COO(R74), N(R75)CO(C1-C6)-alkyl, N(R76)(R77) or SO2CH3;
    • preferably (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may comprise 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R71), CON(R72)(R73), hydroxy, N(R75)CO(C1-C6)-alkyl, N(R76)(R77) or SO2CH3;
    • particularly preferably (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono- or bicyclic ring which may comprise 0 to 2 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, oxo, CO(R71), CON(R72)(R73), N(R75)CO(C1-C6)-alkyl, or SO2CH3;
  • R71, R72, R73, R74, R75, R76, R77
    • independently of one another H, (C1-C8)-alkyl;


      or
  • R72 and R73, R76 and R77
    • independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur; or


      the N-oxides and the physiologically tolerated salts thereof.


In a further preferred embodiment, A, B, G and D in formula I are CH or:


If E is 1,4-phenylene, the preferred meanings for A, B, G and D are furthermore those listed in table I below:














TABLE I







A
B
G
D









N
CH
CH
CH



CH
N
CH
CH



C—Cl
N
CH
CH



C—F
CH
C—F
CH



CH
CH
C—F
CH



CH
C—F
CH
CH



CH
CH
CH
CF



CH
C—Br
CH
CH



CH
CH
C—Br
CH



CH
C—Cl
CH
CH



CH
CH
C—Cl
CH



CH
CH
C—CN
CH



CH
CH
CH
C—CN



CH
CH
C—CH3
CH



CH
CH
CH
C—CH3



CH
CH
C—CF3
CH



CH
CH
CH
C—CF3



CH
CH
CH
CH2OH



CH
C—F
CH
C—F



CH
C—F
C—F
CH



CH
CH
C—F
C—F



CH
CH
C—F
C—Cl



CH
CH
C—Cl
C—CN



CH
C—CH3
C—Cl
CH



CH
N
CH
C—CH3



CH
C—CH3
CH
N



CH
N
C—CH3
CH












CH
CH


embedded image












If E is




embedded image



the preferred meanings for A, B, G and D are furthermore those listed in table 11 below:














TABLE II







A
B
G
D









CH
C—CH3
CH
CH



CH
C—F
CH
CH



CH
CH
C—CH3
CH



CH
CH
C—F
CH



CH
N
CH
CH



CH
CH
CH
N



C—F
CH
C—F
CH










If E is




embedded image



the preferred meanings for A, B, G and D are furthermore those listed in table III below:














TABLE III







A
B
G
D









CH
CH
C—F
CH



CH
N
CH
CH



CH
CH
CH
N










Further preferred combinations for E and A, B, G and D are listed in table IV.















TABLE IV







E
A
B
G
D











embedded image


CH
C—F
CH
CH









embedded image


CH
CH
C—F
CH









embedded image


CH
C—F
CH
CH









embedded image


CH
C—F
CH
CH









embedded image


CH
CF
CH
CH









embedded image


CH
CF
CH
CH









embedded image


CH
C—F
CH
CH









embedded image


CH
C—F
CH
CH









embedded image


CH
C—F
CH
CH









embedded image


CH
C—F
CH
CH









embedded image


CH
C—F
CH
CH









embedded image


CH
C—F
CH
CH









embedded image


CH
C—F
CH
CH









embedded image


CH
C—F
CH
CH









embedded image


CH
C—F
CH
CH









embedded image


CH
C—F
CH
CH










The radicals R11, K, X and E in formula I have in a particularly preferred embodiment one of the following meanings:


R11is preferably selected from the group consisting of:

  • n-propyl, n-butyl, iso-butyl, iso-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohex-(1)-enyl, phenyl, p-fluorophenyl, p-chlorophenyl, p-bromophenyl, p-tolyl, p-methoxyphenyl, p-trifluoromethylphenyl, p-methylthiophenyl, o-fluorophenyl, o-chlorophenyl, o-cyanophenyl, m-fluorophenyl, 2,4-difluorophenyl, 3-fluoro-4-methylphenyl, 2-nitro-4-methylphenyl, 2-amino-4-methylphenyl,




embedded image


K is preferably selected from the group consisting of:

  • —O—, bond, C≡C, CH2, CH2O, CONH, OCH2, CO, SCH2 and (CH2)2O.


X is preferably selected from the group consisting of bond, NH and CH2.


E is preferably selected from the group consisting of:




embedded image


Preferred combinations of R11, K, X and E are listed below:


If K and X are each a bond, the particularly preferred meanings for E and R11 areas follows:

    • If E is 1,4-phenylene, R11 is selected from the group consisting of:
      • cyclohexyl, p-tolyl, p-fluorophenyl, o-fluorophenyl, p-methoxyphenyl, p-chlorophenyl, o-chlorophenyl, 2,4-difluorophenyl, 3-fluoro-4-methylphenyl, o-cyanophenyl,




embedded image




    • If E is







embedded image



R 11 selected from the group consisting of: p-chlorophenyl, p-tolyl, p-fluorophenyl, p-methoxyphenyl, p-trifluoromethylphenyl, o-fluorophenyl, phenyl and




embedded image


Further combinations of E and R11 or the case where K and X are each a bond are listed in table V:












TABLE V







R11
E









p-Chlorophenyl
1,4-Cyclohexylene







2-Nitro-4-methylphenyl


embedded image









p-Chlorophenyl


embedded image









p-Bromophenyl


embedded image









p-Fluorophenyl


embedded image









p-Chlorophenyl


embedded image











embedded image




embedded image









p-Tolyl


embedded image









n-Butyl


embedded image









p-Chlorophenyl


embedded image











embedded image




embedded image











embedded image




embedded image









p-Methylthiophenyl


embedded image









2-Amino-4-methylphenyl


embedded image












If K is —O— and X is a bond, NH or CH2, the particularly preferred meanings for E and R11 are as follows:

    • If E is 1,4-phenylene, R11 is selected from the group consisting of:
    • phenyl, cyclopentyl, n-butyl, iso-butyl, iso-pentyl, 2,4-difluorophenyl and p-fluorophenyl.


Further combinations of E and R11 for the case where K is —O— and X is a bond, NH or CH2 are listed in table VI:












TABLE VI







R11
E









Phenyl


embedded image









Cyclopentyl


embedded image









Phenyl


embedded image









n-Butyl


embedded image









n-Butyl


embedded image












If K is C≡C and X is a bond, the particularly preferred meanings of E and R11 are as follows:

    • If E is




embedded image



R11 is selected from the group consisting of:

    • phenyl, p-fluorophenyl and p-chlorophenyl.


If K is CH2 and X is a bond, the particularly preferred meanings of E and R11 are indicated in table VII below:












TABLE VII







R11
E









Phenyl
1,4-Phenylene









embedded image


1,4-Phenylene







p-Chlorophenyl


embedded image












If K is CH2O and X is a bond, the particularly preferred meanings of E and R11 areas follows:

    • If E is 1,4-phenylene, R11 is selected from the group consisting of:
      • phenyl, cyclopropyl and cyclohexyl.


If K is CONH and X is a bond, the particularly preferred meanings of E and R11 are indicated in table VIII below:












TABLE VIII







R11
E









Cyclopentyl
1,4-Phenylene



Cyclohex-(1)-enyl
1,4-Phenylene







Cyclopentyl


embedded image












If K is OCH2 and X is a bond, the particularly preferred meanings of E and R11 are indicated in table IX below:












TABLE IX







R11
E









o-Chlorophenyl


embedded image









p-Tolyl
1,4-Phenylene



n-Propyl
1,4-Phenylene



Cyclobutyl
1,4-Phenylene










The combinations of R11, K and E listed in table X below are furthermore particularly preferred in addition to the aforementioned combinations, with X very particularly preferably being a bond:













TABLE X







R11
K
E









o-Fluorophenyl
CO


embedded image









Phenyl
SCH2
1,4-Phenylene







Cyclopropyl
(CH2)2O


embedded image












The compounds of the formula I are in a very particularly preferred embodiment compounds of the formula Ia




embedded image



in which the radicals R1, R2, R10, R11, R42, and groups X, E, K have the aforementioned meanings, and R42′ is defined as R42, where R42 and R42′ in the compounds of the formula Ia may be identical or different, or the N-oxides and the physiologically tolerated salts thereof.


In a preferred embodiment of the invention, the radicals R1, R2, R10, R11, R42, R42′ and groups X, E, K have the following meanings:

  • R1, R2 independently of one another H, (C1-C8)-alkyl, —(CR78R79)o—R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may comprise 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, (C1-C6)-alkyl, O—(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R26), CON(R27)(R28), hydroxy, N(R31)(R32) or SO2CH3; where R1 and R2 are not both CO(R26),
    • preferably H, (C1-C8)-alkyl, —(CR78R79)o—R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono- or bicyclic ring which, apart from the nitrogen atom, may comprise 0 to 2 additional heteroatoms selected from the group of oxygen and nitrogen, where the heterocyclic ring system may additionally be substituted by F, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, oxo, CO(R26), hydroxy, N(R31)(R32);
  • o 0, 1, 2, 3, 4, preferably
    • 0, 1, 2, 3;
  • q 1, 2, 3, preferably
    • 1 or 2;
  • s 0, 1, 2;
  • R15, R16, R17, R18, R23, R24, R25, R26, R27, R28, R31, R32
    • independently of one another H, (C1-C6)-alkyl;


      or
  • R17 and R18, R27 and R28, R31 and R32
    • independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur, preferably the ring is a pyrrolidine, piperidine, N-methylpiperazine, morpholine ring;
  • R12 OH, O—(C1-C6)-alkyl, O—(C0-C2)-alkylene-aryl, CN, S—(C1-C6)-alkyl, 3-12 membered mono-, bi- or spirocyclic ring which may comprise 1 to 3 heteroatoms from the group of N, O and S, and the 3-12 membered ring may comprise further substituents such as F, OH, CF3, CN, oxo, (C1-C6)-alkyl, (C0-C2)-alkylene-aryl, N(R34)(R35), COO(R40), CO(C1-C6)-alkyl, preferably OH, O—(C1-C6)-alkyl, 3-10 membered mono- or bicyclic ring which may comprise 1-2 heteroatoms from the group of N, O and S, and the 3-10 membered ring may comprise further substituents such as F, OH, oxo, (C1-C6)-alkyl, CO(C1-C6)-alkyl;
  • R34, R35
    • independently of one another H, (C1-C4)-alkyl;
  • R40 H, (C1-C6)-alkyl, (C0-C2)-alkylene-aryl;
  • R78, R79 independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl;
  • R42, R42′ independently of one another H, F, Cl, Br, CF3, CN, (C1-C6)-alkyl;
  • R10 H, (C1-C8)-alkyl;
  • X N(R52), a bond, C═C, C(R53)(R54), CH2CH2;
  • R52, R53, R54


independently of one another H, (C1-C8)-alkyl;

  • E 5-7 membered bivalent carbo- or heterocyclic ring structure with 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, CF3, OH, CN, OCF3, NO2, O—(C1-C6)-alkyl, (C1-C6)-alkyl, SO2—CH3, CO(R65);
    • preferably 5-7 membered bivalent carbo- or heterocyclic ring structure with 0-2 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, N(R57)(R58), SO2—CH3, CO(R65) e.g. E is selected from the group consisting of




embedded image



which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, N(R57)(R58), SO2—CH3, CO(R65);


preferably




embedded image



which may optionally have the aforementioned substituents;

  • R65 H, (C1-C8)-alkyl;
  • K a bond, O, OCH2, CH2O, S, SO2, N(R66), N(R67)CO, CON(R68), (C(R69)(R70))v, CO, C≡C, SCH2, SO2CH2;
    • preferably a bond, O, OCH2, CH2O, CON(R68), (C(R69)(R70))v, particularly preferably CH2, CO, C≡C;
  • v 1, 2, 3, preferably
    • 1, 2;
  • R66, R67, R68, R69, R70
    • independently of one another H, (C1-C8)-alkyl;
  • R11 (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may comprise 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, oxo, CO(R71), hydroxy, N(R75)CO(C1-C6)-alkyl, or SO2CH3;
    • preferably (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono- or bicyclic ring which may comprise 0 to 2 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, oxo, CO(R71), CON(R72)(R73), N(R75)CO(C1-C6)-alkyl, or SO2CH3;
  • R71, R72, R73, R74, R75, R76, R77
    • independently of one another H, (C1-C8)-alkyl;


      or
  • R72 and R73, R76 and R77
    • independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur.


In a preferred embodiment, the present invention relates to compounds of the formula Ia,


in which




  • X is CH2CH2, N(R52), CH2, OCH2, SCH2, CH═CH, preferably CH2CH2, CH═CH;

  • E is





embedded image


  • K is a bond, O or C(R69)(R70);


    and the other symbols R1, R2, R10, R11, R42, R42′, R52, R69 and R70 have the meanings indicated above in relation to a definition of the radicals of the compound of the formula Ia.



In a further preferred embodiment, the present invention relates to compounds of the formula Ia,


in which




  • X is N(R52), preferably NH, or C(R53)(R54);

  • E is





embedded image


  • K is a bond, O or C(R69)(R70), preferably 0;
    • preferably O


      and the other symbols R1, R2, R10, R11, R42, R42′, R52, R53, R54, R69 and R70 have the meanings indicated above in relation to a definition of the radicals of the compound of the formula Ia.



In a further particularly preferred embodiment, the compounds of the formula I are compounds of the formula Ib




embedded image



in which the radicals R1, R2, R10 and R11 and the groups E and D have the aforementioned meanings, or the N-oxides and the physiologically tolerated salts thereof.


In a preferred embodiment, the radicals R1, R2, R10 and R11 the groups E and D have the following meanings:

  • R1, R2 independently of one another H, (C1-C8)-alkyl, —(CR78R79)o—R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, CO—(C1-C8)-alkyl, —CO—(CH2)o—R12, CO-aryloxy-(C1-C4)-alkyl, COCH═CH(R13), COCC(R14), CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))rCON(R21)(R22), CO(C(R23)(R24))sO(R25); or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono-, bi- or spirocyclic ring which, apart from the nitrogen atom, may comprise 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C1-C6)-alkyl, O—(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R26), CON(R27)(R28), hydroxy, COO(R29), N(R30)CO(C1-C6)-alkyl, N(R31)(R32) or SO2CH3, where R1 and R2 are not both CO(R26);
    • preferably independently of one another H, (C1-C8)-alkyl, —(CR78R79)o—R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, CO—(C1-C8)-alkyl, —CO—(CH2)o—R12, COCH═CH(R13), COCC(R14), CO(C(R15)(R16))qN(R17)(R18), CO(C(R23)(R24))sO(R25);
    • or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono- or bicyclic ring which, apart from the nitrogen atom, may comprise 0 to 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the heterocyclic ring system may additionally be substituted by F, Cl, CF3, (C1-C6)-alkyl, O—(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, hydroxy, N(R31)(R32) or SO2CH3, where R1 and R2 are not both CO—(C1-C8)-alkyl;
    • particularly preferably independently of one another H, (C1-C8)-alkyl, —(CR78R79)o—R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, CO—(C1-C8)-alkyl, —CO—(CH2)o—R12, CO(C(R15)(R16))qN(R17)(R18), or R1 and R2 form together with the nitrogen atom to which they are bonded a 4 to 10-membered mono- or bicyclic ring which, apart from the nitrogen atom, may comprise 0 to 2 additional heteroatoms selected from the group of oxygen and nitrogen, where the heterocyclic ring system may additionally be substituted by F, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, oxo, CO(C1-C8)-alkyl, hydroxy, N(R31)(R32), where R1 and R2 are not both CO(C1-C8)-alkyl;
  • o 0, 1, 2, 3, 4, 5, 6; preferably 0, 1, 2, 3, 4; particularly preferably 0, 1, 2, 3;
  • q, r independently of one another 1, 2, 3; preferably q is 1 or 2;
  • s 0, 1, 2, 3, 4; preferably 0, 1, 2, 3; particularly preferably 0, 1, 2;
  • R13, R14 independently of one another a phenyl ring which may comprise 0-1 nitrogen atoms;
  • R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32
    • independently of one another H, (C1-C6)-alkyl;
  • R18 H, (C1-C6)-alkyl, CO(C1-C6)-alkyl, CO(R33); preferably H, (C1-C6)-alkyl, CO(C1-C6)-alkyl; particularly preferably H, (C1-C6)-alkyl;


    or
  • R17 and R18, R21 and R22, R27 and R28, R31 and R32 independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur; preferably the ring is pyrrolidine, piperidine, N-methylpiperazine, morpholine;
  • R33 a 5-10 membered aromatic ring system which may comprise a further heteroatom from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;
  • R12 is OH, O—(C1-C6)-alkyl, O—(C0-C8)-alkylene-aryl, CN, S—(C1-C6)-alkyl, COO(R80), CON(R81)(R82), 3-12 membered mono-, bi- or spirocyclic ring which may comprise one or more heteroatoms from the group of N, O and S and the 3-12 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, O—(C0-C8)-alkylene-aryl, (C0-C8)-alkylene-aryl, N(R34)(R35), COCH═CH(R36), (C(R37)(R38))t (R39), CO(C(R37)(R38)) (R39), CO(C1-C6)-alkyl, COCOO(C1-C6)-alkyl, COO(R40), S(O)u (R41);
    • preferably OH, O—(C1-C6)-alkyl, O—(C0-C8)-alkylene-aryl, CN, 3-10 membered mono- or bicyclic ring which may comprise 1-3 heteroatoms from the group of N, O and S, and the 3-10 membered ring may comprise further substituents such as F, Cl, Br, OH, CF3, CN, oxo, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, (C0-C2)-alkylene-aryl, N(R34)(R35), CO(C1-C6)-alkyl;
    • particularly preferably OH, O—(C1-C6)-alkyl, 3-10 membered mono- or bicyclic ring which may comprise 1-2 heteroatoms from the group of N, O and S and the 3-10 membered ring may comprise further substituents such as F, OH, oxo, (C1-C6)-alkyl, CO(C1-C6)-alkyl;
  • t 0, 1, 2, 3, 4, 5, 6;
  • u 0, 1, 2; preferably 0 or 2; particularly preferably 2;
  • R34, R35, R37, R38
    • independently of one another H, (C1-C8)-alkyl;


      or
  • R34 and R35
    • optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur and may optionally be substituted by 1-2 oxo groups;
  • R36, R39 independently of one another (C3-C8)-cycloalkyl, 5-10 membered aromatic ring system which may comprise 0-2 further heteroatoms from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;
  • R40 H, (C1-C8)-alkyl, (C2-C6)-alkenyl, (C0-C8)-alkylene-aryl;
  • R41 (C1-C6)-alkyl, 5-10 membered aromatic ring system which may comprise 0-2 further heteroatoms from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;
  • R78, R79 independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH, (C1-C4)-alkoxy-(C1-C4)-alkyl;
  • R80, R81 independently of one another H, (C1-C8)-alkyl;
  • R10 H, (C1-C8)-alkyl;
  • E 3-8 membered bivalent carbo- or heterocyclic ring structure with 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alky S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, S-aryl, N(R57)(R58), SO2—CH3, N(R61 )CO(R62), N(R63)SO2(R64), CO(R65) and may be mono- or bicyclic;
    • preferably 5-7 membered bivalent carbo- or heterocyclic ring structure with 0-3 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, O—(C0-C8)-alkylene-aryl, S-aryl, N(R57)(R58), SO2—CH3, N(R61 )CO(R62), CO(R65) and may be mono- or bicyclic;
    • particularly preferably 5-7 membered bivalent carbo- or heterocyclic ring structure with 0-2 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, N(R57)(R58), SO2—CH3, CO(R65)
    • e.g. E is selected from the group consisting of




embedded image



which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, N(R57)(R58), SO2—CH3, CO(R65);


preferably




embedded image



which may optionally have the aforementioned substituents;

  • R57, R58, R61, R63
    • independently of one another H, (C1-C8)-alkyl;
  • R62, R64, R65
    • independently of one another H, (C1-C8)-alkyl, aryl; preferably independently of one another H, (C1-C8)-alkyl;
  • K a bond, O, OCH2, CH2O, S, SO, SO2, N(R66), N(R67)CO, CON(R68), (C(R69)(R70))v, CO, C═C, C≡C, SCH2, SO2CH2;
    • preferably a bond, O, OCH2, CH2O, N(R66), CON(R68), (C(R69)(R70))v, CO, C≡C, SCH2; particularly preferably a bond, O, OCH2, CH2O, CON(R68), (C(R69)(R70))v, CO, C≡C;
  • v 1, 2, 3, 4; preferably 1, 2, 3; particularly preferably 1, 2;
  • R66, R67, R68, R69, R70
    • independently of one another H, (C1-C8)-alkyl;
  • R11 H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may comprise 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R71), CON(R72)(R73), hydroxy, COO(R74), N(R75)CO(C1-C6)-alkyl, N(R76)(R77) or SO2CH3SCF3;
    • preferably (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may comprise 0 to 3 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R71), CON(R72)(R73), hydroxy, N(R75)CO(C1-C6)-alkyl, N(R76)(R77) or SO2CH3;
    • particularly preferably (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, a 3 to 10-membered mono- or bicyclic ring which may comprise 0 to 2 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, oxo, CO(R71), CON(R72)(R73), N(R75)CO(C1-C6)-alkyl, or SO2CH3;
  • R71, R72, R73, R74, R75, R76, R77
    • independently of one another H, (C1-C8)-alkyl;


      or
  • R72 and R73, R76 and R77
    • independently of one another optionally together with the nitrogen atom to which they are bonded a 5-6 membered ring which, apart from the nitrogen atom, may also comprise 0-1 further heteroatoms from the group of N—(C1-C6)-alkyl, oxygen and sulfur.


In a preferred embodiment, the present invention relates to compounds of the formula Ib


in which




  • X is a bond,

  • E is





embedded image



where the aforementioned groups may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, N(R57)(R58), SO2—CH3, CO(R65);


preferably E is




embedded image



in which the groups may have the aforementioned substituents;

  • K is a bond; and


    the other radicals R1, R2, R10 and R11 and the group D have the meanings indicated above in relation to the definition of the radicals of the compound of the formula Ib.


R11 in the aforementioned compounds of the formula Ib is particularly preferably a substituted mono- or bicyclic ring system with 5-10 members, which may have 0-3 heteroatoms, in particular N, O and/or S, particularly preferably phenyl with 0-1 N atom, cyclohexyl or a bicyclic system with 8-10 members and 1-2 heteroatoms, in particular N, O and/or S.


In a further preferred embodiment, the present invention relates to compounds of the formula Ib


in which




  • X is a bond;

  • E is





embedded image



where the aforementioned groups may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, N(R57)(R58), SO2CH3 and CO(R65);


preferably




embedded image



in which the groups may have the aforementioned substituents;

  • K is CH2, CH2CH2, O, CH2O, OCH2, CON(R68), N(R67)CO, S, SO2, SCH2, SO2, SO2CH2, CO or a triple bond;
    • preferably CH2, O, CH2O, OCH2, CON(R68), SCH2, CO or a triple bond; and


      the other radicals R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R67 and R68 and the group D have the meanings indicated above in relation to the definition of the radicals of the compound of the formula Ib.


The amount of a compound of formula (I) necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient. The daily dose is generally in the range from 0.3 mg to 100 mg (typically from 3 mg to 50 mg) per day and per kilogram of bodyweight, for example 3-10 mg/kg/day. An intravenous dose may be, for example, in the range from 0.3 mg to 1.0 mg/kg, which can suitably be administered as infusion of 10 ng to 100 ng per kilogram and per minute. Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Single doses may contain, for example, from 1 mg to 10 g of the active ingredient. Thus, ampoules for injections may contain, for example, from 1 mg to 100 mg, and single-dose formulations which can be administered orally, such as, for example, tablets or capsules, may contain, for example, from 1.0 to 1000 mg, typically from 10 to 600 mg. In the case of pharmaceutically acceptable salts, the aforementioned weight data are based on the weight of the free compound from which the salt is derived. For the prophylaxis and therapy of the abovementioned conditions, the compounds of formula (I) may be used as the compound itself, but they are preferably in the form of a pharmaceutical composition with an acceptable carrier. The carrier must, of course, be acceptable in the sense that it is compatible with the other ingredients of the composition and is not harmful for the patient's health. The carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet, which may contain from 0.05% to 95% by weight of the active ingredient. Other pharmaceutically active substances may likewise be present, including other compounds of formula (I). The pharmaceutical compositions of the invention can be produced by one of the known pharmaceutical methods, which essentially consist of mixing the ingredients with pharmacologically acceptable carriers and/or excipients.


Pharmaceutical compositions of the invention are those suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be treated and on the nature of the compound of formula (I) used in each case. Coated formulations and coated slow-release formulations also belong within the framework of the invention. Preference is given to acid- and gastric juice-resistant formulations. Suitable coatings resistant to gastric juice comprise cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.


Suitable pharmaceutical compounds for oral administration may be in the form of separate units such as, for example, capsules, cachets, suckable tablets or tablets, each of which contain a defined amount of the compound of formula (I); as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact. The compositions are generally produced by uniform and homogeneous mixing of the active ingredient with a liquid and/or finely divided solid carrier, after which the product is shaped if necessary. Thus, for example, a tablet can be produced by compressing or molding a powder or granules of the compound, where appropriate with one or more additional ingredients. Compressed tablets can be produced by tableting the compound in free-flowing form such as, for example, a powder or granules, where appropriate mixed with a binder, glidant, inert diluent and/or one or more surface-active/dispersing agent(s) in a suitable machine. Molded tablets can be produced by molding the compound, which is in powder form and is moistened with an inert liquid diluent, in a suitable machine.


Pharmaceutical compositions which are suitable for peroral (sublingual) administration comprise suckable tablets which contain a compound of formula (I) with a flavoring, normally sucrose and gum arabic or tragacanth, and pastilles which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.


Pharmaceutical compositions suitable for parenteral administration comprise preferably sterile aqueous preparations of a compound of formula (I), which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also take place by subcutaneous, intramuscular or intradermal injection. These preparations can preferably be produced by mixing the compound with water and making the resulting solution sterile and isotonic with blood. Injectable compositions of the invention generally contain from 0.1 to 5% by weight of the active compound.


Pharmaceutical compositions suitable for rectal administration are preferably in the form of single-dose suppositories. These can be produced by mixing a compound of the formula (I) with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.


Pharmaceutical compositions suitable for topical use on the skin are preferably in the form of ointment, cream, lotion, paste, spray, aerosol or oil. Carriers which can be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances. The active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%.


Transdermal administration is also possible. Pharmaceutical compositions suitable for transdermal uses can be in the form of single plasters which are suitable for long-term close contact with the patient's epidermis. Such plasters suitably contain the active ingredient in an aqueous solution which is buffered where appropriate, dissolved and/or dispersed in an adhesive or dispersed in a polymer. A suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%. A particular possibility is for the active ingredient to be released by electrotransport or iontophoresis as described, for example, in Pharmaceutical Research, 2(6): 318 (1986).


As used herein, the following definitions apply:


“Patient” means a warm blooded animal, such as for example rat, mice, dogs, cats, guinea pigs, and primates such as humans.


“Treat” or “treating” means to alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms of the named disorder or condition.


“Therapeutically effective amount” means a quantity of the compound which is effective in treating the named disorder or condition.


“Pharmaceutically acceptable carrier” is a non-toxic solvent, dispersant, excipient, adjuvant or other material which is mixed with the active ingredient in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to the patient. One example of such a carrier is a pharmaceutically acceptable oil typically used for parenteral administration.


The compounds of the formula I are distinguished by beneficial effects on lipid metabolism, and they are particularly suitable for weight reduction and for maintaining a reduced weight after weight reduction has taken place in mammals and as anorectic agents. The compounds are distinguished by their low toxicity and their few side effects. The compounds can be employed alone or in combination with other weight-reducing or anorectic active ingredients. Further anorectic active ingredients of this type are mentioned, for example, in the Rote Liste, chapter 01 under weight-reducing agents/appetite suppressants, and they also include active ingredients which increase the energy turnover of the organism and thus lead to weight reduction or else those which influence the general metabolism of the organism in such a way that an increased calorie intake does not lead to an enlargement of the fat depots and a normal calorie intake leads to a reduction of the fat depots of the organism. The compounds are suitable for the prophylaxis and, in particular, for the treatment of excessive weight or obesity. The compounds are further suitable for the prophylaxis and, in particular, for the treatment of type II diabetes, of arteriosclerosis and for normalizing lipid metabolism and for the treatment of high blood pressure. The compounds act as MCH antagonists and are also suitable for the treatment of disturbances of wellbeing and of psychiatric indications such as, for example, depressions, anxiety states, anxiety neuroses, schizophrenia and for the treatment of disorders associated with the circadian rhythm and for the treatment of drug abuse.


In a further aspect of the invention, the compounds of the formula I can be administered in combination with one or more other pharmacologically active substances which are selected, for example, from antidiabetics, antiobesity agents, active ingredients which lower blood pressure, lipid-lowering agents and active ingredients for the treatment and/or prevention of complications caused by diabetes or associated with diabetes.


Further pharmacologically active substances suitable in particular are:

  • all antidiabetics mentioned in the Rote Liste 2001, chapter 12. They may be combined with the compounds of the formula I of the invention in particular for a synergistic improvement of the effect. Administration of the active ingredient combination may take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. Most of the active ingredients listed below are disclosed in the USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001.


Suitable antidiabetics include insulin and insulin derivatives such as, for example, Lantus® or HMR 1964, fast-acting insulins (see U.S. Pat. No. 6,221,633), amylin, GLP-1 and GLP-2 derivatives such as, for example, those disclosed in WO 98/08871 of Novo Nordisk A/S, and orally effective hypoglycemic active ingredients.


The orally effective hypoglycemic active ingredients include, preferably, sulfonylureas, biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon receptor antagonists, GLP-1 agonists, potassium channel openers such as, for example, those disclosed in WO 97/26265 and WO 99/03861 of Novo Nordisk A/S, insulin sensitizers, activators of insulin receptor kinase, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and/or glycogenolysis, for example inhibitors of glycogen phosphorylase, modulators of glucose uptake and glucose excretion, compounds which alter lipid metabolism, such as antihyperlipidemic active ingredients and antilipidemic active ingredients, e.g. HMGCoA reductase inhibitors, inhibitors of cholesterol transport/of cholesterol uptake, inhibitors of bile acid reabsorption or inhibitors of microsomal triglyceride transfer protein (MTP), compounds which reduce food intake, PPAR and RXR agonists and active ingredients which act on the ATP-dependent potassium channel of the beta cells.


In one embodiment of the invention, the present compounds are administered in combination with insulin.


In one embodiment of the invention, the compounds of the formula I are administered in combination with an HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin.


In one embodiment of the invention, the compounds of the formula I are administered in combination with a cholesterol absorption inhibitor such as, for example, ezetimibe, tiqueside, pamaqueside.


In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPAR gamma agonist, such as, for example, rosiglitazone, pioglitazone, JTT-501, GI 262570.


In one embodiment of the invention, the compounds of the formula I are administered in combination with PPAR alpha agonist, such as, for example, GW 9578, GW 7647.


In one embodiment of the invention, the compounds of the formula I are administered in combination with a mixed PPAR alpha/gamma agonist, such as, for example, GW 1536, AVE 8042, AVE 8134, AVE 0847, or as described in PCT/US 11833, PCT/US 11490, DE10142734.4.


In one embodiment of the invention, the compounds of the formula I are administered in combination with a fibrate such as, for example, fenofibrate, clofibrate, bezafibrate.


In one embodiment of the invention, the compounds of the formula I are administered in combination with an MTP inhibitor such as, for example, implitapide, BMS-201038, R-103757.


In one embodiment of the invention, the compounds of the formula I are administered in combination with bile acid absorption inhibitor (see, for example, U.S. Pat. No. 6,245,744 or U.S. Pat. No. 6,221,897), such as, for example, HMR 1741.


In one embodiment of the invention, the compounds of the formula I are administered in combination with a CETP inhibitor, such as, for example, JTT-705.


In one embodiment of the invention, the compounds of the formula I are administered in combination with a polymeric bile acid adsorbent such as, for example, cholestyramine, colesevelam.


In one embodiment of the invention, the compounds of the formula I are administered in combination with an LDL receptor inducer (see U.S. Pat. No. 6,342,512), such as, for example, HMR1171, HMR1586.


In one embodiment of the invention, the compounds of the formula I are administered in combination with an ACAT inhibitor, such as, for example, avasimibe.


In one embodiment of the invention, the compounds of the formula I are administered in combination with an antioxidant, such as, for example, OPC-14117.


In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein lipase inhibitor, such as, for example, NO-1886.


In one embodiment of the invention, the compounds of the formula I are administered in combination with an ATP-citrate lyse inhibitor, such as, for example, SB-204990.


In one embodiment of the invention, the compounds of the formula I are administered in combination with a squalene synthetase inhibitor, such as, for example, BMS-188494.


In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein(a) antagonist, such as, for example, CI-1027 or nicotinic acid.


In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipase inhibitor, such as, for example, orlistat.


In one embodiment of the invention, the compounds of the formula I are administered in combination with insulin.


In one embodiment, the compounds of the formula I are administered in combination with a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide or glimepiride.


In one embodiment, the compounds of the formula I are administered in combination with a biguanide, such as, for example, metformin.


In one further embodiment, the compounds of the formula I are administered in combination with a meglitinide, such as, for example, repaglinide.


In one embodiment, the compounds of the formula I are administered in combination with a thiazolidinedione, such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidined


In one embodiment, the compounds of the formula I are administered in combination with an α-glucosidase inhibitor, such as, for example, miglitol or acarbose.


In one embodiment, the compounds of the formula I are administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.


In one embodiment, the compounds of the formula I are administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, with a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc. The compounds of the invention may moreover be administered in combination with one or more antiobesity agents or appetite-controlling active ingredients.


In a further embodiment, the compounds of the formula I are administered in combination with CART modulators (see “Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice” Asakawa, A, et al., M.: Hormone and Metabolic Research (2001), 33(9), 554-558), NPY antagonists, e.g. naphthalene-1-sulfonic acid {4-[(4-aminoquinazolin-2-ylamino)methyl]cyclohexyl-methyl}amide; hydrochloride (CGP 71683A)), MC4 agonists (e.g. 1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid [2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethy]-amide; (WO 01/91752)), orexin antagonists (e.g.1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-ylurea; hydrochloride (SB-334867-A)), H3 agonists (3-cyclohexyl-1-(4,4-dimethyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)propan-1-one oxalic acid salt (WO00/63208)); TNF agonists, CRF antagonists (e.g. [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1,3,9-triazafluoren-4-yl]dipropylamine (WO 00/66585)), CRF BP antagonists (e.g. urocortin), urocortin agonists, β3 agonists (e.g. 1-(4-chloro-3-methanesulfonylmethylphenyl)-2-[2-(2,3-dimethyl-1H-indol-6-yloxy)ethylamino]-ethanol hydrochloride (WO 01/83451)), MSH (melanocyte-stimulating hormone) agonists, CCK-A agonists (e.g. {2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2-ylcarbamoyl]-5,7-dimethylindol-1-yl}acetic acid trifluoroacetic acid salt (WO 99/15525)), serotonin reuptake inhibitors (e.g. dexfenfluramine), mixed sertoninergic and noradrenergic compounds (e.g. WO 00/71549), 5HT agonists e.g. 1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO 01/09111), bombesin agonists, galanin antagonists, growth hormone (e.g. human growth hormone), growth hormone-releasing compounds (6-benzyloxy-1-(2-diisopropylaminoethylcarbamoyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (WO 01/85695)), TRH agonists (see, for example, EP 0 462 884), uncoupling protein 2 or 3 modulators, leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhavskaya-Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001), 26(9), 873-881), DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors (e.g. WO 00/40569), PPAR modulators (e.g. WO 00/78312), RXR modulators or TR-β agonists.


In one embodiment of the invention, the other active ingredient is leptin; see, for example, “Perspectives in the therapeutic use of leptin”, Salvador, Javier; Gomez-Ambrosi, Javier; Fruhbeck, Gema, Expert Opinion on Pharmacotherapy (2001), 2(10), 1615-1622.


In one embodiment, the other active ingredient is dexamphatamine or amphetamine.


In one embodiment, the other active ingredient is fenfluramine or dexfenfluramine.


In another embodiment, the other active ingredient is sibutramine or the mono- and bisdemethylated active metabolites of sibutramine.


In one embodiment, the other active ingredient is orlistat.


In one embodiment, the other active ingredient is mazindol or phentermine.


In one embodiment, the compounds of the formula I are administered in combination with bulking agents, preferably insoluble bulking agents (see, for example, carob/Caromax® (Zunft H J; et al., Carob pulp preparation for treatment of hypercholesterolemia, ADVANCES IN THERAPY (2001 September-October), 18(5), 230-6.) Caromax is a carob-containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, Industriepark Höchst, 65926 Frankfurt/Main)). Combination with Caromax® is possible in one preparation or by separate administration of compounds of the formula I and Caromax®. Caromax® can in this connection also be administered in the form of food products such as, for example, in bakery products or muesli bars.




embedded image


embedded image


The present compounds may additionally be administered in combination with one or more antihypertensive active ingredients. Examples of antihypertensive active ingredients are beta blockers such as alprenolol,atenol, timolol, pindolol, propanolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as, for example, benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and rampril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and alpha blockers such as doxazosin, urapidil, prazosin and terazosin. Reference may furthermore be made to Remington: The Science and Practice of Pharmacy, 19th edition, Gennaro, editor, Mack Publishing Co., Easton, Pa., 1995.


It will be appreciated that every suitable combination of the compounds of the invention with one or more of the aforementioned compounds and optionally one or more other pharmacologically active substances is to be regarded as covered by the scope of protection of the present invention.


The citation of any reference herein should not be construed as an admission that such reference is available as “Prior Art” to the instant application.


The present invention is not to be limited in scope by the specific embodiments describe herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.


Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.







EXAMPLES

The efficacy of the compounds was tested as follows:


Biological Test Model:


The anorectic effect was tested on female NMRI mice. After withdrawal of food for 17 hours, the test product was administered by gavage. The animals were housed singly with free access to drinking water and were offered condensed milk 30 minutes after administration of the product. The condensed milk consumption was determined every half hour for 7 hours, and the general wellbeing of the animals was observed. The measured milk consumption was compared with the vehicle-treated control animals.









TABLE 1







Anorectic effect measured as the reduction in the cumulative milk


consumption of treated compared with control animals













Number of
Number of
Reduction in




animals/-
animals/-
the




cumulative milk
cumulative milk
cumulative




consumption of
consumption of
milk



Oral
the treated
the control
consumption



dose
animals
animals
as % of the


Example
[mg/kg]
N/[ml]
N/[ml]
control





Example 4
30
5/3.55
5/1.76
50


Example
30
5/3.70
5/1.34
64


13









DESCRIPTION OF EXPERIMENTS

Functional Measurements to Find IC50 Values


The cloning of the cDNA for the human MCH receptor, preparation of a recombinant HEK293 cell line which expresses the human MCH receptor, and functional measurements with the recombinant cell line took place in analogy to the description by Audinot et al. (J. Biol. Chem. 276, 13554-13562, 2001). A difference from the reference was, however, the use of the plasmid pEAK8 from EDGE Biosystems (USA) to construct the expression vector. The host used for the transfection was a transformed HEK cell line named “PEAK Stable Cells” (likewise from EDGE Biosystems). The functional measurements of the cellular calcium flux after addition of agonist (MCH) in the presence of ligand of the invention took place with the aid of the FLIPR apparatus from Molecular Devices (USA) using the protocols of the apparatus manufacturer.


The examples and preparation methods detailed below serve to illustrate the invention without, however, restricting it.


The compounds of the formula I of the invention can be prepared with the aid of reactions which are known in principle. For example, the compounds were obtained in accordance with the following general reaction schemes.




embedded image


embedded image


Other compounds of the invention can be obtained by further routes which are outlined by way of example in the following scheme.




embedded image


embedded image


Yet other examples were obtained as indicated in the following scheme.




embedded image


Descriptions of the general methods used are to be found by way of example described at the following places:

  • Methods A, B and C in example 1;
  • Method D in example 2;
  • Method E in example 3;
  • Method E-a in example 275;
  • Method E-b in example 286;
  • Method F in example 4;
  • Method F-a in example 264;
  • Method G in example 15;
  • Method H in example 237;
  • Method H-a in example 298;
  • Method I in example 238;
  • Method J in example 245;
  • Method J-a in example 297;
  • Method K in example 250;
  • Method L in example 254;
  • Method M in example 274;
  • Method N in example 277;
  • Method O in example 279;
  • Method O-a in example 292;
  • Method O-b in example 280;
  • Method P in example 285;
  • Method Q in example 290;
  • Method R in example 309.


    General Explanations


    a) Mode of Drawing the Structural Formulae


Only non-hydrogen atoms are depicted for clarity in the structural formulae of the given examples.


In tables 6-13, enantiomer-enriched compounds are identified by a marked hydrogen atom on the stereogenic center. Unless expressly noted otherwise, the enantiomer-enriched examples shown have the (R) configuration on the 3-aminopyrrolidine stereocenter.


b) Salt Forms


Many of the compounds of the invention are bases and can form salts with appropriately strong acids. In particular, after purification of the compounds by HPLC chromatography using a trifluoroacetic acid-containing mobile phase they may be in the form of hydrotrifluoroacetates. These can be converted into the free bases shown by simple treatment of a solution of the salts for example with sodium carbonate solution.


c) Units of the Characterizing Data


The unit of the stated molecular weight is “g/mol”. Peaks observed in the mass spectrum are indicated as the integral quotient of the molar molecular ion mass and the charge of the molecular ion (m/z).


Example 1
N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]phenyl}pyrrolidin-3-yl)acetamide



embedded image



Method A


A solution of 4-phenoxyaniline (3.33 g) in DMF (10 ml) was added dropwise to a solution of carbonyldiimidazole (2.92 g) in DMF (12 ml) cooled to 0° C. After 30 minutes, N-[1-(4-aminophenyl)pyrrolidin-3-yl]-N-methylacetamide (3.80 g) in DMF (10 ml) was added dropwise. The reaction solution was kept initially at room temperature for 2 hours and then at 80° C. for 30 minutes. The mixture was added dropwise to water (600 ml) and the resulting precipitate was filtered off with suction and washed with water. Alternatively, the product can also be extracted with ethyl acetate and purified by chromatography after concentration. This resulted in the product with the molecular weight of 444.54 (C26H28N4O3); MS (ESI): 445 (M+H+).


N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide

Method B


A suspension of N-methyl-N-[1-(4-nitrophenyl)pyrrolidin-3-yl]acetamide (3.5 g) and palladium(II) hydroxide (20% on carbon; 0.9 g) in ethanol (150 ml) and ethyl acetate (300 ml) was vigorously stirred under a hydrogen atmosphere (atmospheric pressure) for 3 hours. The catalyst was then removed by filtration, and the filtrate was concentrated. This resulted in the product with the molecular weight of 233.32 (C13H19N3O); MS (ESI): 234 (M+H+).


N-Methyl-N-[1-(4-nitrophenyl)pyrrolidin-3-yl]acetamide

Method C


4-Fluoronitrobenzene (25.0 g) was slowly added to a suspension of N-methyl-N-pyrrolidin-3-ylacetamide (25.2 g) and cesium carbonate (57.6 g) in DMF (300 ml). After 2 hours, the reaction mixture was poured into water, and the resultant precipitate was filtered off with suction. Alternatively, the product can also be extracted with ethyl acetate and purified by chromatography after concentration. This results in the product with the molecular weight of 263.30 (C13H17N3O3): MS (ESI): 264 (M+H+).


Example 2
1-[4-(3-Methylaminopyrrolidin-1-yl)phenyl]-3-(4-phenoxyphenyl)urea



embedded image



Method D


A mixture of N-methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]phenyl}pyrroldin-3-yl)acetamide (6.0 g), ethanol (250 ml), water (60 ml) and sodium hydroxide solution (10 M; 80 ml) was heated under reflux for 12 hours. The alcohol was distilled out and the resulting precipitate was filtered off with suction and washed with dichloromethane. Additional product was obtained by concentration of the organic phase and chromatography (silica gel, dichloromethane/methanol 9:1 with 1% triethylamine). This resulted in the product with the molecular weight of 402.50 (C24H26N4O2); MS (ESI): 403 (M+H+).


Example 3
N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]phenyl}pyrrolidin-3-yl)-2-phenylacetamide



embedded image



Method E


TOTU (327 mg) was added to a solution of 1-[4-(3-methylaminopyrrolidin-1-yl)phenyl]-3-(4-phenoxyphenyl)urea (402 mg) in DMF (3 ml) at 0° C. After 10 minutes, Hünig's base (130 mg) and then a solution of phenylacetic acid (136 mg) in DMF (1 ml) was added. After a reaction time of 12 hours at room temperature, water was added to the mixture, and it was extracted with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. The residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 520.64 (C32H32N4O3); MS (ESI): 521 (M+H+) as hydrotrifluoroacetate.


Example 4
(R)-N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]phenyl}pyrrolidin-3-yl)acetamide



embedded image


(R)-N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 4-phenoxyaniline by method A. This resulted in the product with the molecular weight of 444.54 (C26H28N4O3); MS (ESI): 445 (M+H+).


(R)-N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide

(R)-N-Methyl-N-[1-(4-nitrophenyl)pyrrolidin-3-yl]acetamide was hydrogenated by method B. This resulted in the product with the molecular weight of 233.32 (C13H19N3O); MS (ESI): 234 (M+H+).


(R)-N-Methyl-N-[1-(4-nitrophenyl)pyrrolidin-3-yl]acetamide

Method F


(R)-N-[1-(4-Nitrophenyl)pyrrolidin-3-yl]acetamide (1.3 g) was added in portions to a suspension of sodium hydride (50% in oil; 0.25 g) in DMF (50 ml). After gas evolution had ceased, iodomethane (0.82 g) was added. After one hour, the reaction mixture was cautiously hydrolyzed with water and extracted with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. This resulted in the product with the molecular weight of 263.30 (C13H17N3O3); MS (ESI): 264 (M+H+).


(R)-N-[1-(4-Nitrophenyl)pyrrolidin-3-yl]acetamide

(R)-N-pyrrolidin-3-ylacetamide was reacted with 4-fluoronitrobenzene by method C. This resulted in the product with the molecular weight of 249.27 (C12H15N3O3); MS (ESI): 250 (M+H+).


Example 5
(S)-N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]phenyl}pyrrolidin-3-yl)acetamide



embedded image


The sequence described in example 4 was applied to (S)-N-pyrrolidin-3-ylacetamide. This resulted in the product with the molecular weight of 444.54 (C26H28N4O3); MS (ESI): 445 (M+H+).


Example 6
(R)-1-[4-(3-Methylaminopyrrolidin-1-yl)phenyl]-3-(4-phenoxyphenyl)urea



embedded image


(R)-N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]phenyl}pyrrolidin-3-yl)acetamide was reacted by method D. This resulted in the product with the molecular weight of 402.50 (C24H26N4O2); MS (ESI): 403 (M+H+).


Example 7
(S)-1-[4-(3-Methylaminopyrrolidin-1-yl)phenyl]-3-(4-phenoxyphenyl)urea



embedded image


(S)-N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]phenyl}pyrrolidin-3-yl)acetamide was reacted by method D. This resulted in the product with the molecular weight of 402.50 (C24H26N4O2); MS (ESI): 403 (M+H+).


Example 8
(R)-N-(1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]phenyl}pyrrolidin-3-yl)-N-methylacetamide



embedded image


(R)-N-[1-(4-Aminophenyl)pyrrolidin-3-yl)-N-methylacetamide was reacted with 4-cyclopentyloxyaniline by method A. This resulted in the product with the molecular weight of 436.56 (C25H32N4O3); MS (ESI): 437 (M+H+).


(S)-N-(1-{4-[3-(4-cyclopentyloxy-phenyl)-ureido]-phenyl}-pyrrolidin-3-yl)-N-methyl-acetamide was obtained analogously from (S)-N-[1-(4-amino-phenyl)-pyrrolidin-3-yl]-N-methyl-acetamide.


4-Cyclopentyloxyaniline

A mixture of 4-nitrophenol (63.7 g), bromocyclopentane (68.2 g), potassium carbonate (63.3 g) and DMF (300 ml) was heated at 80° C. for 24 hours. After cooling, it was diluted with water and extracted with ethyl acetate. The organic phase was washed with water, dried over magnesium sulfate and concentrated. The residue was hydrogenated by method B. This resulted in the product with the molecular weight of 177.25 (C11H15NO); MS (ESI): 178 (M+H+).


Example 9
1-(4-Cyclopentyloxyphenyl)-3-[4-(3-methylaminopyrrolidin-1-yl)phenyl]urea



embedded image


N-(1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]phenyl}pyrrolidin-3-yl)-N-methylacetamide was reacted by method D. This resulted in the product with the molecular weight of 394.52 (C23H30N4O2); MS (ESI): 395 (M+H+).


(R)- and (S)-1-(4-cyclopentyloxy-phenyl)-3-[4-(3-methylamino-pyrrolidin-1-yl)-phenyl]-urea was obtained analogously from (R)- and (S)-N-(1-{4-[3-(4-cyclopentyloxy-phenyl)-ureido]-phenyl}-pyrrolidin-3-yl)-N-methyl-acetamide.


Example 10
Ethyl (1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]phenyl}pyrrolidin-3-yl)methyl-carbamate



embedded image


Ethyl chloroformate (8 μl) was added dropwise to a solution of 1-(4-cyclopentyloxyphenyl)-3-[4-(3-methylaminopyrrolidin-1-yl)phenyl]urea (20 mg) and Hünig's base (10 mg) in dichloromethane (3 ml). After 12 hours, the reaction mixture was concentrated and the residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 466.59 (C26H34N4O4); MS (ESI): 467 (M+H+) as hydrotrifluoroacetate.


Example 11
1-(1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]phenyl}pyrrolidin-3-yl)-3-ethyl-1-methylurea



embedded image


Ethyl isocyanate (7 μl) was added dropwise to a solution of 1-(4-cyclopentyloxyphenyl)-3-[4-(3-methylaminopyrrolidin-1-yl)phenyl]urea (20 mg) and Hünig's base (10 mg) in dichloromethane (3 ml). After 12 hours, the reaction mixture was concentrated and the residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 465.60 (C26H35N5O3); MS (ESI): 466 (M+H+) as hydrotrifluoroacetate.


Example 12
1-(4-Cyclopentyloxyphenyl)-3-(4-{3-[methyl-((R)-5-oxo-pyrrolidin-2-ylmethyl)amino]pyrrolidin-1-yl}phenyl)urea



embedded image


(R)-5-Bromomethylpyrrolidin-2-one (15 mg) was added to a suspension of 1-(4-cyclopentyloxyphenyl)-3-[4-(3-methyaminopyrrolidin-1-yl)phenyl]urea (30 mg) and potassium carbonate (20 mg) in DMF (3 ml). After 2 hours, the reaction mixture was filtered and concentrated, and the residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 491.64 (C28H37N5O3); MS (ESI): 492 (M+H+) as hydrotrifluoroacetate.


Example 13
4-(4-Chlorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}amide



embedded image


N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with carbonyldiimidazole and then with 4-(4-chlorophenyl)piperidine by method A. This resulted in the product with the molecular weight of 455.00 (C25H31ClN4O2); MS (ESI): 455 (M+H+).


(R)- and (S)-4-(4-chlorophenyl)piperidine-1-carboxylic acid {4-[3-(acetyl-methylamino)pyrrolidin-1-yl]phenyl}amide were obtained analogously from (R)- and (S)-N-[1-(4-aminophenyl)pyrrolidin-3-yl]-N-methylacetamide.


Example 14
tert-Butyl (R)-[1-(4-{[4-(4-chlorophenyl)piperidine-1-carbonyl]amino}-phenyl)pyrrolidin-3-yl]methylcarbamate



embedded image


tert-Butyl (R)-[1-(4-aminophenyl)pyrrolidin-3-yl]methylcarbamate was reacted with carbonyldiimidazole and then with 4-(4-chlorophenyl)piperidine by method A. This resulted in the product with the molecular weight of 513.09 (C28H37ClN4O3); MS (ESI): 513 (M+H+).


tert-Butyl (R)-[1-(4-aminophenyl)pyrrolidin-3-yl]methylcarbamate

tert-Butyl (R)-methyl-[1-(4-nitrophenyl)pyrrolidin-3-yl]carbamate was hydrogenated by method B. This resulted in the product with the molecular weight of 291.40 (C16H25N3O2); MS (ESI): 292 (M+H+).


tert-Butyl (R)-methyl-[1-(4-nitrophenyl)pyrrolidin-3-yl]carbamate

tert-Butyl (R)-[1-(4-nitrophenyl)pyrrolidin-3-yl]carbamate was alkylated with iodomethane by method F. This resulted in the product with the molecular weight of 321.38 (C16H23N3O4); MS (ESI): 322 (M+H+).


tert-Butyl (R)-[1-(4-nitrophenyl)pyrrolidin-3-yl]carbamate

tert-Butyl (R)-pyrrolidin-3-ylcarbamate was reacted with 4-fluoronitro-benzene by method C. This resulted in the product with the molecular weight of 307.35 (C15H21N3O4); MS (ESI): 308 (M+H+).


Example 15
(R)-4-(4-Chlorophenyl)piperidine-1-carboxylic acid [4-(3-methylamino-pyrrolidin-1-yl)phenyl]amide



embedded image



Method G


Trifluoroacetic acid (6.67 g) was added to a solution of tert-butyl (R)-[1-(4-{[4-(4-chlorophenyl)piperidin-1-carbonyl]amino}phenyl)pyrrolidin-3-yl]methylcarbamate (1.5 g) in dichloromethane (50 ml). After 3 hours, volatile fractions were removed and the residue was taken up in dichloromethane. After washing with sodium carbonate solution, the organic phase was dried over magnesium sulfate and concentrated. This resulted in the product with the molecular weight of 412.97 (C23H29ClN4O); MS (ESI): 413 (M+H+).


Example 16
4-(4-Chlorophenyl)piperidine-1-carboxylic acid (4-{(R)-3-[methyl-(1-methyl-piperidin-3-ylcarbonyl)amino]pyrrolidin-1-yl}phenyl)amide



embedded image


(R)-4-(4-Chlorophenyl)piperidine-1-carboxylic acid [4-(3-methylamino-pyrrolidin-1-yl)phenyl]amide was reacted with 1-methylpiperidine-3-carboxylic acid by method E. This resulted in the product with the molecular weight of 538.14 (C30H40ClN5O2); MS (ESI): 538 (M+H+).


Example 17
4-(4-Chlorophenyl)piperidine-1-carboxylic acid (4-(R)-{3-[methyl-(2-piperidin-1-ylacetyl)amino]pyrrolidin-1-yl}phenyl)amide



embedded image


(R)-4-(4-Chlorophenyl)piperidine-1-carboxylic acid [4-(3-methylamino-pyrrolidin-1-yl)phenyl]amide was reacted with piperidin-1-ylacetic acid by method E. This resulted in the product with the molecular weight of 538.14 (C30H40ClN5O2); MS (ESI): 538 (M+H+).


Example 18
4-(4-Chlorophenyl)piperidine-1-carboxylic acid (4-(R)-{3-[methyl-(2-oxo-thiazolidine-4-carbonyl)amino]pyrrolidin-1-yl}phenyl)amide



embedded image


(R)-4-(4-Chlorophenyl)piperidin-1-carboxylic acid [4-(3-methylamino-pyrrolidin-1-yl)phenyl]amide was reacted with 2-oxothiazolidine-4-carboxylic acid by method E. This resulted in the product with the molecular weight of 542.10 (C27H32ClN5O3S); MS (ESI): 542 (M+H+).


Example 19
(R)-4-(4-Chlorophenyl)piperidine-1-carboxylic acid (4-{3-[methyl-(2,2,2-trifluoroacetyl)amino]pyrrolidin-1-yl}phenyl)amide



embedded image


(R)-[N-[1-(4-aminophenyl)pyrrolidin-3-yl]-2,2,2-trifluoro-N-methylacetamide was reacted with carbonyldiimidazole and then with 4-(4-chlorophenyl)-piperidine by method A. This resulted in the product with the molecular weight of 508.98 (C25H28ClF3N4O2); MS (ESI): 509 (M+H+).


(R)-[N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-2,2,2-trifluoro-N-methylacetamide

(R)-2,2,2-Trifluoro-N-methyl-N-[1-(4-nitrophenyl)pyrrolidin-3-yl]acetamide was hydrogenated by method B. This resulted in the product with the molecular weight of 287.29 (C13H16F3N3O); MS (ESI): 288 (M+H+).


(R)-2,2,2-Trifluoro-N-methyl-N-[1-(4-nitrophenyl)pyrrolidin-3-yl]acetamide

Trifluoroacetic anhydride (0.5 ml) was added dropwise to a solution of (R)-methyl-[1-(4-nitrophenyl)pyrrolidin-3-yl]amine (0.48 g) in pyridine (2 ml). After 3 hours, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with citric acid solution, dried over magnesium sulfate and concentrated. This resulted in the product with the molecular weight of 317.27 (C13H14F3N3O3); MS (ESI): 318 (M+H+).


(R)-Methyl-[1-(4-nitrophenyl)pyrrolidin-3-yl]amine

A solution of tert-butyl (R)-methyl-[1-(4-nitrophenyl)pyrrolidin-3-yl]-carbamate (0.7 g) in dichloromethane (5 ml) was treated with trifluoroacetic acid (3 ml) for 1 hour. The reaction solution was concentrated and the residue was taken up in dichloromethane. After washing with sodium carbonate solution, the organic phase was dried over magnesium sulfate and concentrated. This resulted in the product with the molecular weight of 221.26 (C11H15N3O2); MS (ESI): 222 (M+H+).


Example 20
4-(4-Chlorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}methylamide



embedded image


4-(4-Chlorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}amide was reacted with iodomethane by method F. This resulted in the product with the molecular weight of 469.03 (C26H33ClN4O2); MS (ESI): 469 (M+H+).


Example 21
(R)-4-(4-Chlorophenyl)piperidine-1-carboxylic acid (4-{3-[acetyl-(2-diethylaminoethyl)amino]pyrrolidin-1-yl}phenyl)amide



embedded image


(R)-N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-(2-diethylaminoethyl)acetamide was reacted with 4-(4-chlorophenyl)piperidine by method A. This resulted in the product with the molecular weight of 540.15 (C30H42ClN5O2); MS (ESI): 540 (M+H+).


(R)-N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-(2-diethylaminoethyl)acetamide (R)-N-(2-Diethylaminoethyl)-N-[1-(4-nitrophenyl)pyrrolidin-3-yl]acetamide was hydrogenated by method B. This resulted in the product with the molecular weight of 318.47 (C18H30N4O); MS (ESI): 319 (M+H+).


(R)-N-(2-Diethylaminoethyl)-N-[1-(4-nitrophenyl)pyrrolidin-3-yl]acetamide

(R)-N-[1-(4-nitrophenyl)pyrrolidin-3-yl]acetamide was reacted with 2-chloroethyldiethylamine by method F. This resulted in the product with the molecular weight of 348.45 (C18H28N4O3); MS (ESI): 349 (M+H+).


Example 22
1-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]-3-(4-phenoxyphenyl)urea



embedded image


Dimethylpyrrolidin-3-ylamine was reacted with 4-fluoronitrobenzene, the resulting nitro compound was reduced with hydrogen and finally the aniline was reacted with CDI and 4-phenoxyaniline by method A, B and C. This resulted in the product with the molecular weight of 416.53 (C25H28N4O2); MS (ESI): 417 (M+H+).


Example 23
N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-isobutoxyphenyl)propionamide



embedded image


N-[1-(4-aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 2-(4-isobutoxyphenyl)propionic acid by method E. This resulted in the product with the molecular weight of 437.59 (C26H35N3O3); MS (ESI): 438 (M+H+).


Example 24
N-(1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]phenyl}pyrrolidin-3-yl)acetamide



embedded image


N-Pyrrolidin-3-ylacetamide was reacted with 4-fluoronitrobenzene, the resulting nitro compound was reduced with hydrogen and finally the aniline was reacted with CDI and 4-cyclopentyloxyaniline by method A, B and C. This resulted in the product with the molecular weight of 422.53 (C24H30N4O3); MS (ESI): 423 (M+H+).


(R)- and (S)-N-(1-{4-[3-(4-cyclopentyloxyphenyl)ureido]phenyl}pyrrolidin-3-yl)acetamide were obtained in an analogous manner starting from (R)- and (S)-N-pyrrolidin-3-ylacetamide.


Example 25
N-(1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]phenyl}pyrrolidin-3-yl)-N-ethylacetamide



embedded image


N-Ethyl-N-pyrrolidin-3-ylacetamide was reacted with 4-fluoronitrobenzene, the resulting nitro compound was reduced with hydrogen and finally the aniline was reacted with CDI and 4-cyclopentyloxyaniline by method A, B and C. This resulted in the product with the molecular weight of 450.59 (C26H34N4O3); MS (ESI): 451 (M+H+).


Example 26
4-(4-Chlorophenyl)piperidin-1-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]-3-methylphenyl}amide



embedded image


N-Methyl-N-pyrrolidin-3-ylacetamide was reacted with 1-fluoro-2-methyl-4-nitrobenzene, the resulting nitro compound was reduced with hydrogen and finally the aniline was reacted with CDI and 4-(4-chlorophenyl)piperidine by method A, B and C. This resulted in the product with the molecular weight of 469.03 (C26H33ClN4O2); MS (ESI): 469 (M+H+).


Example 27
4-(4-Chlorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl)-3-fluorophenyl}amide



embedded image


N-Methyl-N-pyrrolidin-3-ylacetamide was reacted with 1,2-difluoro-4-nitrobenzene, the resulting nitro compound was reduced with hydrogen and finally the aniline was reacted with CDI and 4-(4-chlorophenyl)piperidine by method A, B and C. This resulted in the product with the molecular weight of 472.99 (C25H30ClFN4O2); MS (ESI): 473 (M+H+).


Example 28
4-(4-Chlorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]-2,6-difluorophenyl}amide



embedded image


N-Methyl-N-pyrrolidin-3-ylacetamide was reacted with 1,3,5-trifluoro-2-nitrobenzene, the resulting nitro compound was reduced with hydrogen and finally the aniline was reacted with CDI and 4-(4-chlorophenyl)piperidine by method A, B and C. This resulted in the product with the molecular weight of 490.99 (C25H29ClF2N4O2); MS (ESI): 491 (M+H+).


Example 29
4-(4-Chlorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]-2-methylphenyl}amide



embedded image


N-Methyl-N-pyrrolidin-3-ylacetamide was reacted with 4-fluoro-2-methyl-1-nitrobenzene, the resulting nitro compound was reduced with hydrogen and finally the aniline was reacted with CDI and 4-(4-chlorophenyl)piperidine by method A, B and C. This resulted in the product with the molecular weight of 469.03 (C26H33ClN4O2); MS (ESI): 469 (M+H+).


Example 30
4-(4-Chlorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]-2-fluorophenyl}amide



embedded image


N-Methyl-N-pyrrolidin-3-ylacetamide was reacted with 2,4-difluoro-1-nitrobenzene, the resulting nitro compound was reduced with hydrogen and finally the aniline was reacted with CDI and 4-(4-chlorophenyl)piperidine by method A, B and C. This resulted in the product with the molecular weight of 472.99 (C25H30ClFN4O2); MS (ESI): 473 (M+H+).


Example 31
tert-Butyl (R)-[1-(5-{[4-(4-Chlorophenyl)piperidin-1-carbonyl]amino}pyridin-2-yl)pyrrolidin-3yl]methylcarbamate



embedded image


The synthetic sequence for preparing tert-butyl (R)-[1-(4-{[4-(4-chlorophenyl)piperidin-1-carbonyl]amino}phenyl)pyrrolidin-3-yl]methylcarbamate was carried out starting from 2-chloro-5-nitropyridine instead of 4-fluoronitrobenzene. This resulted in the product with the molecular weight of 514.07 (C27H36ClN5O3); MS (ESI): 514 (M+H+).


Example 32
(R)-[4-(4-Chlorophenyl)piperidine-1-carboxylic acid [6-(3-methylamino-pyrrolidin-1-yl)pyridin-3-yl]amide



embedded image


tert-Butyl (R)-[1-(5-{[4-(4-chlorophenyl)piperidine-1-carbonyl]amino}pyridin-2-yl)pyrrolidin-3yl]methylcarbamate was treated with trifluoroacetic acid by method G. This resulted in the product with the molecular weight of 413.95 (C22H28ClN5O); MS (ESI): 414 (M+H+).


It was possible to obtain racemic [4-(4-chlorophenyl)piperidine-1-carboxylic acid [6-(3-methylaminopyrrolidin-yl)pyridin-3-yl]amide in a similar manner.


Example 33
4-(4-Chlorophenyl)piperidine-1-carboxylic acid {6-[3-(acetylmethylamino)-pyrrolidin-1-yl]pyridin-3-yl}amide



embedded image


N-Methyl-N-pyrrolidin-3-ylacetamide was reacted with 2-chloro-5-nitro-pyridine, the resulting nitro compound was reduced with hydrogen and finally the aniline was reacted with CDI and 4-(4-chlorophenyl)piperidine by method A, B and C. This resulted in the product with the molecular weight of 490.99 (C25H29ClF2N4O2); MS (ESI): 491 (M+H+).


Example 34
1-[4-(4-Dimethylaminopiperidin-1-yl)phenyl]-3-(4-phenoxyphenyl)urea



embedded image


Dimethylpiperidin-4-ylamine was reacted with 4-fluoronitrobenzene, the resulting nitro compound was reduced with hydrogen and finally the aniline ([1-(4-aminophenyl)piperidin-4-yl]dimethylamine) was reacted with CDI and 4-phenoxyaniline by method A, B and C. This resulted in the product with the molecular weight of 430.55 (C26H30N4O2); MS (ESI): 431 (M+H+).


Example 35
1-(4-Cyclopentyloxyphenyl)-3-[4-(4-morpholin-4-ylpiperidin-1-yl)phenyl]urea



embedded image


4-Piperidin-4-ylmorpholine was reacted with 4-fluoronitrobenzene, the resulting nitro compound was reduced with hydrogen and finally the aniline was reacted with CDI and 4-cyclopentyloxyaniline by method A, B and C. This resulted in the product with the molecular weight of 464.61 (C27H36N4O3); MS (ESI): 465 (M+H+).


Example 36
4-Butoxy-N-[4-(4-dimethylaminopiperidin-1-yl)phenyl]benzamide



embedded image


([1-(4-Aminophenyl)piperidin-4-yl]dimethylamine) was reacted with 4-4-butoxybenzoic acid by method E. This resulted in the product with the molecular weight of 395.55 (C24H33N3O2); MS (ESI): 396 (M+H+).


Example 37
4-(4-Chlorophenyl)piperidin-1-carboxylic acid {4-[3-(acetylmethylamino)-azetidin-1-yl]phenyl}amide



embedded image


N-[1-(4-aminophenyl)azetidin-3-yl]-N-methylacetamide was reacted with carbonyldiimidazole and 4-(4-chlorophenyl)piperidine by method A. This resulted in the product with the molecular weight of 440.98 (C24H29ClN4O2); MS (ESI): 441 (M+H+).


N-[1-(4-Aminophenyl)azetidin-3-yl]-N-methylacetamide

N-Methyl-N-[1-(4-nitrophenyl)azetidin-3-yl]acetamide was hydrogenated by method B. This resulted in the product with the molecular weight of 219.29 (C12H17N3O); MS (ESI): 220 (M+H+).


N-Methyl-N-[1-(4-nitrophenyl)azetidin-3-yl]acetamide

N-[1-(4-nitrophenyl)azetidin-3-yl]acetamide was alkylated with iodomethane by method F. This resulted in the product with the molecular weight of 249.27 (C12H15N3O3); MS (ESI): 250 (M+H+).


N-[1-(4-Nitrophenyl)azetidin-3-yl]acetamide

Acetic anhydride (0.6 ml) was added to a solution of 1-(4-nitrophenyl)-azetidin-3-ylamine (0.5 g ) in pyridine (1.2 ml). After one hour, volatile fractions were removed. This resulted in the product with the molecular weight of 235.24 (C11H13N3O3); MS (ESI): 236 (M+H+).


1-(4-Nitrophenyl)azetidin-3-ylamine

tert-Butyl [1-(4-nitrophenyl)azetidin-3-yl]carbamate was treated with trifluoroacetic acid by method G. This resulted in the product with the molecular weight of 193.21 (C9H11N3O2); MS (ESI): 194 (M+H+).


tert-Butyl [1-(4-nitrophenyl)azetidin-3-yl]carbamate

tert-Butyl azetidin-3-ylcarbamate was reacted with 4-fluoronitrobenzene by method C. This resulted in the product with the molecular weight of 293.33 (C14H19N3O4); MS (ESI): 294 (M+H+).


Example 38
tert-Butyl [1-(4-{[4-(4-Chlorophenyl)piperidin-1-carbonyl]amino}-phenyl)azetidin-3-yl]methylcarbamate



embedded image


tert-Butyl [1-(4-aminophenyl)azetidin-3-yl]methylcarbamate was reacted with carbonyldiimidazole and 4-(4-chlorophenyl)piperidine by method A. This resulted in the product with the molecular weight of 499.06 (C27H35ClN4O3; MS (ESI): 499 (M+H+).


tert-Butyl [1-(4-aminophenyl)azetidin-3-yl]methylcarbamate

tert-Butyl methyl-[1-(4-nitrophenyl)azetidin-3-yl]carbamate was hydrogenated by method B. This resulted in the product with the molecular weight of 277.37 (C15H23N3O2); MS (ESI): 278 (M+H+).


tert-Butyl methyl-[1-(4-nitrophenyl)azetidin-3-yl]carbamate

tert-Butyl [1-(4-nitrophenyl)azetidin-3-yl]carbamate was alkylated with iodomethane by method F. This resulted in the product with the molecular weight of 307.35 (C15H21N3O4); MS (ESI): 308 (M+H+).


Example 39
4-(4-Chlorophenyl)piperidin-1-carboxylic acid [4-(3-methylaminoazetidin-1-yl)phenyl]amide



embedded image


tert-Butyl [1-(4-{[4-(4-chlorophenyl)piperidin-1-carbonyl]amino}-phenyl)azetidin-3-yl]methylcarbamate was reacted with trifluoroacetic acid by method G. This resulted in the product with the molecular weight of 398.94 (C22H27ClN4O); MS (ESI): 399 (M+H+).


Example 40
N-Methyl-N-[1-(4-{3-[4-(pyridin-3-yloxy)phenyl]ureido}phenyl)pyrrolidin-3-yl]acetamide



embedded image


N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with carbonyldiimidazole and then with 4-(pyridin-3-yloxy)phenylamine by method A. This resulted in the product with the molecular weight of 445.53 (C25H27N5O3); MS (ESI): 446 (M+H+).


Example 41
N-Methyl-N-(1-{4-[3-(4-piperidin-1-ylphenyl)ureido]phenyl}pyrrolidin-3-yl)acetamide



embedded image


N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with carbonyldiimidazole and then with 4-piperidin-1-ylphenylamine by method A. This resulted in the product with the molecular weight of 435.57 (C25H33N5O2); MS (ESI): 436 (M+H+).


Example 42
N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-4-phenoxybenzamide



embedded image


N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 4-phenoxybenzoic acid by method E. This resulted in the product with the molecular weight of 429.52 (C26H27N3O3); MS (ESI): 430 (M+H+).


Example 43
N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-4-butoxybenzamide



embedded image


N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 4-butoxybenzoic acid by method E. This resulted in the product with the molecular weight of 409.53 (C24H31N3O3); MS (ESI): 410 (M+H+).


Example 44
4-(4-Chlorophenyl)cyclohexanecarboxylic acid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}amide



embedded image


N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 4-(4-chlorophenyl)cyclohexanecarboxylic acid by method E. This resulted in the product with the molecular weight of 454.02 (C26H32ClN3O2); MS (ESI): 454 (M+H+).


Example 45
N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-3-(4-isopropylphenyl)-acrylamide



embedded image


N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 3-(4-isopropylphenyl)acrylic acid by method E. This resulted in the product with the molecular weight of 405.54 (C25H31N3O2); MS (ESI): 406 (M+H+).


Example 46
Tetrahydrofuran-2-carboxylic acid (1-{4-[3-(4-cyclopentyloxyphenyl)-ureido]phenyl}pyrrolidin-3-yl)methylamide



embedded image


1-(4-Cyclopentyloxyphenyl)-3-[4-(3-methylaminopyrrolidin-1-yl)phenyl]urea was reacted with tetrahydrofuran-2-carboxylic acid by method E. This resulted in the product with the molecular weight of 492.62 (C28H36N4O4); MS (ESI): 493 (M+H+).


Example 47
1-Acetylpyrrolidin-2-carboxylic acid (1-{4-[3-(4-cyclopentyloxyphenyl)-ureido]phenyl}pyrrolidin-3-yl)methylamide



embedded image


1-(4-Cyclopentyloxyphenyl)-3-[4-(3-methylaminopyrrolidin-1-yl)phenyl]urea was reacted with 1-acetylpyrrolidine-2-carboxylic acid by method E. This resulted in the product with the molecular weight of 533.68 (C30H39N5O4); MS (ESI): 534 (M+H+).


Example 48
5-Oxopyrrolidine-2-carboxylic acid (1-{4-[3-(4-cyclopentyloxyphenyl)-ureido]phenyl}pyrrolidin-3-yl)methylamide



embedded image


1-(4-Cyclopentyloxyphenyl)-3-[4-(3-methylaminopyrrolidin-1-yl)phenyl]urea was reacted with 5-oxo-pyrrolidine-2-carboxylic acid by method E. This resulted in the product with the molecular weight of 505.62 (C28H35N5O4); MS (ESI): 506 (M+H+).


Example 49
2-Oxothiazolidine-4-carboxylic acid (1-{4-[3-(4-cyclopentyloxyphenyl)-ureido]phenyl}pyrrolidin-3-yl)methylamide



embedded image


1-(4-Cyclopentyloxyphenyl)-3-[4-(3-methylaminopyrrolidin-1-yl)phenyl]urea was reacted with 2-oxothiazolidine-4-carboxylic acid by method E. This resulted in the product with the molecular weight of 523.66 (C27H33N5O4S); MS (ESI): 524 (M+H+).


Example 50
(R)-1-Methylpiperidine-3-carboxylic acid {1-[4-(4-cyclohexylbenzoyl-amino)phenyl]pyrrolidin-3-yl}methylamide



embedded image


(R)4-Cyclohexyl-N-[4-(3-methylaminopyrrolidin-1-yl)phenyl]benzamide was reacted with 1-methylpiperidine-3-carboxylic acid by method E. This resulted in the product with the molecular weight of 502.71 (C31H42N4O2); MS (ESI): 503 (M+H+).


Example 51
N-(1-{4-[3-(6-Cyclopentyloxypyridin-3-yl)ureido]phenyl}pyrrolidin-3-yl)-N-methylacetamide



embedded image


N-[1-(4-aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with carbonyldiimidazole and then 6-cyclopentyloxypyridin-3-ylamine by method A. This resulted in the product with the molecular weight of 437.55 (C24H31N5O3); MS (ESI): 438 (M+H+).


6-Cyclopentyloxypyridin-3-ylamine

A mixture of 5-nitropyridin-2-ol (14.0 g), bromocyclopentane (8.0 g), potassium carbonate (14 g) and DMF (200 ml) was heated at 80° C. for 6 hours. After cooling, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with water, dried over magnesium sulfate and concentrated. The residue was purified by chromatography on silica gel. The resulting product (2-cyclopentyloxy-5-nitropyridine) was hydrogenated by method B. This resulted in the product with the molecular weight of 178.24 (C10H14N20); MS (ESI): 179 (M+H+).


Example 52
1-(6-Cyclopentyloxypyridin-3-yl)-3-[4-(3-methylaminopyrrolidin-1-yl)-phenyl]urea



embedded image


N-(1-{4-[3-(6-Cyclopentyloxypyridin-3-yl)ureido]phenyl}pyrrolidin-3-yl)-N-methylacetamide was treated with sodium hydroxide solution by method D. This resulted in the product with the molecular weight of 395.51 (C22H29N5O2); MS (ESI): 395 (M+H+).


Example 53
4′-Fluorobiphenyl-4-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide



embedded image


N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 4′-fluorobiphenyl-4-carboxylic acid by method E. This resulted in the product with the molecular weight of 431.51 (C26H26FN3O2); MS (ESI): 432 (M+H+).


Example 54
4′-Trifluoromethylbiphenyl-4-carboxylic acid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}amide



embedded image


N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 4′-trifluoromethylbiphenyl-4-carboxylic acid by method E. This resulted in the product with the molecular weight of 481.52 (C27H26F3N3O2); MS (ESI): 482 (M+H+).


Examples 55-103

1-(4-Phenoxyphenyl)-3-[4-(3-methylaminopyrrolidin-1-yl)phenyl]urea was reacted with various carboxylic acids by method E. The products are compiled in table 2.


Examples 104-144

1-(4-Cyclopentyloxyphenyl)-3-[4-(3-methylaminopyrrolidin-1-yl)phenyl]urea was reacted with various carboxylic acids by method E. The products are compiled in table 3.


Examples 145-185

N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with various carboxylic acids by method E. The products are compiled in table 4.


Examples 186-234

N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with carbonyldiimidazole and then with various amines by method A. The products are compiled in table 5.














TABLE 2









Molecu-



Ex.


Molecular
lar


No.
Structure
Name
formula
weight
M + H+







55


embedded image


Cyclopropanecarboxylic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl)pyrrolidin-3-yl)amide
C28H30N4O3
470.58
471





56


embedded image


3,N-Dimethyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)butyramide
C29H34N4O3
486.62
487





57


embedded image


2,N-Dimethyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)butyramide
C29H34N4O3
486.62
487





58


embedded image


N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)benzamide
C31H30N4O3
506.61
507





59


embedded image


(E)-N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)-3-phenylacrylamide
C33H32N4O3
532.65
533





60


embedded image


2-Cyclopentyl-N-methyl-N-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)acetamide
C31H36N4O3
512.66
513





61


embedded image


Cyclohexanecarboxylic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C31H36N4O3
512.66
513





62


embedded image


N-Methyl-2-methylsulfanyl-N-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenylpyrrolidin-3-yl)acetamide
C27H30N4O3S
490.63
491





63


embedded image


N-Methoxy-N-methyl-N-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenylpyrrolidin-3-yl)acetamide
C27H30N4O4
474.56
475





64


embedded image


2-Oxothiazolidine-4-carboxylicacid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C28H29N5O4S
531.64
532





65


embedded image


4-Fluoro-N-methyl-N-(1-{4-[3-(4-phenoxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)benzamide
C31H29FN4O3
524.60
525





66


embedded image


Pyridine-2-carboxylic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C30H29N5O3
507.60
508





67


embedded image


2-Acetylamino-N-methyl-N-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)acetamide
C28H31N5O4
501.59
502





68


embedded image


2,2,3,3-Tetramethylcyclopropanecarboxylic acidmethyl-(1-{4-[3-(4-phenoxyphenyl)ureido]phenyl}-pyr-rolidin-3-yl)amide
C32H38N4O3
526.68
527





69


embedded image


3,5-Dimethylisoxazole-4-carboxylicacid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C30H31N5O4
525.61
526





70


embedded image


2-Ethoxy-N-methyl-N-(1-{4-[3-(4-phenoxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)acetamide
C28H32N4O4
488.59
489





71


embedded image


3-Methoxy-N-methyl-N-(1-{4-[3-(4-phenoxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)propionamide
C28H32N4O4
488.59
489





72


embedded image


2,2,N-Trimethyl-N-(1-{4-[3-(4-phenoxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)butyramide
C30H36N4O3
500.65
501





73


embedded image


1-Methylcyclopropanecarboxylic acidmethyl-(1-{4-[3-(4-phenoxyphenyl)ureido]phenyl}-pyr-rolidin-3-yl)amide
C29H32N4O3
484.60
485





74


embedded image


Cyclobutanecarboxylic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C29H32N4O3
484.60
485





75


embedded image


N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)isonicotinamide
C30H29N5O3
507.60
508





76


embedded image


Pyrazine-2-carboxylic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C29H28N6O3
508.58
509





77


embedded image


5-Oxopyrrolidine-2-carboxylic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C29H31N5O4
513.60
514





78


embedded image


Thiophene-2-carboxylic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C29H28N4O3S
512.64
513





79


embedded image


Furan-3-carboxylic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C29H28N4O4
496.57
497





80


embedded image


N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)nicotinamide
C30H29N5O3
507.60
508





81


embedded image


4-Cyano-N-methyl-(1-{4-[3-(4-phenoxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)benzamide
C32H29N5O3
531.62
532





82


embedded image


1-Methyl-1H-pyrrole-2-carboxylicacid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C30H31N5O3
509.61
510





83


embedded image


3-Cyclopentyl-N-methyl-N-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)propionamide
C32H38N4O3
526.68
527





84


embedded image


N,N,N′-Trimethyl-N′-(1-{4-[3-(4-phenoxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)succinamide
C30H35N5O4
529.64
530





85


embedded image


3-Phenylpropynoic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C33H30N4O3
530.63
531





86


embedded image


(1R,4S)-Bicyclo[2.2.1]heptane-2-carboxylic acidmethyl-(1-{4-[3-(4-phenoxyphenyl)ureido]phenyl}-pyr-rolidin-3-yl)amide
C32H36N4O3
524.67
525





87


embedded image


[1,2,3]Thiadiazol-4-carboxylic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C27H26N6O3S
514.61
515





88


embedded image


Isoxazole-5-carboxylic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C28H27N5O4
497.56
498





89


embedded image


2,N-Dimethyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)benzamide
C32H32N4O3
520.64
521





90


embedded image


2-Methanesulfonyl-N-methyl-N-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)-aceta-mide
C27H30N4O5S
522.63
523





91


embedded image


(E)-N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)-3-pyridin-3-ylacrylamide
C32H31N5O3
533.64
534





92


embedded image


4,4,4-Trifluoro-N-methyl-N-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)butyramide
C28H29F3N4O3
526.56
527





93


embedded image


2-Dimethylamino-N-methyl-N-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)acetamide
C28H33N5O3
487.61
488





94


embedded image


3-Acetylamino-N-methyl-N-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)propionamide
C29H33N5O4
515.62
516





95


embedded image


Tetrahydrofuran-2-carboxylic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)-amide
C29H32N4O4
500.60
501





96


embedded image


N-Methyl-2-(3-methylisoxazol-5-yl)-N-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)-ace-tamide
C30H31N5O4
525.61
526





97


embedded image


(S)-1-Acetylpyrrolidine-2-carboxylicacid methyl-(1-{4-[3-(4-phe-noxyphenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C31H35N5O4
541.66
542





98


embedded image


4-Methyl-[1,2,3]thiadiazole-5-carboxylic acidmethyl-(1-{4-[3-(4-phenoxyphenyl)ureido]-phe-nyl}pyrrolidine-3-yl)amide
C28H28N6O3S
528.64
529





99


embedded image


1,5-Dimethyl-1H-pyrazole-3-carboxylic acidmethyl-(1-{4-[3-(4-phenoxyphenyl)ureido]phenyl}-pyr-rolidin-3-yl)amide
C30H32N6O3
524.63
525





100


embedded image


5-Methylhexanoic acid methyl-(1-{4-[3-(4-phenoxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)amide
C31H38N4O3
514.67
515





101


embedded image


Tetrahydropyran-4-carboxylic acid methyl-(1-{4-[3-(4-phe-noxyphenyl)ureido]phenyl}pyrrolidin-3-yl)-amide
C30H34N4O4
514.63
515





102


embedded image


N-Methyl-N-(1-{4-[3-(4-phenoxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)-2-piperi-din-1ylacetamide
C31H37N5O3
527.67
528





103


embedded image


1,3-Dimethyl-1H-pyrazole-4-carboxylic acidmethyl-(1-{4-[3-(4-phenoxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)amide
C30H32N6O3
524.63
525





















TABLE 3









Molecu-



Ex.


Molecular
lar


No.
Structure
Name
formula
weight
M + H+







104


embedded image


Benzyl(S)-5-[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylcarbamoyl]-2-oxo-imidazolidine-1-carboxylate
C35H40N6O6
640.75
641





105


embedded image


Benzyl(R)-2-[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylcarbamoyl]-pyr-rolidine-1-carboxylate
C36H43N5O5
625.77
626





106


embedded image


N-(1-{4-[3-(4-cyclopentyloxyphenyl)ureido]-phe-nyl]pyrrolidin-3-yl)-3-dimethylamino-N-methyl-benzamide
C32H39N5O3
541.70
542





107


embedded image


Benzyl(S)-2-[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylcarbamoyl]-5-oxo-pyrrolidine-1-carboxylate
C36H41N5O6
639.76
640





108


embedded image


tert-Butyl 3-[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methyl-carbamoyl]piperidine-1-carboxylate
C34H47N5O5
605.78
606





109


embedded image


Benzyl 5-[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylcarbamoyl]-2-oxo-imidazolidine-1-carboxylate
C35H40N6O6
640.75
641





110


embedded image


1-Methylpiperidine-3-carboxylicacid (1-{4-[3-(4-cyclo-pentyloxyphenyl)ureido]phenyl}pyr-rolidin-3-yl)methyl-amide
C30H41N5O3
519.69
520





111


embedded image


2,6-Dioxohexahydropyrimidine-4-carboxylic acid(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylamide
C28H34N6O5
534.62
535





112


embedded image


2-Methyl-5-oxopyrrolidine-2-carboxylicacid (1-{4-[3-(4-cyclo-pentyloxyphenyl)ureido]phenyl}-pyr-rolidin-3-yl)methylamide
C29H37N5O4
519.65
520





113


embedded image


tert-Butyl 4-[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylcarbamoyl]-thia-zolidine-3-carboxylate
C32H43N5O5S
609.79
610





114


embedded image


Benzyl(2S,4R)-4-tert-butoxy-2-[(1-{4-[3-(4-cyclo-pentyloxyphenyl)ureido]phenyl}pyr-rolidin-3-yl)methyl-carbamoyl]pyrrolidine-1-carboxylate
C40H51N5O6
697.88
698





115


embedded image


N-(1-{4-[3-(4-Cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)-3-(2,5-di-oxopyrrolidin-1-yl)-N-methyl-5-tri-fluoromethylbenzamide
C35H36F3N5O5
663.70
664





116


embedded image


tert-Butyl-2-[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylcarbamoyl]-mor-pholine-4-carboxylate
C33H45N5O6
607.76
608





117


embedded image


(R)-1-(Toluene-4-sulfonyl)pyrrolidine-2-carboxylicacid(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylamide
C35H43N5O5S
645.83
646





118


embedded image


{(3aS,6aS)-2-[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylcarbamoyl]-hexa-hydrocyclopenta[b]pyrrol-1-yl}oxoacetic acidmethyl ester
C34H43N5O6
617.75
618





119


embedded image


(S)-1-(2,2,2,-Trifluoroacetyl)pyrrolidine-2-carboxylicacid(1-{4-[3-(4-cyclopentyloxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)methylamide
C30H36F3N5O4
587.65
588





120


embedded image


2-Chloro-N-{[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methyl-carbamoyl]-methyl}benzamide
C32H36ClN5O4
590.13
590





121


embedded image


N-{1-[(1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)methylcarbamoyl]ethyl}-4-methyl-benzamide
C34H41N5O4
583.74
584





122


embedded image


N-{[(1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)methylcarbamoyl]methyl}-3,3-di-methylbutyramide
C31H43N5O4
549.72
550





123


embedded image


N-(1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)-2-(1H-imidazol-4-yl)-N-methyl-acetamide
C28H34N6O3
502.62
503





124


embedded image


Benzyl 3-[(1-(4-[3-(4-cyclo-pentyloxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)methylcarbamoyl]piperidine-1-car-boxylate
C37H45N5O5
639.80
640





125


embedded image


1-(Furan-2-carbonyl)piperidine-3-carboxylic acid(1-{4-[3-(4-cyclopentyloxyphenyl)ureido]phenyl}-pyr-rolidin-3-yl)methylamide
C34H41N5O5
599.74
600





126


embedded image


(E)-N-(1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)-N-methyl-3-pyridin-2-yl-acryl-amide
C31H35N5O3
525.66
526





127


embedded image


(E)-N-(1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)-N-methyl-3-pyridin-4-yl-acryl-amide
C31H35N5O3
525.66
526





128


embedded image


N-(1-{4-[3-(4-Cyclopentyl-oxyphenyl)ureido]phenyl}-pyr-rolidin-3-yl)-N-methyl-2-pyridin-3-ylacetamide
C30H35N5O3
513.65
514





129


embedded image


4-Methyl-3-oxo-3,4-dihy-dro-2H-benzo[1,4]thiazine-6-car-boxylic acid(1-{4-[3-(4-cyclopentyloxy-phenyl)ureido]phenyl}pyrrolidin-3-yl)methylamide
C33H37N5O4S
599.76
600





130


embedded image


Benzyl 2-[(1-{4-[3-(4-cyclo-pentyloxyphenyl)ureido]-phe-nyl}pyrrolidin-3-yl)methylcarbamoyl]piperidin-1-car-boxylate
C37H45N5O5
639.80
640





131


embedded image


Benzyl(S)-2-[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylcarbamoyl]-pipe-ridin-1-carboxylate
C36H43N5O5
625.77
626





132


embedded image


(R)-1-Acetylpyrrolidine-2-carboxylicacid(1-{4-[3-(4-cyclo-pentyloxyphenyl)ureido]phenyl}pyr-rolidin-3-yl)methyl-amide
C30H39N5O4
533.68
534





133


embedded image


(S)-1-((E)-3-Furan-2-ylacryloyl)pyrrolidine-2-car-boxylic acid(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylamide
C35H41N5O5
611.75
612





134


embedded image


1-(2,2-Dimethylpropionyl)pyrrolidine-2-carboxylicacid(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylamide
C33H45N5O4
575.76
576





135


embedded image


(trans)-1-Methyl-5-oxo-2-py-ridin-3-ylpyrrolidine-3-car-boxylic acid(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylamide
C34H40N6O4
596.74
597





136


embedded image


(S)-1-Benzylpyrrolidine-2-carboxylicacid (1-{4-[3-(4-cyclo-pentyloxyphenyl)ureido]phenyl}pyr-rolidin-3-yl)methyl-amide
C35H43N5O3
581.76
582





137


embedded image


Isobutyl 2-[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylcarbamoyl]-pyr-rolidine-1-carboxylate
C33H45N5O5
591.76
592





138


embedded image


Allyl (S)-2-[(1-{4-[3-(4-cyclopentyloxyphenyl)-urei-do]phenyl}pyrrolidin-3-yl)methylcarbamoyl]-pyr-rolidine-1-carboxylate
C32H41N5O5
575.71
576





139


embedded image


2-Oxoimidazolidine-4-carboxylicacid(1-{4-[3-(4-cyclo-pentyloxyphenyl)ureido]phenyl}pyrrolidin-3-yl)meth-ylamide
C27H34N6O4
506.61
507





140


embedded image


(R)-5-Oxopyrrolidine-2-carboxylicacid(1-{4-[3-(4-cyclo-pentyloxyphenyl)ureido]phenyl}pyrrolidin-3-yl)meth-ylamide
C28H35N5O4
505.62
506





141


embedded image


1-Methyl-5-oxopyrrolidine-3-carboxylicacid(1-{4-[3-(4-cyclo-pentyloxyphenyl)ureido]phenyl}-pyr-rolidin-3-yl)methylamide
C29H37N5O4
519.65
520





142


embedded image


1-Benzyl-5-oxopyrrolidine-3-carboxylicacid(1-{4-[3-(4-cyclo-pentyloxyphenyl)ureido]phenyl}-pyr-rolidine-3-yl)methylamide
C35H41N5O4
595.75
596





143


embedded image


5-Oxo-1-phenylpyrrolidine-3-carboxylicacid(1-{4-[3-(4-cyclo-pentyloxyphenyl)ureido]phenyl}-pyr-rolidin-3-yl)methylamide
C34H39N5O4
581.72
582





144


embedded image


5-Oxo-1-p-tolylpyrrolidine-3-carboxylicacid(1-{4-[3-(4-cyclopentyloxy-phenyl)ureido]phenyl}-pyr-rolidin-3-yl)methylamide
C35H41N5O4
595.75
596





















TABLE 4





Ex. No.
Structure
Name
Molecular formula
Molecular weight
M + H+




















145


embedded image


(E)-N-{4-[3-(Acetylmethylamin-o)pyrrolidin-1-yl]-phenyl}-3-(5,6-dimethylbenzooxazol-2-yl)-a-crylamide
C25H28N4O3
432.53
433





146


embedded image


4′-Ethylbiphenyl-4-carboxylicacid {4-[3-(acetyl-methylamino)-pyrrolidin-1-yl]phenyl}amide
C28H31N3O2
441.58
442





147


embedded image


4′-Propylbiphenyl-4-carboxylicacid {4-[3-(acetyl-methylamino)-pyrrolidin-1-yl]phenyl}amide
C29H33N3O2
455.61
456





148


embedded image


2′-Fluorobiphenyl-4-carboxylicacid {4-[3-(acetyl-methylamino)-pyrrolidin-1-yl]phenyl}amide
C26H26FN3O2
431.51
432





149


embedded image


4′-Cyanobiphenyl-4-carboxylicacid {4-[3-(acetyl-methylamino)-pyrrolidin-1-yl]phenyl}amide
C27H26N4O2
438.53
439





150


embedded image


4′-Bromobiphenyl-4-carboxylicacid {4-[3-(acetyl-methylamino)-pyrrolidin-1-yl]phenyl}amide
C26H26BrN3O2
492.42
492





151


embedded image


4′-Ethoxybiphenyl-4-carboxylicacid {4-[3-(acetyl-methylamino)-pyrrolidin-1-yl]phenyl}amide
C28H31N3O3
457.58
458





152


embedded image


3′,4′-Dichlorobiphenyl-4-car-boxylic acid {4-[3-(acetylme-thylamino)pyrrolidin-1-yl]-phenyl}amide
C26H25Cl2N3O2
482.41
482





153


embedded image


2-Ethylbiphenyl-4-carboxylicacid {4-[3-(acetyl-methylamino)-pyrrolidin-1-yl]phenyl}amide
C28H31N3O2
441.58
442





154


embedded image


N-{4-[3-(Acetylmethyla-mino)pyrrolidin-1-yl]phenyl}-4-benzenesulfonylbenzamide
C26H27N3O4S
477.59
478





155


embedded image


N-{4-[3-(Acetylmethyla-mino)pyrrolidin-1-yl]phenyl}-4-cyclopentyloxybenzamide
C25H31N3O3
421.54
422





156


embedded image


N-{4-[3-(Acetylmethyla-mino)pyrrolidin-1-yl]phenyl}-4-(4-chlorophenoxy)-3-nitro-benzamide
C26H25ClN4O5
508.97
509





157


embedded image


N-{4-[3-(Acetylmethyla-mino)pyrrolidin-1-yl]phenyl}-4-(4-fluorophenoxy)benzamide
C26H26FN3O3
447.51
448





158


embedded image


N-{4-[3-(Acetylmethyla-mino)pyrrolidin-1-yl]phenyl}-4-(4-chlorophenoxy)benzamide
C26H26ClN3O3
463.97
464





159


embedded image


N-{4-[3-(Acetylmethyla-mino)pyrrolidin-1-yl]phenyl}-4-cyclohexylbenzamide
C26H33N3O2
419.57
420





160


embedded image


1-(4-Nitrophenyl)piperidine-4-carboxylic acid {4-[3-(acetylmethylamino)pyrro-lidin-1-yl]phenyl}amide
C25H31N5O4
465.56
466





161


embedded image


N-{4-[3-(Acetylmethyla-mino)pyrrolidin-1-yl]phenyl}-3-phenoxybenzamide
C26H27N3O3
429.52
430





162


embedded image


N-{4-[3-(Acetylmethyla-mino)pyrrolidin-1-yl]phenyl}-4-propoxybenzamide
C23H29N3O3
395.51
396





163


embedded image


N-{4-[3-(Acetylmethyla-mino)pyrrolidin-1-yl]phenyl}-4-(cyclohex-2-enyloxy)-benzamide
C26H31N3O3
433.56
434





164


embedded image


N-{4-[3-(Acetylmethyla-mino)pyrrolidin-1-yl]phenyl}-4-(3-methylbutoxy)benzamide
C25H33N3O3
423.56
424





165


embedded image


N-{4-[3-(Acetylmethyla-mino)pyrrolidin-1-yl]phenyl}-4-isobutoxybenzamide
C24H31N3O3
409.53
410





166


embedded image


5-(4-Chlorophenyl)furan-2-carboxylic acid {4-[3-(ace-tylmethylamino)pyrrolidin-1-yl]phenyl}amide
C24H24ClN3O3
437.93
438





167


embedded image


5-(4-Methoxyphenyl)thiophene-2-carboxylic acid {4-[3-(ace-tylmethylamino)pyrrolidin-1-yl]-phenyl}amide
C25H27N3O3S
449.58
450





168


embedded image


5-(4-Chloro-2-nitrophenyl)-furan-2-carboxylic acid {4-[3-(acetylmethylamino)pyrroli-din-1-yl]phenyl}amide
C24H23ClN4O5
482.93
483





169


embedded image


5-(4-Methyl-2-nitrophenyl)furan-2-carboxylic acid {4-[3-(acetylmethylamino)pyrroli-din-1-yl]phenyl}-amide
C25H26N4O5
462.51
463





170


embedded image


5-(4-Fluorophenyl)thiophene-2-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}-amide
C24H24FN3O2S
437.54
438





171


embedded image


5-(2,4-Dichlorophenyl)furan-2-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide
C24H23Cl2N3O3
472.38
472





172


embedded image


4-Methyl-2-(4-trifluoromethyl-phenyl)thiazole-5-carboxylicacid{ 4-[ 3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}amide
C25H25F3N4O2S
502.56
503





173


embedded image


2-(4-Chlorophenyl)-4-methyl-thiazole-5-carboxylic acid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}amide
C24H25ClN4O2S
469.01
469





174


embedded image


5-Benzyloxy-1H-indole-2-carboxylic acid {4-[3-(acetylmethylamino)pyr-rolidin-1-yl]phenyl}amide
C29H30N4O3
482.59
483





175


embedded image


N-{4-[3-(Acetylmethylamino)-pyrrolidin-1-yl]phenyl}-4-benzyloxybenzamide
C27H29N3O3
443.55
444





176


embedded image


5-Phenylethynylfuran-2-carboxylic acid {4-[3-(acetylmethylamino)pyr-rolidin-1-yl]phenyl}amide
C26H25N3O3
427.51
428





177


embedded image


N-{4-[3-(Acetylmethylamino)-pyrrolidin-1-yl]phenyl}-2-biphenyl-4-ylacetamide
C27H29N3O2
427.55
428





178


embedded image


N-{4-[3-(Acetylmethylamino)-pyrrolidin-1-yl]phenyl}-2-(4-butoxyphenyl)acetamide
C25H33N3O3
423.56
424





179


embedded image


N-{4-[3-(Acetylmethylamino)-pyrrolidin-1-yl]phenyl}-2-(4-benzyloxyphenyl)acetamide
C28H31N3O3
457.58
458





180


embedded image


N-{4-[3-(Acetylmethylamino)-pyrrolidin-1-yl]phenyl}-2-(4-phenoxyphenyl)acetamide
C27H29N3O3
443.55
444





181


embedded image


N-{4-[3-(Acetylmethylamino)-pyrrolidin-1-yl]phenyl}-2-(4-benzyloxy-3-methoxy-phenyl)acetamide
C29H33N3O4
487.60
488





182


embedded image


N-{4-[3-(Acetylmethylamino)-pyrrolidin-1-yl]phenyl}-2-(4′-fluorobiphenyl-4-yl)acetamide
C27H28FN3O2
445.54
446





183


embedded image


N-{4-[3-(Acetylmethylamino)-pyrrolidin-1-yl]phenyl}-2-[4-(2,5-dimethylpyrrol-1-yl)phenyl]acetamide
C27H32N4O2
444.58
445





184


embedded image


N-{4-[3-(Acetylmethylamino)-pyrrolidin-1-yl]phenyl}-2-(4-isopropylphenoxy)-acetamide
C24H31N3O3
409.53
410





185


embedded image


N-{4-[3-(Acetylmethylamino)-pyrrolidin-1-yl]phenyl}-2-(4-ethylphenoxy)acetamide
C23H29N3O3
395.51
396





















TABLE 5





Ex. No.
Structure
Name
Molecular formula
Molecular weight
M + H+




















186


embedded image


N-Methyl-N-(1-{4-[3-(6-phe-noxypyridin-3-yl)ureido]phenyl}-pyrrolidin-3-yl)acetamide
C25H27N5O3
445.53
446





187


embedded image


N-[1-(4-{3-[4-(2-Chlorophe-noxy)phenyl]ureido}-phenyl)-pyrrolidin-3-yl]-N-methyl-acetamide
C26H27ClN4O3
478.98
479





188


embedded image


N-[1-(4-{3-[4-(3-Chlorophe-noxy)phenyl]ureido}-phenyl)-pyrrolidin-3-yl]-N-methyl-acetamide
C26H27ClN4O3
478.98
479





189


embedded image


N-Methyl-N-[1-{4-[3-(4-o-tolyloxyphenyl)ureido}-phenyl)-pyrrolidin-3-yl)acetamide
C27H30N4O3
458.57
459





190


embedded image


N-Methyl-N-[1-{4-[3-(4-m-tolyloxyphenyl)ureido}-phenyl)-pyrrolidin-3-yl)acetamide
C27H30N4O3
458.57
459





191


embedded image


N-[1-{4-{3-[4-(2-Fluorophen-oxy)phenyl)ureido}-phenyl)-pyrrolidin-3-yl)-N-methyl-acetamide
C26H27FN4O3
462.53
463





192


embedded image


N-{1-{4-[3-Biphenyl-4-yl-ureido}phenyl]pyrrolidin-3-yl}-N-methylacetamide
C26H28N4O2
428.54
429





193


embedded image


N-[1-(4-{3-[4-(2-Methoxyphe-noxy)phenyl]ureido}-phenyl)-pyrrolidin-3-yl]methyl-acetamide
C27H30N4O4
474.56
475





194


embedded image


N-(1-{4-[3-(4-Isobutoxyphenyl)-ureido}phenyl)pyrrolidin-3-yl]-N-methylacetamide
C24H32N4O3
424.55
425





195


embedded image


N-(1-{4-[3-(4-Cyclopentyloxy-phenyl)ureido}phenyl)pyrro-lidin-3-yl]-N-methylacet-amide
C25H32N4O3
436.56
437





196


embedded image


N-[1-(4-{3-[4-(4-Fluorophe-noxy)phenyl]ureido}-phenyl)-pyrrolidin-3-yl]-N-methyl-acetamide
C26H27FN4O3
462.53
463





197


embedded image


N-[1-(4-{3-[4-(3-Methoxyphe-noxy)phenyl]ureido}-phenyl)-pyrrolidin-3-yl]-N-methyl-acetamide
C27H30N4O4
474.56
475





198


embedded image


4-(3-Acetylaminophenyl)piperi-dine-1-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]-phenylamide
C27H35N5O3
477.61
478





199


embedded image


N-Methyl-N-(1-{4-[3-(5-phenyl-pyridin-2-yl)ureido]-phenyl}-pyrrolidin-3-yl)acetamide
C25H27N5O2
429.53
430





200


embedded image


N-(1-{4-[3-(2-Acetylamino-4-phenylsulfanylphenyl)-ureido]phenyl}pyrrolidin-3-yl)-N-methylacetamide
C28H31N5O3S
517.65
518





201


embedded image


N-(1-{4-[3-(4′-Cyanobiphenyl-4-yl)ureido]phenyl}pyrrolidin-3-yl)-N-methylacetamide
C27H27N5O2
453.55
454





202


embedded image


N-(1-{4-[3-(2-Methoxybiphenyl-4-yl)ureido]phenyl}pyrrolidin-3-yl)-N-methylacetamide
C27H30N4O3
458.57
459





203


embedded image


4-(2-Chlorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)pyr-rolidin-1-yl]phenyl}amide
C25H31ClN4O2
455.00
455





204


embedded image


N-(1-{4-[3-(4-Benzene-sulfonyl-3-chlorophenyl)-ureido]phenyl}pyrrolidin-3-yl)-N-methylacetamide
C26H27ClN4O4S
527.05
527





205


embedded image


4-(4-Chlorophenyl)-4-hydroxy-piperidine-1-carboxylicacid {4-[3-(acetylmethyl-amino)pyrrolidin-1-yl]phenyl}amide
C25H31ClN4O3
471.00
471





206


embedded image


4-Phenylpiperidine-1-carboxylicacid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}amide
C25H32N4O2
420.56
421





207


embedded image


4-Cyano-4-phenylpiperidine-1-carboxylic acid {4-[3-(acetylmethylamino)pyrro-lidin-1-yl]phenyl}amide
C26H31N5O2
445.57
446





208


embedded image


4-Acetyl-4-phenylpiperidine-1-carboxylic acid {4-[3-(acetylmethylamino)pyrro-lidin-1-yl]phenyl}amide
C27H34N4O3
462.60
463





209


embedded image


4-(2-Methoxyphenyl)piperidine-1-carboxylic acid {4-[3-(acetyl-methylamino)pyrrolidin-1-yl]-phenyl}amide
C26H34N4O3
450.59
451





210


embedded image


4-(4-Fluorophenyl)piperidine-1-carboxylic acid {4-[3-(acetyl-methylamino)pyrrolidin-1-yl]-phenyl}amide
C25H31FN4O2
438.55
439





211


embedded image


4-(3-Fluorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)pyrro-lidin-1-yl]phenyl}amide
C25H31FN4O2
438.55
439





212


embedded image


4-(2-Fluorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)pyrro-lidin-1-yl]phenyl}amide
C25H31FN4O2
438.55
439





213


embedded image


4-p-Tolylpiperidine-1-carboxylicacid {4-[3-(acetyl-methylamino)-pyrrolidin-1-yl]phenyl}amide
C26H34N4O2
434.59
435





214


embedded image


4-(4-Trifluoromethylphenyl)pi-peridine-1-carboxylic acid{4-[3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}-amide
C26H31F3N4O2
488.56
489





215


embedded image


4-(3-Trifluoromethylphenyl)pi-peridine-1-carboxylic acid{4-[3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}-amide
C26H31F3N4O2
488.56
489





216


embedded image


4-(2-Trifluoromethylphenyl)pi-peridine-1-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide
C26H31F3N4O2
488.56
489





217


embedded image


4-(4-Methoxyphenyl)piperidine-1-carboxylic acid {4-[3-(acetyl-methylamino)pyrrolidin-1-yl]-phenyl}-amide
C26H34N4O3
450.59
451





218


embedded image


4-(3-Methoxyphenyl)piperidine-1-carboxylic acid {4-[3-(acetyl-methylamino)pyrrolidin-1-yl]-phenyl}-amide
C26H34N4O3
450.59
451





219


embedded image


4-Naphthalen-2-ylpiperidine-1-carboxylic acid {4-[3-(acetyl-methylamino)pyrrolidin-1-yl]-phenyl}amide
C29H34N4O2
470.62
471





220


embedded image


Benzo[c]-1-oxa-8-aza-spiro-[4,5]decane-8-car {4-[3-(acetyl-methylamino)pyrrolidin-1-yl]-phenyl}amide
C26H32N4O3
448.57
449





221


embedded image


N-(1-{4-[3-(9-Ethyl-9H-carbazol-3-yl)ureido]-phenyl}-pyrrolidin-3-yl)-N-methyl-acetamide
C28H31N5O2
469.59
470





222


embedded image


N-(1-(4-{3-[4-(4-Chloro-phenoxy)phenyl]ureido}-phenyl)pyrrolidin-3-yl)-N-methylacetamide
C26H27ClN4O3
478.98
479





223


embedded image


N-(1-{4-[3-(4-Benzylphenyl)-ureido]phenyl}-pyrrolidin-3-yl)-N-methylacetamide
C27H30N4O2
442.57
443





224


embedded image


N-Methyl-N-(1-{4-[3-(4-Pyri-din-4-ylmethylphenyl)-ureido]-phenyl}pyrrolidin-3-yl)aceta-mide
C28H30F3N5O4
443.55
444





225


embedded image


N-[1-(4-{3-[6-(2-Fluorophe-noxy)pyridin-3-yl]ureido}-phenyl}pyrrolidin-3-yl)-N-methylacetamide
C25H26FN5O3
463.52
464





226


embedded image


N-Methyl-N-(1-{4-[3-(4-phenyl-sulfanylphenyl)-ureido]phenyl}-pyrrolidin-3-yl)acetamide
C26H28N4O2S
460.60
461





227


embedded image


N-Methyl-N-[1-(4-{3-[4-(3-tri-fluoromethylphenoxy)-phenyl]-ureido}phenyl)pyrrolidin-3-yl]-acetamide
C27H27F3N4O3
512.54
513





228


embedded image


N-Methyl-N-[1-(4-{3-[6-(pyridin-2-ylsulfanyl)pyridin-3-yl]ureido}phenyl)pyrrolidin-3-yl]acetamide
C26H27F3N6O4S
462.58
463





229


embedded image


N-(1-{4-[3-(4-Butoxyphenyl)-ureido]phenyl}-pyrrolidin-3-yl)-N-methylacetamide
C24H32N4O3
424.55
425





230


embedded image


4-Benzylpiperidine-1-carboxylicacid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}amide
C26H34N4O2
434.59
435





231


embedded image


Benzo-8-azaspiro[4.5]decane-8-carboxylic acid {4-[3-(acetyl-methylamino)pyrrolidin-1-yl]-phenyl}amide
C27H34N4O2
446.60
447





232


embedded image


4-Benzofuran-3-ylpiperidine-1-carboxylic acid {4-[3-(acetyl-methylamino)pyrrolidin-1-yl]-phenyl}amide
C27H32N4O3
460.58
461





233


embedded image


4-p-Tolyloxypiperidine-1-car-boxylic acid {4-[3-(acetyl-methylamino)pyrrolidin-1-yl]-phenyl}amide
C26H34N4O3
450.59
451





234


embedded image


4-(2-Chlorophenoxy)piperidine-1-carboxylic acid {4-[3-(acetyl-methylamino)pyrrolidin-1-yl]phenyl}-amide
C25H31ClN4O3
471.00
471









Example 235
N-(1-{4-[3-(4-Cyclopentyloxyphenyl)ureido]phenyl}pyrrolidin-3-yl)-N-methyl-2-piperidin-1-yl-acetamide



embedded image


1-(4-Cyclopentyloxyphenyl)-3-[4-(3-methylaminopyrrolidin-1-yl)phenyl]urea was reacted with piperidin-1-ylacetic acid by method E. This resulted in the product with the molecular weight of 519.69 (C30H41N5O3); MS (ESI): 520 (M+H+).


Example 236
1-Methylpiperidine-3-carboxylic acid {(R)-1-[5-(4-cyclohexylbenzoylamino)pyridin-2-yl]pyrrolidin-3-yl}methylamide



embedded image


(R)-4-Cyclohexyl-N-[6-(3-methylaminopyrrolidin-1-yl)pyridin-3-yl]benzamide was reacted with 1-methylpiperidin-3-carboxylic acid by method E. This resulted in the product with the molecular weight of 503.69 (C30H41N5O2); MS (ESI): 504 (M+H+).


Example 237
N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-butoxyphenyl)propionamide



embedded image



Method H


Caesium carbonate (36 mg) and n-butyl bromide (15 mg) were added to a solution of N-{4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-hydroxyphenyl)propionamide (27 mg) in DMF (1 ml). After a reaction time of 2 hours at room temperature, water was added to the mixture, and it was extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated, and the residue was crystallized from diethyl ether/methanol. This resulted in the product with the molecular weight of 437.59 (C26H35N3O3); MS (ESI): 438 (M+H+).


N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-hydroxyphenyl)propionamide

N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 2-(4-hydroxyphenyl)propionic acid by method I. This resulted in the product with the molecular weight of 381.48 (C22H27N3O3); MS (ESI): 382 (M+H+).


Example 238
N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-isobutoxyphenyl)acetamide



embedded image


N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-hydroxyphenyl)acetamide was reacted with isobutyl bromide by method H. This resulted in the product with the molecular weight of 423.56 (C25H33N3O3); MS (ESI): 424 (M+H+).


N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-hydroxyphenyl)acetamide

Method I


4-Hydroxyphenylacetic acid (305 mg), 1-hydroxybenzotriazole (300 mg) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (480 mg) in DMF (5 ml) were stirred with N-[1-(4-aminophenyl)pyrrolidin-3-yl]-N-methylacetamide (470 mg) at room temperature for 3 hours. Water was then added to the mixture, which was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried over sodium sulfate, concentrated and crystallized from diethyl ether. This resulted in the product with the molecular weight of 367.45 (C21H25N3O3); MS (ESI): 368 (M+H+).


Example 239
(R)-N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-butoxyphenyl)acetamide



embedded image


(R)-N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 4-butoxyphenylacetic acid by method E. This resulted in the product with the molecular weight of 423.56 (C25H33N3O3); MS (ESI): 424 (M+H+).


Example 240
N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-cyclopropylmethoxyphenyl)propionamide



embedded image


N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-hydroxyphenyl)propionamide was reacted with bromomethylcyclopropane by method H. This resulted in the product with the molecular weight of 435.57 (C26H33N3O3); MS (ESI): 436 (M+H+).


Example 241
N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-cyclobutylmethoxyphenyl)propionamide



embedded image


N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-(4-hydroxyphenyl)propionamide was reacted with bromomethylcyclobutane by method H. This resulted in a product with the molecular weight 449.60 (C27H35N3O3); MS (ESI): 450 (M+H+).


Example 242
1-(4-Methoxyphenyl)cyclopropanecarboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide



embedded image


N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 1-(4-methoxyphenyl)-1-cyclopropanecarboxylic acid by method E. This resulted in the product with the molecular weight of 407.52 (C24H29N3O3); MS (ESI): 408 (M+H+).


Example 243
1-(4-Butoxyphenyl)cyclopropanecarboxylic acid {4-[3-(acetylmethylamino)-pyrrolidin-1-yl]phenyl}amide



embedded image


1-(4-Hydroxyphenyl)cyclopropanecarboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1yl]phenyl}amide was reacted with n-butyl bromide by method H. This resulted in the product with the molecular weight of 449.60, (C27H35N3O3); MS(ESI): 450 (M+H+).


1-(4-Hydroxyphenyl)cyclopropanecarboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide

Boron tribromide-dimethyl sulfide (460 mg) was added to a solution of 1-(4-methoxyphenyl)cyclopropanecarboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide (540 mg) in dichloromethane (5.5 ml) at 0° C. After a reaction time of 12 hours at room temperature, water was added to the mixture, the phases were separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were dried over sodium sulfate, concentrated and purified by chromatography (silica gel, toluene/ethanol/ethyl acetate 8:1:1 with addition of 0.1% triethylamine). This resulted in the product with the molecular weight of 393.49 (C23H27N3O3); MS(ESI): 394 (M+H+).


Example 244
(R)-4-(4-Fluorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}-N-methylamide



embedded image


(R)-4-(4-Fluorophenyl)piperidine-1-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide (22 mg) was added to a suspension of sodium hydride (95% in oil; 0.005 g) in DMF (1 ml). After evolution of gas ceased, iodomethane (0.02 ml) was added. After two hours, the reaction mixture was cautiously hydrolyzed with water and extracted with dichloromethane. The organic phase was dried over magnesium sulfate and concentrated, and the residue was crystallized from pentane. This resulted in the product with the molecular weight of 452.58 (C26H33FN4O2); MS (ESI): 453 (M+H+).


Example 245
5-2-[(2-Fluorophenyl)ethynyl]furan-2-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide



embedded image



Method J


Firstly diisopropylamine (14.9 mg) and then a solution of 5-bromofuran-2-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide (50.0 mg) and 1-ethynyl-2-fluorobenzene (17.7 mg) in dioxane (0.5 ml) and DMF (0.2 ml) were added under inert conditions to a suspension of palladium bis(tri-tert-butylphosphine) dichloride (3.8 mg) and copper(I) iodide (0.9 mg) in DMF (0.5 ml). After a reaction time of 12 hours at room temperature, the mixture was diluted with ethyl acetate and filtered through silica gel, and the filtrate was concentrated and purified by preparative HPLC. This resulted in the product with the molecular weight of 445.18 (C26H24FN3O3); MS(ESI): 446 (M+H+) as hydrotrifluoroacetate.


5-Bromofuran-2-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide

N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-N-methylacetamide was reacted with 5-bromo-2-furancarboxylic acid by method E. This resulted in the product with the molecular weight of 406.28 (C18H20BrN3O3); MS(ESI): 407 (M+H+).


Example 246
5-2-[(4-Fluorophenyl)ethynyl]furan-2-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide



embedded image


5-Bromofuran-2-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide was reacted with 1-ethynyl-4-fluorobenzene by method J. This resulted in the product with the molecular weight of 445.18 (C26H24FN3O3); MS(ESI): 446 (M+H+) as hydrotrifluoroacetate.


Example 247
5-2-[(2-Chlorophenyl)ethynyl]furan-2-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide



embedded image


5-Bromofuran-2-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide was reacted with 1-ethynyl-2-chlorobenzene by method J. This resulted in the product with the molecular weight of 461.15 (C26H24ClN3O3); MS(ESI): 462 (M+H+) as hydrotrifluoroacetate.


Example 248
R-4-Butoxy-N-(3-fluoro-4-{3-[(2-hydroxy-2-methylpropyl)methylamino]-pyrrolidin-1-yl}-phenyl)benzamide



embedded image


A solution of (R)-4-butoxy-N-[3-fluoro-4-(3-methylaminopyrrolidin-1-yl)phenyl]benzamide (0.03 g) and isobutylene oxide in ethanol (5 ml) were heated under reflux for 3 hours. It was then concentrated in vacuo. This resulted in the product with the molecular weight of 457.59 (C26H36FN3O3); MS (ESI): 458 (M+H+).


Example 249
R-4-Butoxy-N-(3-fluoro-4-{3-[(3-hydroxy-3-methylbutyl)methylamino]pyrrolidin-1-yl}-phenyl)-N-methylbenzamide



embedded image


A solution of (R)-4-butoxy-N-[3-fluoro-4-(3-methylaminopyrrolidin-1-yl)phenyl]benzamide (0.03 g), triethylamine (0.02 g) and 4-bromo-2-methylbutan-2-ol (0.03 g) in DMF (2 ml) was heated at 80° C. for 16 hours. After cooling, ethyl acetate (100 ml) was added, the mixture was washed with water (2×50 ml), and the organic phase was dried with sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 471.62 (C27H38FN3O3); MS (ESI): 472 (M+H+).


4-Bromo-2-methylbutan-2-ol

Methylmagnesium bromide (3M in diethyl ether, 46 ml) was added to a solution of ethyl 3-bromopropionate (10 g) in diethyl ether (100 ml) at room temperature under argon. During this, the mixture was kept at above 20° C. and below 35° C. After 2 hours, the mixture was poured into a saturated ammonium chloride solution. This was followed by extraction with diethyl ether, drying with sodium sulfate, filtration and concentration. This resulted in the desired product.


Example 250
R-4-Butoxy-N-[6-(3-dicyclopropylaminopyrrolidin-1-yl)-pyridin-3-yl]benzamide



embedded image



Method K


A solution of (R)-N-[6-(3-aminopyrrolidin-1-yl)pyridin-3-yl]-4-butoxybenzamide (0.065 g) in methanol (2 ml) was mixed with glacial acetic acid (0.11 ml) and [(1-ethoxycyclopropyl)oxy]trimethylsilane (0.19 g). Then sodium cyanoborohydride (0.051 g) was added and the mixture was heated under reflux for 16 hours. The mixture was then filtered, concentrated, taken up in dichloromethane, washed with sodium hydroxide (2N; 20 ml) and sodium chloride solution (20 ml), dried with magnesium sulfate and concentrated. The residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 434.59 (C26H34N4O2); MS (ESI): 435 (M+H+).


Example 251
R-4-Butoxy-N-[6-(3-dicyclopropylaminopyrrolidin-1-yl)pyridin-3-yl]-N-methylbenzamide



embedded image


(R)-4-Butoxy-N-[6-(3-dicyclopropylaminopyrrolidin-1-yl)pyridin-3-yl]benzamide was methylated by method F. This resulted in the product with the molecular weight of 448.61 (C27H36N4O2); MS (ESI): 449 (M+H+).


Example 252
R-4-Butoxy-N-{6-[3-(cyclopropylmethylamino)pyrrolidin-1-yl]pyridin-3-yl}benzamide



embedded image


(R)-4-Butoxy-N-[6-(3-methylaminopyrrolidin-1-yl)pyridin-3-yl]benzamide was cyclopropylated by method K. This resulted in the product with the molecular weight of 408.551 (C24H32N4O2); MS (ESI): 409 (M+H+).


Example 253
tert-Butyl {1-[4-(2-amino-4-butoxybenzoylamino)-3-fluorophenyl]pyrrolidin-3-yl}methylcarbamate



embedded image


tert-Butyl [1-(4-amino-3-fluorophenyl)pyrrolidin-3-yl]methylcarbamate was reacted with 4-butoxy-2-nitrobenzoic acid by method E, followed by hydrogenation. This resulted in the product with the molecular weight of 500.62 (C27H37FN4O4); MS (ESI): 501 (M+H+).


4-Butoxy-2-nitrobenzoic acid

A solution of 4-fluoro-2-nitrobenzoic acid (1.81 g) in butanol (20 ml) was mixed with sulfuric acid (3 ml) and stirred at 110° C. for 4 hours. Ethyl acetate (100 ml) was added, and the mixture was washed with saturated sodium bicarbonate solution (3×50 ml), dried with sodium sulfate, filtered and concentrated in vacuo. The residue (2.2 g) was added dropwise at −10° C. to a sodium butoxylate solution prepared from butanol (20 ml) and sodium hydride (2.18 g) at −10° C. under argon and then stirred for 20 hours. Ethyl acetate (100 ml) was added, and the mixture was washed with water (2×50 ml), dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by preparative HPLC. The butyl 4-butoxy-2-nitrobenzoate was hydrolyzed with sodium hydoxide (5N; 100 ml) in ethanol at room temperature for 3 hours. The mixture was acidified with hydrochloric acid (10N; 100 ml) and extracted with dichloromethane, and the organic phase was dried over sodium sulfate, filtered and concentrated. This resulted in the product with the molecular weight of 239.23 (C11H13NO5); MS (ESI): 240 (M+H+).


Example 254
N-{4-[3-(7-Azabicyclo[2.2.1]hept-7-yl)-2-oxopyrrolidin-1-yl]phenyl}-4-cyclohexyl-N-methylbenzamide



embedded image



Method L


A mixture of N-[4-(3-bromo-2-oxopyrrolidin-1-yl)phenyl]-4-cyclohexyl-N-methylbenzamide (100 mg), potassium carbonate (60 mg), 7-azabicyclo[2.2.1]heptane (44 mg) and DMF (2 ml) was kept at 50° C. for 6 hours. The mixture was diluted with water and extracted with ethyl acetate.


The organic phase was dried over magnesium sulfate and concentrated. The residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 471.65 (C30H37N3O2); MS (ESI): 472 (M+H+).


N-[4-(3-Bromo-2-oxopyrrolidin-1-yl)phenyl]-4-cyclohexyl-N-methylbenzamide

N-(4-Aminophenyl)-4-cyclohexyl-N-methylbenzamide (3.0 g) in acetonitrile (30 ml) was mixed with trisodium phosphate (0.95 g) and, at 0° C., 2-bromo-4-chlorobutyryl bromide (2.9 g) was added. After one hour, a solution of sodium hydroxide (0.85 g) in water (10 ml) was added and the mixture was stirred vigorously at room temperature for 6 hours. The same amount of sodium hydroxide solution was then added, and stirring was continued for 48 hours. The reaction solution was diluted with water and extracted with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. The residue was purified by chromatography on silica gel (mobile phase ethyl acetate/heptane 1:2). This resulted in the product with the molecular weight of 455.40 (C24H27BrN2O2); MS (ESI): 456 (M+H+).


N-(4-Aminophenyl)-4-cyclohexyl-N-methylbenzamide

4-Cyclohexylcarboxylic acid (5.0 g) and 4-nitrophenylisocyanate (4.0 g) were stirred in toluene (150 ml) for 3 hours and then left to stand overnight. The precipitate was filtered off with suction and washed with diethyl ether. The resulting amide was ethylated by method F and hydrogenated by method B. This resulted in the product with the molecular weight of 308.43 (C20H24N2O); MS (ESI): 309 (M+H+).


Example 255
4-Cyclohexyl-N-methyl-N-[4-(3-morpholin-4-yl-2-oxopyrrolidin-1-yl)phenyl]benzamide



embedded image


N-[4-(3-Bromo-2-oxopyrrolidin-1-yl)phenyl]-4-cyclohexyl-N-methylbenzamide was reacted with morpholine by method L. This resulted in the product with the molecular weight 461.61 (C28H35N3O3); MS (ESI): 462 (M+H+).


Example 256
4-Cyclohexyl-N-methyl-N-[4-(2-oxo-3-piperidin-1-ylpyrrolidin-1-yl)phenyl]benzamide



embedded image


N-[4-(3-Bromo-2-oxopyrrolidin-1-yl)phenyl]-4-cyclohexyl-N-methylbenzamide was reacted with piperidine by method L. This resulted in the product with the molecular weight of 459.64 (C29H37N3O2); MS (ESI): 460 (M+H+).


Example 257
4-Cyclohexyl-N-methyl-N-[4-(2′-oxo[1,3′]bipyrrolidinyl-1′-yl)phenyl]benzamide



embedded image


N-[4-(3-Bromo-2-oxopyrrolidin-1-yl)phenyl]-4-cyclohexyl-N-methylbenzamide was reacted with pyrrolidine by method L. This resulted in the product with the molecular weight of 445.61 (C28H35N3O2); MS (ESI): 446 (M+H+).


Example 258
4-Cyclohexyl-N-methyl-N-[4-(3-methylamino-2-oxopyrrolidin-1-yl)phenyl]benzamide



embedded image


N-[4-(3-Bromo-2-oxopyrrolidin-1-yl)phenyl]-4-cyclohexyl-N-methylbenzamide was reacted with methylamine by method L. This resulted in the product with the molecular weight of 405.54 (C25H31N3O2); MS (ESI): 406 (M+H+).


Example 259
4-Cyclohexyl-N-[4-(3-cyclohexylamino-2-oxopyrrolidin-1-yl)phenyl]-N-methylbenzamide



embedded image


N-[4-(3-Bromo-2-oxopyrrolidin-1-yl)phenyl]-4-cyclohexyl-N-methylbenzamide was reacted with cyclohexylamine by method L. This resulted in the product with the molecular weight of 473.66 (C30H39N3O2); MS (ESI): 474 (M+H+).


Example 260
4-Cyclohexyl-N-{4-[3-(cyclopropylmethylamino)-2-oxopyrrolidin-1-yl]phenyl}-N-methylbenzamide



embedded image


N-[4-(3-Bromo-2-oxopyrrolidin-1-yl)phenyl]-4-cyclohexyl-N-methylbenzamide was reacted with cyclopropylmethylamine by method L. This resulted in the product with the molecular weight of 445.61 (C28H35N3O2); MS (ESI): 446 (M+H+).


Example 261
N-{4-[3-(Acetylmethylamino)-2-oxopyrrolidin-1-yl]phenyl}-4-cyclohexyl-N-methyl-benzamide



embedded image


4-Cyclohexyl-N-methyl-N-[4-(3-methylamino-2-oxopyrrolidin-1-yl)phenyl]benzamide (52 mg) was mixed with pyridine (0.5 ml) and acetic anhydride (130 mg) and, after 3 hours, volatile fractions were removed in vacuo. This resulted in the product with the molecular weight of 447.58 (C27H33N3O3); MS (ESI): 448 (M+H+).


Example 262
4-Cyclohexyl-N-methyl-N-[4-(4-methylamino-2-oxopyrrolidin-1-yl)phenyl]benzamide



embedded image


tert-Butanol (8 ml), triethylamine (350 mg) and finally diphenylphosphoryl azide (1.18 g) were added to 1-{4-[(4-cyclohexylbenzoyl)methylamino]phenyl}-5-oxopyrrolidin-3-carboxylic acid (1.5 g), and the mixture was heated at 95° C. for 48 hours. The reaction solution was diluted with ethyl acetate and washed twice with water. The organic phase was dried over magnesium sulfate and concentrated. The crude product was reacted further by method G. This resulted in the product with the molecular weight of 405.54 (C25H31N3O2); MS (ESI): 406 (M+H+).


1-{4-[(4-Cyclohexylbenzoyl)methylamino]phenyl}-5-oxo-pyrrolidine-3-carboxylic acid

N-(4-Aminophenyl)-4-cyclohexyl-N-methylbenzamide (3.0 g) was heated with itaconic acid (1.27 g) at 100° C. for 3 hours. Purification took place by filtration through silica gel (mobile phase ethyl acetate/methanol 5:1). This resulted in the product with the molecular weight of 420.51 (C25H28N2O4); MS (ESI): 421 (M+H+).


Example 263
N-{4-[4-(Acetylmethylamino)-2-oxopyrrolidin-1-yl]phenyl}-4-cyclohexyl-N-methylbenzamide



embedded image


4-Cyclohexyl-N-methyl-N-[4-(4-methylamino-2-oxopyrrolidin-1-yl)phenyl]benzamide (101 mg) was mixed with pyridine (20 mg) and acetic anhydride (25 mg) and, after 3 hours, volatile fractions were removed in vacuo. This resulted in the product with the molecular weight of 447.58 (C27H33N3O3); MS (ESI): 448 (M+H+).


Example 264
tert-Butyl (1-{5-[(4-cyclohexylbenzoyl)propylamino]pyridin-2-yl}pyrrolidin-3-yl)methylcarbamate



embedded image



Method F-a


tert-Butyl {1-[5-(4-cyclohexylbenzoylamino)pyridin-2-yl]pyrrolidin-3-yl}methylcarbamate (50 mg), cesium carbonate (249 mg), potassium iodide (17 mg), N-methylpyrrolidone (1.5 ml) and propyl iodide (40 mg) were stirred at 60° C. for 5 hours. If conversion was incomplete, the mixture was heated to 100° C. and, after addition of further propyl iodide (40 mg), heated at 140° C. for 12 hours. The reaction mixture was diluted with ethyl acetate, washed with water and sodium bicarbonate solution, dried over Chromabond XTR and concentrated. The residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 520.72 (C31H44N4O3); MS (ESI): 521 (M+H+).


Example 265
tert-Butyl (1-{5-[(4-cyclohexylbenzoyl)-(1-ethylpropyl)amino]pyridin-2-yl}pyrrolidin-3-yl)-methylcarbamate



embedded image


tert-Butyl {1-[5-(4-cyclohexylbenzoylamino)pyridin-2-yl]pyrrolidin-3-yl}methylcarbamate was reacted with 2-ethylbutyl bromide by method F-a. This resulted in the product with the molecular weight of 548.78 (C33H48N4O3); MS (ESI): 549 (M+H+).


Example 266
tert-Butyl (1-{5-[(4-cyclohexylbenzoyl)-(3-methylbut-2-enyl)amino]pyridin-2-yl}pyrrolidin-3-yl)methylcarbamate



embedded image


tert-Butyl {1-[5-(4-cyclohexylbenzoylamino)pyridin-2-yl]pyrrolidin-3-yl}methylcarbamate was reacted with 3-methyl-2-butenyl bromide by method F-a. This resulted in the product with the molecular weight of 546.76 (C33H46N4O3); MS (ESI): 547 (M+H+).


Example 267
tert-Butyl (1-{5-[(4-cyclohexylbenzoyl)methylamino]pyridin-2-yl}pyrrolidin-3-yl)methylcarbamate



embedded image


tert-Butyl {1-[5-(4-cyclohexylbenzoylamino)pyridin-2-yl]pyrrolidin-3-yl}methylcarbamate was reacted with methyl iodide by method F-a. This resulted in the product with the molecular weight of 492.67 (C29H40N4O3); MS (ESI): 493 (M+H+).


The following further compounds were obtained by method F-a from tert-butyl {1-[5-(4-cyclohexylbenzoylamino)pyridin-2-yl]pyrrolidin-3-yl}methylcarbamate and the appropriate alkylating agent:

  • tert-Butyl (1-{5-[sec-butyl-(4-cyclohexylbenzoyl)amino]pyridin-2-yl}pyrrolidin-3-yl)methylcarbamate
  • tert-Butyl (1-{5-[(4-cyclohexylbenzoyl)isopropylamino]pyridin-2-yl}pyrrolidin-3-yl)methylcarbamate
  • tert-Butyl (1-{5-[(4-cyclohexylbenzoyl)prop-2-inylamino]pyridin-2-yl}pyrrolidin-3-yl)-methylcarbamate


Example 268
5-p-Tolylethinylfuran-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide



embedded image


0.042 ml of diisopropylamine was added under argon to 3.8 mg of Pd(tBu)2Cl2 and 0.95 mg of Cul in 0.2 ml of DMF. A solution of 94.6 mg of 5-bromofuran-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-amide in 0.3 ml of DMF and a solution of 4-ethynyltoluene in 0.3 ml of DMF were then added dropwise. The solution was stirred at room temperature overnight. The precipitate which had separated out was filtered off with suction and the filtrate purified by preparative HPLC. The desired product with the molecular weight of 413.52; MS (ESI): 414 was obtained as hydrotrifluoroacetate.


5-Bromofuran-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide

[1-(4-Aminophenyl)pyrrolidin-3-yl]dimethylamine was reacted with 5-bromo-2-furancarboxylic acid by method E. The product with a molecular weight of 378.27 (C17H20BrN3O2); MS (ESI): 379 (M+H+) was obtained as hydrotrifluoroacetate.


Examples 269-273 were prepared analogously:


















Molecular
Molecular



Ex. No.
Structure
formula
weight
M+H+







269


embedded image


C26H27N303
429.21
430





270


embedded image


C25H23F2N3O2
435.18
436





271


embedded image


C26H27N3O3
429.21
430





272


embedded image


C25H24FN3O2
417.19
418





273


embedded image


C25H24CIN3O2
433.16
434









Example 274
(R)-4′-Fluorobiphenyl-4-carboxylic acid [6-(3-dimethylaminopyrrolidin-1-yl)pyridin-3-yl]-amide



embedded image



Method M


(R)-4′-Fluorobiphenyl-4-carboxylic acid [6-(3-methylaminopyrrolidin-1-yl)pyridin-3-yl]-amide (390 mg) dissolved in formic acid (230 mg) was mixed with formaldehyde solution (37% aq.; 0.4 ml) and the mixture was heated at 80° C. for 3 hours. The cooled reaction solution was concentrated and partitioned between ethyl acetate and a saturated sodium carbonate solution. The organic phase was dried over magnesium sulfate and concentrated. The crude product was purified by preparative HPLC. This resulted in the product with the molecular weight of 404.49 (C24H25FN4O); MS (ESI): 405 (M+H+).


Example 275
1-(4-Fluorophenyl)piperidine-4-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide



embedded image



Method E-a


A mixture of 0.048 g of 1-(4-fluorophenyl)piperidine-4-carboxylic acid and 0.5 ml of SOCl2 and one drop of DMF were stirred at room temperature for 2 hours. The excess SOCl2 was then removed in vacuo. The residue was dissolved in 0.4 ml of DMF, and 0.033 ml of triethylamine and 0.048 g of N-[1-(4-aminophenyl)pyrrolidin-3-yl]-N-methylacetamide were added. The solution was stirred at room temperature overnight. The solution was then filtered and purified by preparative HPLC. This resulted in the product with the molecular weight of 438.20 (C25H31FN4O2); MS (ESI): 439 (M+H+) as hydrotrifluoroacetate.


1-(4-Fluorophenyl)piperidine-4-carboxylic acid

0.875 g of 4-bromofluorobenzene, 0.016 g of Pd(dba)3*CHCl3, 0.022 g 2-(dicyclohexylphosphino)biphenyl and 2.28 g of cesium carbonate were put in a heat-dried and argon-flushed flask, and 0.943 g of ethyl 4-piperidinecarboxylate in 5 ml of degassed toluene was added. The solution was heated at 100° C. overnight. The mixture was cooled and then concentrated in vacuo. The residue was taken up in ethyl acetate/water. The organic phase was washed with 10% NaHCO3 solution, dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative HPLC.


4.4 ml of a 2N potassium hydroxide solution were added to a solution of 1.1 g of ethyl 1-(4-fluorophenyl)piperidine-4-carboxylate in 100 ml of methanol. The mixture was stirred at room temperature overnight. The pH was then adjusted to 6 with 5% hydrochloric acid, and the solution was concentrated in vacuo. The residue was purified by preparative HPLC.


Example 276
4-Phenoxycyclohexanecarboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}amide



embedded image


0.251 g of PyBOP and 0.135 ml of triethylamine were added to a solution of 0.106 g of 4-phenoxycyclohexanecarboxylic acid and 0.113 g of N-[1-(4-aminophenyl)pyrrolidin-3-yl]-N-methylacetamide in 9 ml of DMF at 0° C. After 10 minutes, the solution was allowed to reach room temperature and was stirred at this temperature overnight. The solvent was then removed in vacuo, and the residue was taken up in water/ethyl acetate. The ethyl acetate phase was washed with 10% citric acid and 10% NaHCO3 solution and dried over sodium sulfate, and the solvent was removed in vacuo. The residue was purified by preparative HPLC. The desired product was obtained. Molecular weight 435.25 (C26H33N3O3), MS: 436 (M+H+).


4-Phenoxycyclohexanecarboxylic acid

0.63 g of p-toluenesulfonyl chloride was added to a solution of 0.522 g of ethyl 4-hydroxycyclohexanecarboxylate in 5.0 ml of pyridine. The reaction was stirred at room temperature for 3 hours. The reaction mixture was concentrated in vacuo. The resulting solid was taken up in water and ethyl acetate, and the organic phase was washed three times with 2N hydrochloric acid and once with saturated NaCl solution. The organic phase was dried over sodium sulfate and concentrated in vacuo. The resulting product was employed without further purification in the next step. The resulting product (0.55 g) was dissolved in 11.2 ml of DMF, and 0.159 g of phenol and 0.549 g of cesium carbonate were added. The solution was then heated at 80° C. for 6 hours. After cooling, the mixture was concentrated in vacuo and purified by column chromatography on silica gel (eluent: ethyl acetate/n-heptane 1:1). The desired product was obtained. Molecular weight 248.32 (C15H20O3), MS: 249 (M+H+).


0.06 ml of 2N potassium hydroxide solution was added to a solution of 0.12 g of ethyl 4-phenoxycyclohexanecarboxylate in 8 ml of water/THF (1:1). The solution was heated at 60° C. for 3 hours. Ethyl acetate and 10% citric acid were added to the mixture. The aqueous phase was extracted three times with ethyl acetate, dried over sodium sulfate and concentrated in vacuo. The resulting compound was employed without further purification in the next stage.


Example 277
N-[4-(3-Cyclohexylaminopyrrolidin-1-yl)phenyl]-4-isobutoxybenzamide



embedded image



Method N


(4-Isobutoxy-N-[4-(3-oxopyrrolidin-1-yl)phenyl]benzamide (50 mg) in methanol (2 ml) was mixed with aminocyclohexane (28 mg) and glacial acetic acid (10 mg), and a solution of sodium cyanoborohydride (1M in toluene; 0.17 ml) was added. After 8 hours, the reaction solution was concentrated and partitioned between ethyl acetate and water. The organic phase was dried over magnesium sulfate and concentrated. The crude product was purified by preparative HPLC. This resulted in the. product with the molecular weight of 435.61 (C27H37N3O2); MS (ESI): 436 (M+H+).


4-Isobutoxy-N-[4-(3-oxopyrrolidin-1-yl)phenyl]benzamide

4-Isobutoxybenzoic acid was reacted with 4-(1,4-dioxa-7-azaspiro[4.4]non-7-yl)phenylamine by method E-a. The resulting amide (0.25 g) in acetone (10 ml) was mixed with para-toluene sulfonic acid (monohydrate, 109 mg), and the mixture was boiled under reflux for 8 hours. After adding triethylamine (0.5 ml), the mixture was diluted with water and extracted with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. This resulted in the product with the molecular weight of 352.44 (C21H24N2O3); MS (ESI): 353 (M+H+).


4-Butoxy-N-[4-(3-oxopyrrolidin-1-yl)-phenyl]benzamide was obtained using 4-butoxybenzoic acid in an analogous way. Likewise, 4-butoxybenzoic acid and 4-(1,4-dioxa-7-azaspiro[4.4]non-7-yl)-3-fluorophenylamine initially resulted in 4-butoxy-N-[4-(1,4-dioxa-7-azaspiro[4.4]non-7-yl)-3-fluorophenyl]benzamide which, after methylation by method F and treatment with para-toluenesulfonic acid as described above, afforded 4-butoxy-N-[3-fluoro-4-(3-oxopyrrolidin-1-yl)phenyl]benzamide.


4-(1,4-Dioxa-7-azaspiro[4.4]non-7-yl)phenylamine

Trimethylchlorosilane (9.3 g) was slowly added to a solution of 1-benzyl-3-pyrrolidinone (5.0 g) in dichloromethane (30 ml) and ethylene glycol (2.67 g). After 18 hours, the mixture was poured into sodium hydroxide solution (1N). The organic phase was separated off, dried over magnesium sulfate and concentrated. The residue was dissolved in methanol (30 ml) and ammonium formate (5.2 g) and palladium hydroxide (10% on carbon, 300 mg) were added. The mixture was boiled under reflux for 8 hours, filtered and concentrated. The residue was reacted with 4-fluoronitrobenzene by method C. Hydrogenation was finally carried out by method B. This resulted in the product with the molecular weight of 220.27 (C12H16N2O2); MS (ESI): 221 (M+H+).


4-(1,4-Dioxa-7-azaspiro[4.4]non-7-yl)-3-fluorophenylamine was obtained analogously using 3,4-difluoronitrobenzene.


Example 278
(R)-4-(4-Chlorophenyl)piperidin-1-carboxylic acid {4-[3-(methylpyrimidin-2-yl-amino)pyrrolidin-1-yl]-phenyl}amide



embedded image


(R)-4-(4-Chlorophenyl)piperidine-1-carboxylic acid [4-(3-methylaminopyrrolidin-1-yl)phenyl]amide (100 mg) was reacted with potassium carbonate (100 mg) and 2-bromopyrimidine (50 mg) in N-methylpyrrolidone (3 ml) at 100° C. for 4 hours. The reaction solution was then partitioned between ethyl acetate and water. The organic phase was dried over magnesium sulfate and concentrated. The crude product was purified by preparative HPLC. This resulted in the product with the molecular weight of 491.04 (C27H31ClN6O); MS (ESI): 491 (M+H+).


Example 279
tert-Butyl [1-(4-{[5-(2-fluorophenyl)furan-2-carbonyl]amino}phenyl)pyrrolidin-3-yl]methylcarbamate



embedded image



Method O


Tetrakis(triphenylphosphine)palladium(0) (20 mg) was added to a solution of tert-butyl (1-{4-[(5-bromofuran-2-carbonyl)amino]phenyl}pyrrolidin-3-yl)methylcarbamate (252 mg) in degassed toluene (4 ml) under argon in a 10 ml two-necked flask and stirred at room temperature for 10 minutes. Then a solution of 2-fluorobenzeneboronic acid (73 mg in 1 ml of ethanol) and 0.35 ml of 2M sodium carbonate solution were added, and the mixture was stirred at 100° C. for 24 hours.


Then water (5 ml) and ethyl acetate (5 ml) were added to the reaction mixture, the organic phase was separated off, and the aqueous phase was extracted 2× with ethyl acetate (10 ml). The combined organic phases were concentrated and the residue was purified by preparative HPLC. The desired product with the molecular weight of 479.56 (C27H30FN3O4); MS (ESI): 480 (M+H+) was obtained as hydrotrifluoroacetate. It is alternatively possible to use cesium carbonate as base and to heat the reaction at 150° C. in a microwave apparatus for 3 minutes.

  • tert-Butyl (1-{4-[(5-bromofuran-2-carbonyl)amino]phenyl}pyrrolidin-3-yl)methylcarbamate
  • 5-Bromofuran-2-carboxylic acid was reacted with tert-butyl [1-(4-aminophenyl)pyrrolidin-3-yl]methylcarbamate by method E. This resulted in the product with the molecular weight of 464.36 (C21H26BrN3O4); MS (ESI): 464 (M+H+).


The following compounds were prepared analogously:

  • 5-Bromofuran-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide
  • tert-Butyl (1-{4-[(5-bromothiophene-2-carbonyl)amino]phenyl}pyrrolidin-3-yl)methylcarbamate
  • 2-Bromothiazole-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide
  • 4-Iodo-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]benzamide
  • (R)-N-[4-(3-Dimethylaminopyrrolidin-1-yl)-3-fluorophenyl]-4-iodobenzamide
  • 4-Bromo-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-3-fluorobenzamide


Example 280
(3R)-3′-Cyanobiphenyl-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)-3-fluorophenyl]amide



embedded image



Method O-b


0.002 mg of Pd(PPh3)4 were added to a solution of 0.022 g of (R)-N-[4-(3-dimethylaminopyrrolidin-1-yl)-3-fluorophenyl]-4-iodobenzamide in 0.45 ml of degassed DMF and stirred at room temperature for 10 minutes. 0.035 ml of water, 0.021 g of K3PO4 and 0.008 g of 3-cyanophenylboronic acid were then added to the solution. The reaction solution was heated at 80° C. overnight. The solution was then filtered and purified by preparative HPLC. This resulted in the product with the molecular weight of 428.20 (C26H25FlN4O); MS (ESI): 429 (M+H+) as hydrotrifluoroacetate.


Example 281
3,2′,4′-Trifluorobiphenyl-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-amide



embedded image


1-Bromo-2,4-difluorobenzene was reacted with N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-2-fluoro-4-boronic acid benzamide by method O-b. This resulted in the product with the molecular weight of 439.19 (C25H24F3N3O); MS (ESI): 440 (M+H+) as hydrotrifluoroacetate.


N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]-2-fluoro-4-boronic acid benzamide

4-Carboxy-3-fluorophenylboronic acid was reacted with [1-(4-aminophenyl)pyrrolidin-3-yl]dimethylamine by method E-b. This resulted in the product with the molecular weight of 371.18 (C19H23BFN3O3); MS (ESI): 372 (M+H+) as hydrotrifluoroacetate.


Example 282
5-(2,4-Difluorophenyl)thiophen-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)-phenyl]amide



embedded image


1-Bromo-2,4-difluorobenzene was reacted with 2-boronic acid thiophen-5-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide by method O-b. This resulted in the product with molecular weight of 427.52 (C23H23F2N3OS); MS (ESI): 428 (M+H+) as hydrotrifluoroacetate.


2-Boronic acid thiophene-5-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide

5-Carboxy-2-thiopheneboronic acid was reacted with [1-(4-aminophenyl)pyrrolidin-3-yl]-dimethylamine by method E-b. This resulted in the product with the molecular weight of 359.15 (C17H22BN3O3S); MS (ESI): 360 (M+H+) as hydrotrifluoroacetate.


Example 283
N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]-6-(4-fluorophenyl)nicotinamide



embedded image


5-[4-(3-Dimethylaminopyrrolidin-1-yl)phenylcarbamoyl]pyridin-2-yl [trifluoro-methanesulfonate was reacted with 4-fluorobenzeneboronic acid under the conditions of method O-b. (Heating at 140° C. in a microwave apparatus for 15 minutes). This resulted in the product with the molecular weight of 404.20 (C24H25FN4O); MS (ESI): 405 (M+H+) as hydrotrifluoroacetate.


5-[4-(3-Dimethylaminopyrrolidin-1-yl)phenylcarbamoyl]pyridin-2-yl [trifluoromethanesulfonate

A suspension of 0.05 g of N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-6-hydroxynicotinamide in 0.4 ml of DME was added to a solution of 0.084 ml of LDA solution (2M) in 0.4 ml of DME at 0° C. The mixture was stirred at 0° C. for 2 hours. A solution of 0.055 g of N-phenyltrifluoromethanesulfonimide in 0.2 ml of DME was then added to the mixture. The reaction solution was allowed to reach room temperature and was heated at 80° C. for 3 hours. After cooling, the solution was concentrated in vacuo. The residue was taken up in ethyl acetate/water, and the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were dried over sodium sulfate, concentrated in vacuo and purified by preparative HPLC.


N-[4-(3-Dimethylaminopyrrolidin-1-yl)-phenyl]-6-hydroxynicotinamide

6-Hydroxynicotinic acid was reacted with [1-(4-aminophenyl)pyrrolidin-3-yl]dimethylamine by method E-b. This resulted in the product with the molecular weight of 326.17 (C18H22N4O2); MS (ESI): 327 (M+H+) as hydrotrifluoroacetate.


Example 284
N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]-6-(2,4-difluorophenyl)nicotinamide



embedded image


2,4-Difluorophenylboronic acid was reacted with 5-[4-(3-dimethylaminopyrrolidin-1-yl)-phenylcarbamoyl]pyridin-2-yl [trifluoromethanesulfonate by method O-b. This resulted in the product with the molecular weight of 422.00 (C24H24F2N4O); MS (ESI): 423 (M+H+) as hydrotrifluoroacetate.


Example 285
2′,4′-Difluorobiphenyl-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide



embedded image


2′,4′-Difluorobiphenyl-4-carboxylic acid was reacted with [1-(4-aminophenyl)pyrrolidin-3-yl]dimethylamine by method E-a. This resulted in the product with the molecular weight of 421.20 (C25H25F2N3O); MS (ESI): 422 (M+H+) as hydrotrifluoroacetate.


2′,4′-Difluorobiphenyl-4-carboxylic acid

Method P


0.098 ml of 1 N lithium hydroxide solution was added to a solution of 0.051 g of ethyl 2′,4′-difluorobiphenyl-4-carboxylate in 1 ml THF/water (1:1), and the mixture was stirred at room temperature overnight. 5% hydrochloric acid was used to neutralize the solution, which was concentrated in vacuo, and the residue was purified by preparative HPLC.


Ethyl 2′,4′-difluorobiphenyl-4-carboxylate

0.009 g of Pd(PPh3)4 was added to a solution of 0.091 g of ethyl 4-iodobenzoate in 0.96 ml of degassed toluene and stirred at room temperature for 10 minutes. Then a solution of 0.047 g of 2,4-difluorophenylboronic acid in 0.114 ml of ethanol and 0.201 ml of a 2N Na2CO3 solution was added to the reaction solution. The solution was heated at 100° C. overnight. The reaction mixture was then concentrated in vacuo, and water/ethyl acetate were added to the residue. The aqueous phase was extracted three times with ethyl acetate and dried over sodium sulfate, and the solvent was removed in vacuo and purified by preparative HPLC.


Example 286
2′,4′-Difluorobiphenyl-4-carboxylic acid {4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl}-amide



embedded image



Method E-b


0.095 g of HATU, 0.068 g of HOBT and 0.035 ml of triethylamine were added to a solution of 0.047 g of 2′,4′-difluorobiphenyl-4-carboxylic acid and 0.058 g of N-[1-(4-aminophenyl)pyrrolidin-3-yl]-N-methylacetamide in 2 ml of DMF at 0° C. After 10 minutes, the solution was allowed to reach room temperature and was stirred at this temperature overnight. The solvent was then removed in vacuo, and the residue was taken up in water/ethyl acetate. The ethyl acetate phase was washed with 10% NaHCO3 solution and water. The ethyl acetate phase was dried over sodium sulfate, and the solvent was removed in vacuo. The residue was purified by preparative HPLC. The desired product was obtained. Molecular weight 449.19 (C26H25F2N3O2), MS: 450 (M+H+).


Example 287
N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]-3-fluoro-4-(4-methylpiperidin-1-yl)-benzamide



embedded image


3-Fluoro-4-(4-methylpiperidin-1-yl)benzoic acid was reacted with [1-(4-aminophenyl)-pyrrolidin-3-yl]dimethylamine by method E-a. This resulted in the product with the molecular weight of 424.00 (C25H33FN4O); MS (ESI): 425 (M+H+) as hydrotrifluoroacetate.


3-Fluoro-4-(4-methylpiperidin-1-yl)benzoic acid

Methyl 3-fluoro-4-(4-methylpiperidin-1-yl)benzoate was treated with lithium hydroxide by method P. This resulted in the product with the molecular weight of 237.28 (C13H16FNO2); MS (ESI): 238 (M+H+).


Methyl 3-fluoro-4-(4-methylpiperidin-1-yl)benzoate

0.076 g of potassium carbonate was added to a solution of 0.086 g of methyl 3,4-difluorobenzoate and 0.050 g of 4-methylpiperidine in 0.5 ml of DMF. The reaction was heated at 60° C. for 2 days, filtered and purified by preparative HPLC. This resulted in the product with the molecular weight of 251.3 (C14H18FNO2); MS (ESI): 252 (M+H+) as hydrotrifluoroacetate.


Example 288
4-Butoxy-N-(4-{3-[(2-dimethylaminoacetyl)methylamino]pyrrolidin-1-yl}phenyl)-N-methylbenzamide



embedded image


4-Butoxy-N-methyl-N-[4-(3-methylaminopyrrolidin-1-yl)phenyl]benzamide was reacted with N,N-dimethylglycine by method E. This resulted in the product with the molecular weight of 466.63 (C27H38N4O3); MS (ESI): 467 (M+H+).


(R)-4-Butoxy-N-(4-{3-[(2-dimethylaminoacetyl)methylamino]pyrrolidin-1-yl}phenyl)-N-methylbenzamide was obtained analogously.


Example 289
N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-4-butoxy-N-methylbenzamide



embedded image


4-Butoxy-N-methyl-N-[4-(3-methylaminopyrrolidin-1-yl)phenyl]benzamide was mixed with pyridine and acetic anhydride. Volatile fractions were removed after 2 hours. This resulted in the product with the molecular weight of 423.56 (C25H33N3O3); MS (ESI): 424 (M+H+).


Example 290
4-Butyrylamino-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]benzamide



embedded image



Method Q


4-Amino-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]benzamide (32 mg) in dichloromethane (2 ml) was mixed with potassium carbonate (50 mg) and butyryl chloride (11 mg). The mixture was filtered and concentrated after 12 hours. The residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 394.52 (C23H30N4O3); MS (ESI): 395 (M+H+).


An alternative possibility is to react 4-amino-N-[4-(3-dimethylaminopyrrolidin-1-yl)-phenyl]benzamide with butyric acid by method E.


4-Amino-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]benzamide

4-tert-Butoxycarbonylaminobenzoic acid was reacted with 1-(4-aminophenyl)pyrrolidin-3-yl]dimethylamine by method E, and the product was treated by method G. This resulted in the product with the molecular weight of 324.43 (C19H24N4O); MS (ESI): 325 (M+H+).


Example 291
2-Phenylethynylthiazole-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-amide



embedded image


2-Bromothiazole-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide (100 mg) was dissolved in tetrahydrofuran (2 ml), and phenylacetylene (52 mg), triethylamine (52 mg), triphenylphosphine (17 mg), bis(triphenylphosphine)palladium dichloride (89 mg) and copper (I) iodide (9.6 mg) were added. The reaction mixture was heated at 150° C. in a microwave apparatus for 3 minutes and then concentrated. The residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 416.55 (C24H24N4OS); MS (ESI): 417 (M+H+).


Example 292
5-(4-Fluorophenyl)pyridine-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-amide



embedded image



Method O-a


5-Chloropyridine-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide (100 mg) dissolved in toluene was mixed with 4-fluorophenylboronic acid (81 mg), POPD (15 mg) and cesium carbonate (2M aq.; 0.5 ml). The reaction was heated at 150° C. in a microwave apparatus for 10 minutes and then concentrated. The residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 404.49 (C24H25FN4O); MS (ESI): 405 (M+H+).


5-Chloropyridine-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide

[1-(4-Aminophenyl)pyrrolidin-3-yl]dimethylamine was reacted with 5-chloropyridine-2-carboxylic acid by method E. This resulted in the product with the molecular weight of 344.85 (C18H21 ClN4O); MS (ESI): 345 (M+H+).


Example 293
5-(4-Fluorophenyl)pyridine-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-amide



embedded image


5-Chloropyridine-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide was reacted with 4-methylphenylboronic acid by method O-a. This resulted in the product with the molecular weight of 400.53 (C25H28N4O); MS (ESI): 401 (M+H+).


Example 294
1-Benzenesulfonylpiperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)-phenyl]amide



embedded image


Piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide (70 mg) dissolved in N-methylpyrrolidone (2 ml) was mixed with potassium carbonate (45 mg) and benzenesulfonyl chloride (35 mg). After 12 hours, the mixture was filtered and the filtrate was purified by preparative HPLC. This resulted in the product with the molecular weight of 456.61 (C24H32N4O3S); MS (ESI): 457 (M+H+).


Example 295
1-(4-Fluorobenzenesulfonyl)piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide



embedded image


Piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide (70 mg) dissolved in N-methylpyrrolidone (2 ml) was mixed with potassium carbonate (45 mg) and 4-fluorobenzenesulfonyl chloride (40 mg). After 12 hours, the mixture was filtered and the filtrate was purified by preparative HPLC. This resulted in the product with the molecular weight of 474.60 (C24H31FN4O3S); MS (ESI): 475 (M+H+).


Example 296
1-(Butane-1-sulfonyl)piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)-phenyl]amide



embedded image


Piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide (70 mg) dissolved in N-methylpyrrolidone (2 ml) was mixed with potassium carbonate (45 mg) and butylsulfonyl chloride (30 mg). After 12 hours, the mixture was filtered and the filtrate was purified by preparative HPLC. This resulted in the product with the molecular weight of 436.62 (C22H36N4O3S); MS (ESI): 437 (M+H+).


Example 297
5-(4-Butoxyphenylethynyl)furan-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)-phenyl]amide



embedded image



Method J-a


5-Bromofuran-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide (75 mg) was dissolved together with 1-butoxy-4-ethynylbenzene (35 mg) in N,N-dimethylformamide (1 ml) and, under argon, added dropwise to a suspension of Pd(tBu3P)2Cl2 (4 mg), copper (I) iodide (75 mg) and N,N-diisopropylamine (20 mg) in anhydrous tetrahydrofuran (3 ml). The mixture was stirred at room temperature for 8 hours. The reaction was worked up by filtration through a syringe filter and concentrated, and the crude product was purified by preparative HPLC. This resulted in the product with the molecular weight of 471.6 (C29H33N3O3); MS (ESI): 472 (M+H+) as hydrotrifluoroacetate.


Example 298
6-Butoxy-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]nicotinamide



embedded image



Method H-a


A solution of 0.1 g of potassium hydroxide in 1 ml of DMSO was stirred at room temperature for 10 minutes and then 0.1 g of N-[4-(3-dimethylaminopyrrolidin-1-yl)-phenyl]-6-hydroxynicotinamide was added. The reaction solution was stirred for 10 minutes and then 0.084 g of 1-bromobutane was added. The mixture was stirred at room temperature overnight. After addition of water and ethyl acetate, the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were dried over sodium sulfate, concentrated in vacuo and purified by preparative HPLC. This resulted in the product with the molecular weight of 382.24 (C22H30N4O2); MS (ESI): 383 (M+H+) as hydrotrifluoroacetate.


Example 299
6-Cyclopropylmethoxy-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]nicotinamide



embedded image


(Bromomethyl)cyclopropane was reacted with N-[4-(3-dimethylaminopyrrolidin-1-yl)-phenyl]-6-hydroxynicotinamide by method H-a. This resulted in the product with the molecular weight of 380.22 (C22H28N4O2); MS (ESI): 381 (M+H+) as hydrotrifluoroacetate.


Example 300
N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]-6-isobutoxynicotinamide



embedded image


1-Bromo-2-methylpropane was reacted with N-[4-(3-dimethylaminopyrrolidin-1-yl)-phenyl]-6-hydroxynicotinamide by method H-a. This resulted in the product with the molecular weight of 382.24 (C22H30N4O2); MS (ESI): 383 (M+H+) as hydrotrifluoroacetate.


Example 301
N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]-6-(4-fluorophenoxy)nicotinamide



embedded image


49 mg of potassium carbonate were added to a solution of 0.041 g of 6-chloro-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]nicotinamide and 4-fluorophenol (30 mg) in 0.8 ml of DMF, and the reaction was heated at 140° C. in a microwave apparatus for 90 minutes. After addition of water and ethyl acetate, the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were dried over sodium sulfate, concentrated in vacuo and purified by preparative HPLC. This resulted in the product with the molecular weight of 420.2 (C24H25FN4O2); MS (ESI): 421 (M+H+) as hydrotrifluoroacetate.


6-Chloro-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]nicotinamide

6-Chloronicotinic acid was reacted with [1-(4-amino-phenyl)pyrrolidin-3-yl]dimethylamine by method E-b. This resulted in the product with the molecular weight of 344.14 (C18H21ClN4O); MS (ESI): 345 (M+H+) as hydrotrifluoroacetate.


The following examples were prepared analogously.


















Molecular
Molecular



Ex. No.
Structure
formula
weight
M+H+







302


embedded image


C24H26N4O2
402.21
403





303


embedded image


C24H25ClN4O2
436.17
437





304


embedded image


C25H28N4O2
416.22
417









Example 305
N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]-2-fluoro-4-phenoxybenzamide



embedded image


Powdered molecular sieves (4 A), 0.01 g of copper acetate and 0.02 g of N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-2-fluoro-4-boronic acid benzamide were added to a solution of 0.008 g of phenol in 0.5 ml of methylene chloride and stirred at 40° C. for 24 hours. The solvent was then removed in vacuo, the residue was taken up in water/ethyl acetate, and the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were dried over sodium sulfate, concentrated in vacuo and purified by preparative HPLC. This resulted in the product with the molecular weight of 419.2 (C25H26FN3O2); MS (ESI): 420 (M+H+) as hydrotrifluoroacetate.


N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]-2-fluoro-4-boronic acid benzamide

4-Carboxy-3-fluorophenylboronic acid was reacted with [1-(4-aminophenyl)pyrrolidin-3-yl]dimethylamine by method E-b. This resulted in the product with the molecular weight of 371.18 (C19H23BFN3O3); MS (ESI): 372 (M+H+) as hydrotrifluoroacetate.


Example 306
4-(3-Cyanophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide



embedded image


4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide was reacted with 3-bromobenzonitrile by method O-a. This resulted in the product with the molecular weight of 415.54 (C25H29N5O); MS (ESI): 416 (M+H+)


4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide

4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine was reacted with [1-(4-aminophenyl)pyrrolidin-3-yl]dimethylamine by method A. This resulted in the product with the molecular weight of 440.40 (C24H37BN4O3); MS (ESI): 441 (M+H+)


Example 307
4-(2-Cyanophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid [4-(3-dimethylamino-pyrrolidin-1-yl)phenyl]amide



embedded image


4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide was reacted with 2-bromobenzonitrile by method O-a. This resulted in the product with the molecular weight of 415.54 (C25H29N5O); MS (ESI): 416 (M+H+)


Example 308
4-(3-Methylsulfanylphenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide



embedded image


4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide was reacted with 3-bromothioanisole by method O-a. This resulted in the product with the molecular weight of 436.62 (C25H32N4OS); MS (ESI): 437 (M+H+)


Example 309
4-(5-Chloropyridin-2-yloxy)-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]benzamide



embedded image


0.143 g of potassium carbonate was added to a solution of 0.19 g of 4-[4-(3-dimethylaminopyrrolidin-1-yl)phenylcarbamoyl]phenyl acetate in 2 ml of DMF, and the solution was heated at 130° C. in a microwave apparatus for 15 minutes. The solution was then mixed with water and ethyl acetate, the aqueous phase was freeze-dried, and the residue was employed without further purification in the next stage.


Method R


A solution of 0.05 g of N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-4-hydroxybenzamide, 0.017 g of 2,5-dichloropyridine and 0.064 g of potassium carbonate in 0.8 ml of DMF was heated at 230° C. in a microwave apparatus for 30 minutes. The solution was filtered and purified by preparative HPLC. This resulted in the product with the molecular weight of 436.17 (C24H25ClN4O2); MS (ESI): 437 (M+H+) as hydrotrifluoroacetate.


4-[4-(3-Dimethylaminopyrrolidin-1-yl)phenylcarbamoyl]phenyl Acetate

4-Acetoxybenzoic acid was reacted with [1-(4-aminophenyl)pyrrolidin-3-yl]dimethylamine by method E-b. This resulted in the product with the molecular weight of 367.19 (C21H25N3O3); MS (ESI): 368 (M+H+) as hydrotrifluoroacetate.


Example 310
N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]-4-(5-fluoropyridin-2-yloxy)benzamide



embedded image


2-Chloro-5-fluoropyridine was reacted with N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-4-hydroxybenzamide by method R. This resulted in the product with the molecular weight of 420.2 (C24H25FN4O2); MS (ESI): 421 (M+H+) as hydrotrifluoroacetate.


Example 311
4-(6-Chloropyridin-3-yloxy)-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]benzamide



embedded image



was obtained as by-product of the reaction in example 310. This resulted in the product with the molecular weight of 436.95 (C24H25ClN4O2); MS (ESI): 437 (M+H+) as hydrotrifluoroacetate.


Example 312
5-Chloro-3′,6′-dihydro-2′H-[2,4′]bipyridinyl-1′-carboxylic acid [4-(3-dimethylamino-pyrrolidin-1-yl)phenyl]amide



embedded image


[1-(4-Aminophenyl)pyrrolidin-3-yl]dimethylamine (32 mg) and carbonyldiimidazole (27.1 mg) were dissolved in acetonitrile (1.5 ml), and the mixture was stirred for 3 hours. Triethylamine (63.4 μl) was added to a solution of 5-chloro-1′,2′,3′,6′-tetrahydro-[2,4′]bipyridine (40.7 mg) in THF (1 ml) and chloroform (0.5 ml). After 15 minutes, the mixture was added dropwise to the first solution and stirred overnight. The mixture was concentrated and the residue was partitioned between dichloromethane and water. The organic phase was dried over sodium sulfate, filtered and concentrated. Contamination by the primary and/or secondary amine was removed by dissolving the residue in dichloromethane (1.5 ml) and adding the solution to a stirred suspension of polymer-bound p-toluenesulfonyl chloride (0.5 g) in dichloromethane (6 ml) and triethylamine (128 μl). After 3 hours, the resin was filtered off and washed several times with dichloromethane. The combined organic phases were concentrated. The residue was purified by chromatography (silica gel, mobile phase: ethyl acetate/dichloromethane (5%), ammonia (7N in methanol, 2%), later ethyl acetate/dichloromethane (5%), ammonia (7N in methanol, 3%). This resulted in the product with the molecular weight of 425.97 (C23H28ClN5O); MS (ESI): 426 (M+H+).


5-Chloro-1′,2′,3′,6′-tetrahydro-[2,4′]bipyridine

A solution of tert-butyl 5-chloro-3′,6′-dihydro-2′H-[2,4′]bipyridine-1′-carboxylate (50 mg) in chloroform (2.4 ml) was mixed with hydrogen chloride (4N in dioxane; 0.8 ml) and the mixture was concentrated after 13 hours. This resulted in the product with the molecular weight of 194.67 (C10H11ClN2); MS (ESI): 195 (M+H+).


tert-Butyl 5-chloro-3′,6′-dihydro-2′H-[2,4′]bipyridine-1′-carbamate

A solution of 2-bromo-5-chloropyridine (131 mg) in DMF (degassed with nitrogen; 4.5 ml) was added to a mixture of tert-butyl 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridin-1-carbamate (Eastwood, Paul R., Tetrahedron Lett, 41, 19, 2000, 3705-3708; 200 mg), potassium carbonate (0.265 g) and Pd(dppf)Cl2 (50 mg). The mixture was heated at 80° C. for 8 hours. After cooling, the mixture was diluted with dichloromethane and washed with sodium carbonate solution and water. The organic phase was dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography (silica gel, mobile phase: heptane/ethyl acetate (2%)/dichloromethane (5%), later heptane/ethyl acetate (5%)/dichloromethane (5%).


Example 313
5-(2-Amino-4-methylphenyl)furan-2-carboxylic acid [4-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]amide



embedded image


5-(2-Nitro-4-methylphenyl)furan-2-carboxylic acid [4-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]amide was hydrogenated by method B. This resulted in the product with the molecular weight of 404.22 (C24H28N4O2); MS (ESI): 405 (M+H+).


Example 314
5-(2-Acetylamino-4-methylphenyl)furan-2-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide



embedded image


5-(2-Amino-4-methylphenyl)furan-2-carboxylic acid [4-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]amide was reacted with acetyl chloride by method Q. This resulted in the product with the molecular weight of 446.23 (C26H30N4O3); MS (ESI): 447 (M+H+).


Example 315
5-(2-Isobutyrylamino-4-methylphenyl)furan-2-carboxylic acid [4-(3-dimethylamino-pyrrolidin-1-yl)phenyl]amide



embedded image


5-(2-Amino-4-methylphenyl)furan-2-carboxylic acid [4-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]amide was reacted with isobutyryl chloride by method Q. This resulted in the product with the molecular weight of 474.26 (C28H34N4O3); MS (ESI): 475 (M+H+).


Example 316
5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carboxylic acid [4-(3-dimethylamino-pyrrolidin-1-yl)phenyl]methylamide



embedded image


Piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-methylamide (44.4 mg) and 2,5-dichloropyridine (60 mg) were heated at 160° C. for 15 minutes. o-Xylene (0.5 ml) was added and heating at 160° C. was continued for 2 hours. The cooled crude mixture was purified by chromatography (silica gel, eluent: ethyl acetate/ammonia (7N in methanol)). This resulted in the product with the molecular weight of 442.01 (C24H32ClN5O); MS (ESI): 442 (M+H+).


Piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]methylamide

tert-Butyl 4-{[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]methylcarbamoyl}-piperidine-1-carboxylate was treated with trifluoroacetic acid by method G. This resulted in the product with the molecular weight of 330.48 (C19H30N4O); MS (ESI): 331 (M+H+).


Piperidine-4-carboxylic acid [4-(3-dimethylamino-pyrrolidin-1-yl)phenyl]-amide can be prepared analogously.


tert-Butyl 4-{[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]methylcarbamoyl}-piperidine-1-carboxylate

A solution of N-Boc-piperidine-4-carboxylic acid (550 mg) and pyridine (0.47 ml) in dichloromethane (15 ml) was mixed with thionyl chloride (0.21 ml) and, after 30 minutes, a solution of dimethyl[1-(4-methylaminophenyl)pyrrolidin-3-yl]amine (0.5 g), triethylamine (1.17 ml), DMAP (0.44 g) and dichloromethane (10 ml) was added dropwise. After 16 hours, the mixture was diluted with dichloromethane, washed with water and saturated brine, dried over sodium sulfate and concentrated. The residue was purified by chromatography (silica gel, eluent: ethyl acetate/ammonia (7N in methanol)). This resulted in the product with the molecular weight of 430.60 (C24H38N4O3); MS (ESI): 431 (M+H+).


tert-Butyl 4-{[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]carbamoyl}piperidin-1-carboxylate can be prepared analogously.


The following examples were prepared analogously.


















Molecular
Molecular



Ex. No.
Structure
formula
weight
M+H+







317


embedded image


C25H30ClN5O
466.03
466





318


embedded image


C24H30ClN5O3
471.99
472





319


embedded image


C24H30FN5O3
455.54
456









Example 320
3,4,5,6-Tetrahydro-2H-[1,2′]bipyridinyl-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide



embedded image


Piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]-amide (30 mg) and 2-chloropyridine (90 mg) were heated at 160° C. for 2 hours. 2-Chloropyridine (0.2 ml) was added and the mixture was again heated at 160° C. for 4 hours. The cooled crude mixture was purified by chromatography (silica gel, eluent: ethyl acetate/ammonia (3N in methanol)). This resulted in the product with the molecular weight of 393.54(C23H31N5O); MS (ESI): 394 (M+H+).


The following examples were prepared analogously.


















Molecular
Molecular



Ex. No.
Structure
formula
weight
M+H+







321


embedded image


C25H32ClN5O3
486.02
486





322


embedded image


C24H30FN5O3
469.56
470









Example 323
5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carboxylic acid [4-(3-dimethylamino-pyrrolidin-1-yl)phenyl]amid



embedded image


Piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide (30 mg), 2,5-dichloropyridine (30 mg) and tributylamine (0.2 ml) were heated at 160° C. for 2 hours. The cooled crude mixture was washed with heptane and purified by chromatography (silica gel, eluent: ethyl acetate/ammonia (3N in methanol)). This resulted in the product with the molecular weight of 427.98 (C23H30ClN5O); MS (ESI): 428 (M+H+).


Example 324
1-(4-Chloro-2-cyanophenyl)piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide



embedded image


Piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide was reacted with 2,5-dichlorobenzonitrile as described in example 323. This resulted in the product with the molecular weight of 452.00 (C25H30ClN5O); MS (ESI): 452 (M+H+).


Example 325
1-(2-Acetylamino-4-chlorophenyl)piperidine-4-carboxylic acid [4-(3-dimethylamino-pyrrolidin-1-yl)phenyl]methylamide



embedded image


Palladium on carbon (10%; 10 mg) was added to a solution of 1-(4-chloro-2-nitro-phenyl)piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]methylamide (50 mg) in glacial acetic acid (5 ml). The solution was stirred under a hydrogen atmosphere (1 bar), and acetic anhydride (14 μl) was added. After one hour, further acetic anhydride (6 μl) were added and the mixture was stirred for 15 minutes. The suspension was filtered and the filtrate was concentrated. The residue was purified by chromatography (silica gel, eluent: ethyl acetate/ammonia (7N in methanol)). This resulted in the product with the molecular weight of 498.07 (C27H36ClN5O2); MS (ESI): 498 (M+H+).


The following examples were prepared analogously.


















Molecular
Molecular



Ex. No.
Structure
formula
weight
M+H+







326


embedded image


C27H36FN5O2
481.62
482





327


embedded image


C26H34ClN5O2
484.05
484





328


embedded image


C26H34FN5O3
467.59
468









Example 329
(R)-N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]-2-(4-phenylpiperidin-1-yl)acetamide



embedded image


Cesium carbonate (100 mg) and 4-phenylpiperidine (48 mg) were added to a solution of (R)-2-chloro-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]acetamide (80 mg) in acetonitrile (5 ml) and DMF (1 ml), and the mixture was kept at 65° C. for 12 hours. The mixture was freed of volatile fractions and the residue was partitioned between water and dichloromethane. The organic phase was dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography (silica gel, eluent: methanol/dichloromethane). This resulted in the product with the molecular weight of 406.58 (C25H34N4O); MS (ESI): 407 (M+H+).


It is alternatively possible to use potassium carbonate or pyridine as auxiliary bases, to add potassium iodide as catalyst, or to carry out the reaction at 150° C. in a microwave apparatus.


(R)-2-Chloro-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]acetamide

Triethylamine (2.03 g) was added to a solution of (R)-[1-(4-aminophenyl)pyrrolidin-3-yl]-dimethylamine (3.15 g) in dichloromethane (120 ml), and then chloroacetyl chloride (2.26 g) was added dropwise. After 3 hours, the mixture was diluted with dichloromethane and washed with water and brine. The organic phase was dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography (silica gel, eluent: methanol/dichloromethane). This resulted in the product with the molecular weight of 281.79 (C14H20ClN3O); MS (ESI): 282 (M+H+).


The following were obtained analogously:

  • N-{4-[3-(Acetylmethylamino)pyrrolidin-1-yl]phenyl}-2-chloroacetamide
  • 2-Chloro-N-[4-(3-dimethylaminopyrrolidin-1-yl)phenyl]acetamide
  • (R)-2-Chloro-N-[6-(3-dimethylaminopyrrolidin-1-yl)pyridin-3-yl]acetamide


The following examples were prepared in analogy to the method given in example 329:


















Molecular
Molecular



Ex. No.
Structure
formula
weight
M+H+







330


embedded image


C25H34N4O
406.58
407





331


embedded image


C26H34N4O2
434.59
435





332


embedded image


C26H33ClN4O2
469.03
469





333


embedded image


C27H30N4O3
458.57
459





334


embedded image


C25H29N5O2
431.54
432





335


embedded image


C25H28ClN5O2
465.99
466





336


embedded image


C26H33N5O3
463.59
464





337


embedded image


C25H33ClN4O2
441.02
441





338


embedded image


C25H34N4O2
422.58
423





339


embedded image


C24H33N5O2
423.56
424









Example 340
(R)-4-Benzylpiperidine-1-carboxylic acid [6-(3-dimethylaminopyrrolidin-1-yl)pyridin-3-yl]-amide



embedded image


(R)-6-(3-Dimethylaminopyrrolidin-1-yl)pyridin-3-ylamine was added to a solution of carbonyldiimidazole (53 mg) in DMF (0.5 ml) at 0° C. After 15 minutes, 4-benzylpiperidine (57 mg) was added and the mixture was heated at 90° C. for one hour. The cooled mixture was freed of volatile fractions. The residue was purified by chromatography (silica gel, eluent: methanol/dichloromethane). This resulted in the product with the molecular weight of 407.56 (C24H33N5O); MS (ESI): 408 (M+H+).


The following examples were prepared analogously:


















Molecular
Molecular



Ex. No.
Structure
formula
weight
M+H+







341


embedded image


C24H31N5O2
421.55
422





342


embedded image


C24H33N5O
407.56
408





343


embedded image


C26H34N4O3
450.59
451





344


embedded image


C25H31ClN4O2
455.00
455





345


embedded image


C26H30N4O
414.56
415





346


embedded image


C24H39N5O
413.61
414





347


embedded image


C26H37N5O
435.62
436









Example 348
(R)-4-Cyclopropylmethoxy-N-[4-(3-dimethylaminopyrrolidin-1-yl)-3-fluorophenyl]-benzamide



embedded image


(R)-4-Benzyloxy-N-[4-(3-dimethylaminopyrrolidin-1-yl)-3-fluorophenyl]benzamide underwent debenzylating hydrogenation by method B. The resulting (R)-N-[4-(3-dimethylaminopyrrolidin-1-yl)-3-fluorophenyl]-4-hydroxybenzamide was alkylated with cyclopropylmethyl bromide by method H. This resulted in the product with the molecular weight of 397.50 (C23H28N3O2); MS (ESI): 398 (M+H+).


The following examples were likewise obtained by method H:


















Molecular
Molecular



Ex. No.
Structure
formula
weight
M+H+







349


embedded image


C26H34FN3O2
439.58
440





350


embedded image


C25H32FN3O3
441.55
442





351


embedded image


C24H30FN3O2
411.52
412









Example 352
(R)-N-[4-(3-Dimethylaminopyrrolidin-1-yl)-3-fluorophenyl]-4-(pyridin-2-yloxy)benzamide



embedded image


(R)-N-[4-(3-Dimethylaminopyrrolidin-1-yl)-3-fluorophenyl]-4-hydroxybenzamide was reacted with 2-chloropyridine by method R. This resulted in the product with the molecular weight of 434.52 (C25H27N4O2); MS (ESI): 435 (M+H+).


Example 353-Example 507

Various pyrrolidinylanilines were reacted with diverse amines by method A. The resulting products are summarized in table 6.


Example 508-Example 1130

Various pyrrolidinylanilines were reacted with diverse acids by methods E. The resulting products are summarized in table 7.


Example 1131-Example 1232

Various (hetero)aryl halides were reacted with diverse boronic acids by methods O. The resulting products are summarized in table 8.


Example 1233-Example 1237

Various aryl halides were reacted with diverse acetylenes by methods J. The resulting products are summarized in table 9.


Example 1238-Example 1403

Various aminopyrrolidines and N-arylpyrrolidinones were reacted with diverse aldehydes, ketones and amines by method N. The resulting products are summarized in table 10.


Example 1404-Example 1423

Various aminopyrrolidines were reductively methylated with formaldehyde by method E. The resulting products are summarized in table 11.


Example 1424-Example 1443

Various amides were alkylated by method F. The resulting products are summarized in table 12.


Example 1444-Example 1618

Various tert-butyl carbamates were cleaved by method G. The resulting products were summarized in table 13.













TABLE 6







Molecular
Monoisotopic



Ex. No.
Structure
formula
molecular wt.
M+H+







353


embedded image


C25H31FN4O2
438.24
439





354


embedded image


C25H30N4O4
450.23
451





355


embedded image


C25H31ClN4O3
470.21
471





356


embedded image


C26H30N4O2
430.24
431





357


embedded image


C24H29ClN4O
424.20
425





358


embedded image


C25H35N5O
421.28
422





359


embedded image


C23H3OBrN5O
471.16
472





360


embedded image


C24H34N4O
394.27
395





361


embedded image


C26H28N4O3
444.22
445





362


embedded image


C24H29N5O
403.24
404





363


embedded image


C27H29N5OS
471.21
472





364


embedded image


C26H30N4O2
430.24
431





365


embedded image


C25H30N6O3
462.24
463





366


embedded image


C22H25N5O2
391.20
392





367


embedded image


C26H28N6O
440.23
441





368


embedded image


C24H29FN4O
408.23
409





369


embedded image


C26H30N4O3
446.23
447





370


embedded image


C25H27ClN4O2
450.18
451





371


embedded image


C25H27FN4O2
434.21
435





372


embedded image


C26H30N4O2
430.24
431





373


embedded image


C26H30N4O2
430.24
431





374


embedded image


C26H30N4O3
446.23
447





375


embedded image


C25H27ClN4O2
450.18
451





376


embedded image


C23H32N4O2
396.25
397





377


embedded image


C25H29N5O2
431.23
432





378


embedded image


C24H27N5O2
417.22
418





379


embedded image


C25H35N5O2
437.28
438





380


embedded image


C25H27FN4O2
434.21
435





381


embedded image


C26H27F3N4O2
484.21
485





382


embedded image


C26H27F3N4O
468.21
469





383


embedded image


C24H31ClN4O2
442.21
443





384


embedded image


C25H28N4O
400.23
401





385


embedded image


C26H30N4O2
430.24
431





386


embedded image


C23H32N4O2
396.25
397





387


embedded image


C25H34N4O2
422.27
423





388


embedded image


C24H31ClN4O
426.22
427





389


embedded image


C25H34N4O
406.27
407





390


embedded image


C25H31F3N4O
460.24
461





391


embedded image


C25H31F3N4O2
476.24
477





392


embedded image


C23H31N5O4
441.24
442





393


embedded image


C24H30N4O3
422.23
423





394


embedded image


C24H32ClN5O
441.23
442





395


embedded image


C25H27ClN4O
434.19
435





396


embedded image


C25H28N4O
400.23
401





397


embedded image


C24H28N6O
416.23
417





398


embedded image


C25H34N4O2
422.27
423





399


embedded image


C28H34N4O
442.27
443





400


embedded image


C25H27N5O3
445.21
446





401


embedded image


C25H27ClN4O
434.19
435





402


embedded image


C24H31ClN4O2
442.21
443





403


embedded image


C24H33N5O
407.27
408





404


embedded image


C22H30N4O2
382.24
383





405


embedded image


C25H34N4O
406.27
407





406


embedded image


C22H22Cl2F6N4O2
558.10
559





407


embedded image


C26H27F3N4O2
484.21
485





408


embedded image


C24H31FN4O
410.25
411





409


embedded image


C24H31FN4O
410.25
411





410


embedded image


C24H31FN4O
410.25
411





411


embedded image


C25H34N4O
406.27
407





412


embedded image


C25H34N4O
406.27
407





413


embedded image


C24H32N4O2
408.25
409





414


embedded image


C22H26N6O
390.22
391





415


embedded image


C26H27BrN4O
490.14
491





416


embedded image


C21H24N6OS
408.17
409





417


embedded image


C26H27N5O
425.22
426





418


embedded image


C24H32N4O
392.26
393





419


embedded image


C25H27ClN4O2
450.18
451





420


embedded image


C24H30N4O3
422.23
423





421


embedded image


C24H29ClN4O2
440.20
441





422


embedded image


C26H31ClN4O2
466.21
467





423


embedded image


C28H35ClN4O
478.25
479





424


embedded image


C28H38N4O4
494.29
495





425


embedded image


C24H31ClN4O2
442.21
443





426


embedded image


C25H33ClN4O2
456.23
457





427


embedded image


C25H28N4O3
432.22
433





428


embedded image


C25H29FN4O2
436.23
437





429


embedded image


C24H30BrN5O2
499.16
500





430


embedded image


C25H29ClN4O2
452.20
453





431


embedded image


C25H32N4O3
436.25
437





432


embedded image


C24H32BrN5O2
501.17
502





433


embedded image


C22H30N6O
394.25
395





434


embedded image


C24H30F3N5O
461.24
462





435


embedded image


C21H29N7O
395.24
396





436


embedded image


C23H31N5O
393.25
394





437


embedded image


C22H30N6O
394.25
395





438


embedded image


C21H29N7O
395.24
396





439


embedded image


C23H30ClN5O
427.21
428





440


embedded image


C23H30ClN5O
427.21
428





441


embedded image


C23H30ClN5O
427.21
428





442


embedded image


C23H30FN5O
411.24
412





443


embedded image


C23H30FN5O
411.24
412





444


embedded image


C24H33N5O
407.27
408





445


embedded image


C24H33N5O
407.27
408





446


embedded image


C24H33N5O
407.27
408





447


embedded image


C24H33N5O
407.27
408





448


embedded image


C24H30F3N5O
461.24
462





449


embedded image


C24H30F3N5O
461.24
462





450


embedded image


C24H30N6O
418.25
419





451


embedded image


C24H33N5O2
423.26
424





452


embedded image


C24H33N5O2
423.26
424





453


embedded image


C24H33N5O2
423.26
424





454


embedded image


C25H33N5O2
435.26
436





455


embedded image


C24H29ClF3N5O
495.20
496





456


embedded image


C24H32ClN5O
441.23
442





457


embedded image


C25H35N5O
421.28
422





458


embedded image


C23H29Cl2N5O
461.17
462





459


embedded image


C23H29F3N6O
462.24
463





460


embedded image


C23H29F3N6O
462.24
463





461


embedded image


C23H28ClF3N6O
496.20
497





462


embedded image


C25H35N5O2
437.28
438





463


embedded image


C23H29Cl2N5O
461.17
462





464


embedded image


C25H35N5O
421.28
422





465


embedded image


C23H29Cl2N5O
461.17
462





466


embedded image


C25H35N5O3
453.27
454





467


embedded image


C24H32ClN5O2
457.22
458





468


embedded image


C23H38N6O
414.31
415





469


embedded image


C23H29F2N5O
429.23
430





470


embedded image


C24H30N6O
418.25
419





471


embedded image


C25H35N5O
421.28
422





472


embedded image


C23H37N5O
399.30
400





473


embedded image


C23H32N6O
408.26
409





474


embedded image


C23H32N6O
408.26
409





475


embedded image


C26H37N5O
435.30
436





476


embedded image


C28H36ClN5O2
509.26
510





477


embedded image


C25H34N4O
406.27
407





478


embedded image


C25H31FN4O2
438.24
439





479


embedded image


C23H27ClFN5O
443.96
444





480


embedded image


C23H30FN5O2
427.53
428





481


embedded image


C23H29F2N5O2
445.52
446





482


embedded image


C23H27F2N5O
427.50
428





483


embedded image


C23H29ClFN5O2
461.97
462





484


embedded image


C28H37FN4O4
512.28
513





485


embedded image


C28H32FN5O4
521.24
522





486


embedded image


C23H30ClN5O2
443.98
444





487


embedded image


C23H29ClFN5O2
461.97
462





488


embedded image


C26H34N4O2
434.27
435





489


embedded image


C30H36N4O
468.29
469





490


embedded image


C26H34N4O3
450.26
451





491


embedded image


C25H32N4O2
420.25
421





492


embedded image


C26H34N4O3
450.26
451





493


embedded image


C25H30N4O3
434.23
435





494


embedded image


C26H35N5O2
449.28
450





495


embedded image


C25H30FN5O2
451.24
452





496


embedded image


C25H31N5OS
449.23
450





497


embedded image


C26H33N5O
431.27
432





498


embedded image


C27H35N5O
445.28
446





499


embedded image


C25H31F3N4O2
476.24
477





500


embedded image


C26H35N5O3S
497.25
498





501


embedded image


C25H31N5O3
449.24
450





502


embedded image


C23H29ClN4O
412.20
413





503


embedded image


C23H29FN4O
396.23
397





504


embedded image


C25H31N5O
417.25
418





505


embedded image


C24H30N6O3
450.24
451





506


embedded image


C24H31FN4O2
426.24
427





507


embedded image


C25H31FN4O
422.25
423




















TABLE 7





Ex.

Molecular
Monoisotopic
M +


No.
Structure
formula
molecular wt.
H+



















508


embedded image


C26H33N3O2
419.26
420





509


embedded image


C26H34N4O2
434.27
435





510


embedded image


C26H27N3O2
413.21
414





511


embedded image


C30H35N3O2
469.27
470





512


embedded image


C27H29N3O2
427.23
428





513


embedded image


C27H28N4O6S
536.17
537





514


embedded image


C25H33N3O3
423.25
424





515


embedded image


C24H29N3O3
407.22
408





516


embedded image


C25H33N3O3
423.25
424





517


embedded image


C27H29N3O3
443.22
444





518


embedded image


C27H29N3O2
427.23
428





519


embedded image


C27H29N3O2
427.23
428





520


embedded image


C27H29N3O2
427.23
428





521


embedded image


C27H26F3N3O2
481.20
482





522


embedded image


C27H26F3N3O2
481.20
482





523


embedded image


C28H31N3O4
473.23
474





524


embedded image


C27H28N4O4S
504.18
505





525


embedded image


C26H25ClFN3O3
481.16
482





526


embedded image


C24H25N3O3
403.19
404





527


embedded image


C24H25N3O2S
419.17
420





528


embedded image


C25H28N4O2
416.22
417





529


embedded image


C24H24ClN3O3
437.15
438





530


embedded image


C24H24FN3O3
421.18
422





531


embedded image


C25H33N3O
391.26
392





532


embedded image


C25H27N3O2
401.21
402





533


embedded image


C25H27N3O
385.21
386





534


embedded image


C23H31N3O2
381.24
382





535


embedded image


C26H29N3O2
415.23
416





536


embedded image


C25H27N3O
385.21
386





537


embedded image


C24H31N3O
377.25
378





538


embedded image


C25H26N4O4
446.20
447





539


embedded image


C26H29N3O
399.23
400





540


embedded image


C26H29N3O2
415.23
416





541


embedded image


C28H33N3O2
443.26
444





542


embedded image


C25H29N5O4
463.22
464





543


embedded image


C23H31N3O2
381.24
382





544


embedded image


C25H27N3O2
401.21
402





545


embedded image


C25H31N3O2
405.24
406





546


embedded image


C27H31N3O
413.25
414





547


embedded image


C28H33N3O
427.26
428





548


embedded image


C21H22FN5O2
395.18
396





549


embedded image


C25H25N3O2
399.20
400





550


embedded image


C29H35N3O
441.28
442





551


embedded image


C23H23ClN4O4
454.14
455





552


embedded image


C25H26FN3O2
419.20
420





553


embedded image


C26H29N3O
399.23
400





554


embedded image


C27H29N3O2
427.23
428





555


embedded image


C28H38N4O3
478.29
479





556


embedded image


C25H26FN3O
403.21
404





557


embedded image


C23H24FN3OS
409.16
410





558


embedded image


C26H26F3N3O2
469.20
470





559


embedded image


C29H34N4O2
470.27
471





560


embedded image


C25H26N4O4
446.20
447





561


embedded image


C24H33N3O2
395.26
396





562


embedded image


C24H33N3O2
395.26
396





563


embedded image


C25H26FN3O
403.21
404





564


embedded image


C26H29N3O2
415.23
416





565


embedded image


C25H26ClN30
419.18
420





566


embedded image


C26H29N3O2
415.23
416





567


embedded image


C26H29N3O2
415.23
416





568


embedded image


C25H26FN3O
403.21
404





569


embedded image


C26H27N3O3
429.20
430





570


embedded image


C26H29N3O
399.23
400





571


embedded image


C26H29N3O
399.23
400





572


embedded image


C26H26F3N3O
453.20
454





573


embedded image


C26H26F3N3O
453.20
454





574


embedded image


C26H35N3O2
421.27
422





575


embedded image


C27H31N3O2
429.24
430





576


embedded image


C25H26ClN3O
419.18
420





577


embedded image


C25H25Cl2N3O
453.14
454





578


embedded image


C24H28N4O2
404.22
405





579


embedded image


C27H31N3O3S
477.21
478





580


embedded image


C25H31N5O3
449.24
450





581


embedded image


C24H31N3O2
393.24
394





582


embedded image


C23H31N3O2
381.24
382





583


embedded image


C25H25F3N4O2
470.19
471





584


embedded image


C24H39N3O
385.31
386





585


embedded image


C25H25Cl2N3O
453.14
454





586


embedded image


C25H26BrN3O
463.13
464





587


embedded image


C25H32ClN3O
425.22
426





588


embedded image


C25H32N4O2
420.25
421





589


embedded image


C24H26N4O4
434.20
435





590


embedded image


C24H30FN3O2
411.23
412





591


embedded image


C26H28FN3O
417.22
418





592


embedded image


C25H25N5O2
427.20
428





593


embedded image


C26H26N4O
410.21
411





594


embedded image


C26H32FN3O2
437.25
438





595


embedded image


C25H26ClN3O
419.18
420





596


embedded image


C24H26N4O
386.21
387





597


embedded image


C26H26F3N3O
453.20
454





598


embedded image


C27H31N3O3
445.24
446





599


embedded image


C28H29N3O3
455.22
456





600


embedded image


C24H33N3O2
395.26
396





601


embedded image


C25H27N3O
385.21
386





602


embedded image


C28H30N4O2
454.24
455





603


embedded image


C26H36N4O4
468.27
469





604


embedded image


C28H38N4O3
478.29
479





605


embedded image


C22H28FN3O2S
417.55
418





606


embedded image


C23H29N3O3
395.22
396





607


embedded image


C27H33N3O3
447.25
448





608


embedded image


C27H37N3O4
467.28
468





609


embedded image


C29H39N3O3
477.30
478





610


embedded image


C27H29FN4O3
476.22
477





611


embedded image


C25H34N4O4
454.26
455





612


embedded image


C27H35N3O2
433.27
434





613


embedded image


C25H31N3O3
421.24
422





614


embedded image


C28H32N4O4
488.24
489





615


embedded image


C27H35ClN4O3
498.24
499





616


embedded image


C26H29N5O4
475.22
476





617


embedded image


C28H36F3N3O4
535.27
536





618


embedded image


C27H38N4O4
482.29
483





619


embedded image


C27H38N4O4
482.29
483





620


embedded image


C28H39N3O5
497.29
498





621


embedded image


C23H23N5O3
417.18
418





622


embedded image


C25H26N4O2
414.21
415





623


embedded image


C28H35ClN4O4
526.23
527





624


embedded image


C28H39N3O4
481.29
482





625


embedded image


C27H36ClN3O4
501.24
502





626


embedded image


C27H35F2N3O4
503.26
504





627


embedded image


C27H36FN3O4
485.27
486





628


embedded image


C27H36FN3O4
485.27
486





629


embedded image


C28H39N3O4
481.29
482





630


embedded image


C28H36F3N3O4
535.27
536





631


embedded image


C27H35ClFN3O4
519.23
520





632


embedded image


C28H36N4O4
492.27
493





633


embedded image


C28H38ClN3O4
515.26
516





634


embedded image


C31H39N3O4
517.29
518





635


embedded image


C27H36BrN3O4
545.19
546





636


embedded image


C28H36N4O4
492.27
493





637


embedded image


C26H35ClN4O4
502.23
503





638


embedded image


C27H35F2N3O4
503.26
504





639


embedded image


C27H36BrN3O4
545.19
546





640


embedded image


C27H35F2N3O4
503.26
504





641


embedded image


C23H31N3O3
397.24
398





642


embedded image


C24H33N3O3
411.25
412





643


embedded image


C27H37N3O5
483.27
484





644


embedded image


C25H34N4O4
454.26
455





645


embedded image


C27H36FN3O4
485.27
486





646


embedded image


C27H24FN3O3
457.18
458





647


embedded image


C27H33N3O2
431.26
432





648


embedded image


C23H31N3O3
397.24
398





649


embedded image


C25H24FN3O2
417.18
418





650


embedded image


C27H36N4O3
464.28
465





651


embedded image


C25H26N4O2
414.21
415





652


embedded image


C31H33FN4O3
528.25
529





653


embedded image


C32H38N4O2
510.30
511





654


embedded image


C28H38N4O2
462.30
463





655


embedded image


C29H34N4O2
470.27
471





656


embedded image


C26H26ClN3O2
447.17
448





657


embedded image


C29H38N4O2
474.30
475





658


embedded image


C27H29N3O3
443.22
444





659


embedded image


C24H29N5O4
451.22
452





660


embedded image


C25H33N3O2
407.26
408





661


embedded image


C25H30N4O3S2
498.18
499





662


embedded image


C28H29FN4O3
488.22
489





663


embedded image


C31H44N4O2
504.35
505





664


embedded image


C32H40N4O2
512.32
513





665


embedded image


C25H30N6O3
462.24
463





666


embedded image


C25H30N6O3
462.24
463





667


embedded image


C30H33N5O4
527.25
528





668


embedded image


C27H27N3O4
457.20
458





669


embedded image


C26H31N5O3
461.24
462





670


embedded image


C21H27N3O4
385.20
386





671


embedded image


C25H30N6O3
462.24
463





672


embedded image


C31H35FN4O3
530.27
531





673


embedded image


C26H32N6O3
476.25
477





674


embedded image


C27H42FN3O4
491.32
492





675


embedded image


C25H32N4O
404.26
405





676


embedded image


C27H30N4O2
442.24
443





677


embedded image


C29H34N4O2
470.27
471





678


embedded image


C26H28FN3O
417.22
418





679


embedded image


C25H32FN3O2
425.55
426





680


embedded image


C23H30N4O2
394.24
395





681


embedded image


C25H32N4O2
420.25
421





682


embedded image


C24H30N4O2
406.24
407





683


embedded image


C26H28N4O2
428.22
429





684


embedded image


C23H28N4O2
392.22
393





685


embedded image


C26H34N4O2
434.27
435





686


embedded image


C24H27N5O3
433.21
434





687


embedded image


C24H32N4O2
408.25
409





688


embedded image


C22H30N4O2
382.24
383





689


embedded image


C24H33N5O
407.27
408





690


embedded image


C25H28N4O2
416.22
417





691


embedded image


C24H26N4O
386.21
387





692


embedded image


C22H24N4OS
392.17
393





693


embedded image


C21H24N4OS
380.17
381





694


embedded image


C19H21N3OS2
371.11
372





695


embedded image


C23H24ClN3O2
409.16
410





696


embedded image


C22H24ClN3OS
413.13
414





697


embedded image


C21H21ClFN3OS
417.11
418





698


embedded image


C21H21Cl2N3OS
433.08
434





699


embedded image


C21H21ClN4O3S
444.10
445





700


embedded image


C22H23Cl2N3O2S
463.09
464





701


embedded image


C22H24ClN3O2S
429.13
430





702


embedded image


C23H26ClN3OS
427.15
428





703


embedded image


C24H26ClN3O2S
455.14
456





704


embedded image


C22H24F3N5OS
463.17
464





705


embedded image


C24H23ClF3N3O2
477.14
478





706


embedded image


C24H24F3N3O2
443.18
444





707


embedded image


C23H28BrN5O2
485.14
486





708


embedded image


C24H25F3N4O2S
490.17
491





709


embedded image


C22H22N4OS
390.15
391





710


embedded image


C23H25N3O2
375.20
376





711


embedded image


C24H27N3O2S
421.18
422





712


embedded image


C24H26ClN3O3
439.17
440





713


embedded image


C21H22ClN3OS
399.12
400





714


embedded image


C25H23F6N3O2
511.17
512





715


embedded image


C23H30FN3O2
399.51
400





716


embedded image


C26H34FN3O4
471.25
472





717


embedded image


C26H29N3O2
415.23
416





718


embedded image


C27H31N3O2
429.24
430





719


embedded image


C26H33N3O2
419.26
420





720


embedded image


C25H28N4O4
448.21
449





721


embedded image


C24H33N3O2
395.26
396





722


embedded image


C26H28FN3O2
433.22
434





723


embedded image


C26H27N3O2
413.21
414





724


embedded image


C25H33N3O2
407.26
408





725


embedded image


C26H28BrN3O
477.14
478





726


embedded image


C24H26FN3OS
423.18
424





727


embedded image


C26H28FN3O
417.22
418





728


embedded image


C27H31N3O2
429.24
430





729


embedded image


C26H28ClN3O
433.19
434





730


embedded image


C26H28ClN3O
433.19
434





731


embedded image


C26H28ClN3O
433.19
434





732


embedded image


C24H25ClN4O4
468.16
469





733


embedded image


C26H28FN3O
417.22
418





734


embedded image


C27H29N3O3
443.22
444





735


embedded image


C27H31N3O
413.25
414





736


embedded image


C27H31N3O
413.25
414





737


embedded image


C26H26FN3O2
431.20
432





738


embedded image


C27H29N3O2
427.23
428





739


embedded image


C25H35N3O2
409.27
410





740


embedded image


C26H34ClN3O
439.24
440





741


embedded image


C32H36N6O3
552.28
553





742


embedded image


C26H36FN3O2
411.59
412





743


embedded image


C25H32N4O2
420.25
421





744


embedded image


C24H30N4O2
406.24
407





745


embedded image


C26H28N4O2
428.22
429





746


embedded image


C27H30N4O2
442.24
443





747


embedded image


C24H32N4O2
408.25
409





748


embedded image


C24H30N4O2
406.24
407





749


embedded image


C24H32N4O2
408.25
409





750


embedded image


C25H32N4O2
420.25
421





751


embedded image


C24H30N4O2
406.24
407





752


embedded image


C25H34N4O2
422.27
423





753


embedded image


C22H30N4O2
382.24
383





754


embedded image


C27H35FN4O6
530.25
531





755


embedded image


C24H32N4O2
408.25
409





756


embedded image


C26H27FN4O2
446.21
447





757


embedded image


C25H34N4O2
422.27
423





758


embedded image


C24H32N4O2
408.25
409





759


embedded image


C24H26N4O3
418.20
419





760


embedded image


C24H30N4O2
406.24
407





761


embedded image


C26H32N4O2
432.25
433





762


embedded image


C26H34N4O2
434.27
435





763


embedded image


C26H34N4O3
450.26
451





764


embedded image


C25H31ClN4O2
454.21
455





765


embedded image


C24H30N4O2
406.24
407





766


embedded image


C25H34N4O2
422.27
423





767


embedded image


C24H26N4O2S
434.18
435





768


embedded image


C26H34N4O2
434.27
435





769


embedded image


C23H30ClN3O2
415.20
416





770


embedded image


C24H32FN3O2
413.25
414





771


embedded image


C23H28FN3O2
397.22
398





772


embedded image


C24H30FN3O2
411.23
412





773


embedded image


C24H30FN3O2
411.23
412





774


embedded image


C25H33FN4O2
440.26
441





775


embedded image


C26H33FN4O3
468.25
469





776


embedded image


C23H26N4O
374.21
375





777


embedded image


C28H30N4O
438.24
439





778


embedded image


C21H25N5O2
379.20
380





779


embedded image


C26H27N3O2
413.21
414





780


embedded image


C26H26N4O
410.21
411





781


embedded image


C25H31N5O
417.25
418





782


embedded image


C21H24N6OS
408.17
409





783


embedded image


C22H25N5O
375.21
376





784


embedded image


C24H28F3N5O
459.23
460





785


embedded image


C25H30N6O
430.25
431





786


embedded image


C26H32N6O
444.26
445





787


embedded image


C25H27N3OS
417.19
418





788


embedded image


C30H34N4O
466.27
467





789


embedded image


C24H30N4OS
422.21
423





790


embedded image


C24H26ClN3O3S2
503.11
504





791


embedded image


C23H23Cl2N3O3
459.11
460





792


embedded image


C24H26ClN3O2
423.17
424





793


embedded image


C23H26N4OS
406.18
407





794


embedded image


C25H27N3O3S
449.18
450





795


embedded image


C23H25ClN4OS
440.14
441





796


embedded image


C23H25N3O3
391.19
392





797


embedded image


C23H23F3N4O2
444.18
445





798


embedded image


C23H28N4O3
408.22
409





799


embedded image


C25H30N4O
402.24
403





800


embedded image


C26H29N3O2
415.23
416





801


embedded image


C27H29N5O
439.24
440





802


embedded image


C22H24F3N3O2
419.18
420





803


embedded image


C22H25N3O3
379.19
380





804


embedded image


C22H24N4O
360.20
361





805


embedded image


C22H23F4N3O
421.18
422





806


embedded image


C23H29N3O2
379.23
380





807


embedded image


C26H29N3O2
415.23
416





808


embedded image


C27H30FN3O
431.24
432





809


embedded image


C22H23F3N4O2
432.18
433





810


embedded image


C25H25N3O2
399.20
400





811


embedded image


C25H28N40
400.23
401





812


embedded image


C21H24F3N3O3
423.18
424





813


embedded image


C22H30N4O
366.24
367





814


embedded image


C24H31FN4O2
426.24
427





815


embedded image


C25H31FN4O3
454.24
455





816


embedded image


C25H30FN3O2
423.23
424





817


embedded image


C23H30N4O
378.24
379





818


embedded image


C24H27N3O4
421.20
422





819


embedded image


C30H34FN3O4
519.25
520





820


embedded image


C30H34FN3O4
519.25
520





821


embedded image


C29H34FN3O4S
539.22
540





822


embedded image


C29H38FN3O3
495.29
496





823


embedded image


C30H40FN3O3
509.30
510





824


embedded image


C31H35F2N3O3
535.27
536





825


embedded image


C28H38FN3O4
499.29
500





826


embedded image


C30H39ClFN3O3
543.27
544





827


embedded image


C29H33ClFN3O5
557.21
558





828


embedded image


C29H38FN3O4
511.29
512





829


embedded image


C29H33FN4O6
552.24
553





830


embedded image


C28H38FN3O4
499.29
500





831


embedded image


C30H34FN3O3
503.26
504





832


embedded image


C31H36FN3O4
533.27
534





833


embedded image


C33H37FN4O4
572.28
573





834


embedded image


C31H36FN3O3
517.27
518





835


embedded image


C29H40FN3O4
513.30
514





836


embedded image


C30H33F2N3O3
521.25
522





837


embedded image


C25H32N4O2
420.25
421





838


embedded image


C23H30N4O2S
426.21
427





839


embedded image


C23H30N4O3
410.23
411





840


embedded image


C25H36N4O2
424.28
425





841


embedded image


C24H36N4O2
412.28
413





842


embedded image


C23H34N4O2
398.27
399





843


embedded image


C23H34N4O2
398.27
399





844


embedded image


C25H31FN4O2
438.24
439





845


embedded image


C26H34N4O2
434.27
435





846


embedded image


C25H31ClN4O2
454.21
455





847


embedded image


C23H36N4O2
400.28
401





848


embedded image


C23H36N4O2
400.28
401





849


embedded image


C26H25N3O4S
475.16
476





850


embedded image


C21H23N3O
333.18
334





851


embedded image


C22H25N5O
375.21
376





852


embedded image


C21H23N5OS
393.16
394





853


embedded image


C20H22N6OS
394.16
395





854


embedded image


C20H25N5OS
383.18
384





855


embedded image


C23H29N5O4
439.22
440





856


embedded image


C25H32N4O3S
468.22
469





857


embedded image


C22H30N4OS2
430.19
431





858


embedded image


C24H31BrN4OS
502.14
503





859


embedded image


C24H24FN3O3
421.18
422





860


embedded image


C28H27ClN4O
470.19
471





861


embedded image


C23H31N5OS
425.23
426





862


embedded image


C22H30N4O5S
462.19
463





863


embedded image


C23H32N4O4S
460.21
461





864


embedded image


C27H29N5O
439.24
440





865


embedded image


C22H25N5O2
391.20
392





866


embedded image


C26H29N3O4S
479.19
480





867


embedded image


C23H23F3N4OS
460.15
461





868


embedded image


C22H29N7O2
423.24
424





869


embedded image


C25H26N6O
426.22
427





870


embedded image


C26H32N4O2
432.25
433





871


embedded image


C24H27N3O2
389.21
390





872


embedded image


C27H29N5O
439.24
440





873


embedded image


C23H28N4O3S
440.19
441





874


embedded image


C28H34N4OS
474.24
475





875


embedded image


C24H28N4O3S
452.19
453





876


embedded image


C23H23ClN4O3
438.15
439





877


embedded image


C23H26FN5O
407.21
408





878


embedded image


C25H27ClN4O2
450.18
451





879


embedded image


C24H27N5O
401.22
402





880


embedded image


C24H30F3N5O
461.24
462





881


embedded image


C22H23ClN4O2
410.15
411





882


embedded image


C23H26N4OS
406.18
407





883


embedded image


C24H26N4O
386.21
387





884


embedded image


C24H26N4O
386.21
387





885


embedded image


C24H26N4O
386.21
387





886


embedded image


C21H23F3N6OS
464.16
465





887


embedded image


C23H30N4O3S
442.20
443





888


embedded image


C24H26N4O2
402.21
403





889


embedded image


C24H25F3N4OS
474.17
475





890


embedded image


C27H29N3O
411.23
412





891


embedded image


C26H29N3O
399.23
400





892


embedded image


C28H31N3O2
441.24
442





893


embedded image


C23H28N4O2
392.22
393





894


embedded image


C27H29N3O2
427.23
428





895


embedded image


C21H25N7O
391.21
392





896


embedded image


C21H28N4OS
384.20
385





897


embedded image


C23H26ClN5O
423.18
424





898


embedded image


C21H23N5OS
393.16
394





899


embedded image


C26H26ClN5O
459.18
460





900


embedded image


C23H27N5O
389.22
390





901


embedded image


C25H34N4O
406.27
407





902


embedded image


C24H30N4O2
406.24
407





903


embedded image


C23H30ClN3O2
415.20
416





904


embedded image


C25H25F2N3O2
437.19
438





905


embedded image


C29H39FN4O2
494.31
495





906


embedded image


C29H32F2N4O2
506.25
507





907


embedded image


C30H35FN4O2
502.27
503





908


embedded image


C27H37FN4O3
484.29
485





909


embedded image


C27H37FN4O3
484.29
485





910


embedded image


C25H34FN3O3
443.26
444





911


embedded image


C24H30Cl2FN3O2
481.17
482





912


embedded image


C24H31FN4O4
458.23
459





913


embedded image


C24H31ClFN3O2
447.21
448





914


embedded image


C26H36FN3O2
441.28
442





915


embedded image


C25H32Cl2FN3O3
511.18
512





916


embedded image


C24H28F5N3O2
485.21
486





917


embedded image


C24H31F2N3O2
431.24
432





918


embedded image


C26H34FN3O3
455.26
456





919


embedded image


C28H40FN3O3
485.30
486





920


embedded image


C25H34FN5O
439.27
440





921


embedded image


C23H31FN4O2
414.24
415





922


embedded image


C24H26FN3O3
423.20
424





923


embedded image


C26H28FN3O2
433.22
434





924


embedded image


C26H33FN4O2
452.26
453





925


embedded image


C26H32ClFN4O2
486.22
487





926


embedded image


C25H31FN4O2
438.24
439





927


embedded image


C26H31F3N4O3
504.23
505





928


embedded image


C26H33ClN4O3
484.22
485





929


embedded image


C25H31ClN4O2
454.21
455





930


embedded image


C24H31ClFN3O2
447.21
448





931


embedded image


C25H34FN3O2
427.26
428





932


embedded image


C27H33FN4O2
464.26
465





933


embedded image


C26H28FN3O2
433.22
434





934


embedded image


C25H28FN3O2S
453.19
454





935


embedded image


C25H32FN3O
409.25
410





936


embedded image


C26H34FN3O
423.27
424





937


embedded image


C27H29F2N3O
449.23
450





938


embedded image


C24H32FN3O2
413.25
414





939


embedded image


C26H33ClFN3O
457.23
458





940


embedded image


C24H32FN3O2
413.25
414





941


embedded image


C26H28FN3O
417.22
418





942


embedded image


C27H30FN3O2
447.23
448





943


embedded image


C29H31FN4O2
486.24
487





944


embedded image


C27H30FN3O
431.24
432





945


embedded image


C25H34FN3O2
427.26
428





946


embedded image


C26H27F2N3O
435.21
436





947


embedded image


C25H27FN4O2
434.52
435





948


embedded image


C25H27FN4O4
466.20
467





949


embedded image


C24H29FN4O3
440.22
441





950


embedded image


C27H30FN3O2
447.23
448





951


embedded image


C23H31FN4O
398.25
399





952


embedded image


C24H26ClFN4OS
472.15
473





953


embedded image


C25H25F2N3O3
453.19
454





954


embedded image


C24H27F2N5O
439.22
440





955


embedded image


C26H31F2N3O2
455.24
456





956


embedded image


C23H31N3O2
381.24
382





957


embedded image


C24H33N3O2
395.26
396





958


embedded image


C24H33N3O2
395.26
396





959


embedded image


C26H29N3O2
415.23
416





960


embedded image


C25H29N5O2
431.23
432





961


embedded image


C24H24ClFN4O3
470.15
471





962


embedded image


C27H36FN3O2
453.61
454





963


embedded image


C24H30N4O2
406.24
407





964


embedded image


C24H28N4O2
404.22
405





965


embedded image


C27H29N5O
439.24
440





966


embedded image


C25H28N4O4S
480.18
481





967


embedded image


C24H26N4O2
402.21
403





968


embedded image


C27H27BrN4O2
518.13
519





969


embedded image


C22H24ClN5O
409.17
410





970


embedded image


C22H23F2N3O3
415.17
416





971


embedded image


C21H23N5OS
393.16
394





972


embedded image


C23H24ClN3OS
425.13
426





973


embedded image


C22H24N4O3
392.18
393





974


embedded image


C25H27ClN4O2
450.18
451





975


embedded image


C25H30N4O
402.24
403





976


embedded image


C22H25N5O
375.21
376





977


embedded image


C22H27N3O3S
413.18
414





978


embedded image


C20H23F3N4OS
424.15
425





979


embedded image


C21H24F3N3OS
423.16
424





980


embedded image


C26H24BrF3N6O
572.11
573





981


embedded image


C23H25ClN4OS
440.14
441





982


embedded image


C24H32N4O3S
456.22
457





983


embedded image


C24H31ClN4O3S
490.18
491





984


embedded image


C23H25N3O4S
439.16
440





985


embedded image


C26H32N4O3
448.25
449





986


embedded image


C26H32N4O
416.26
417





987


embedded image


C22H27N3OS
381.19
382





988


embedded image


C24H31N3O2
393.24
394





989


embedded image


C22H24F3N3OS
435.16
436





990


embedded image


C24H33N3O
379.26
380





991


embedded image


C22H29N3O2
367.23
368





992


embedded image


C25H35N3O
393.28
394





993


embedded image


C25H30N4O
402.24
403





994


embedded image


C22H26N4OS2
426.15
427





995


embedded image


C29H32N4O2
468.25
469





996


embedded image


C23H26FN5O
407.21
408





997


embedded image


C28H28ClN5O
485.20
486





998


embedded image


C20H23N5O2S
397.16
398





999


embedded image


C25H26N6O
426.22
427





1000


embedded image


C22H24N4O2
376.19
377





1001


embedded image


C26H35FN4O2
454.27
455





1002


embedded image


C25H34FN3O2
427.57
428





1003


embedded image


C24H25FN4O
404.20
405





1004


embedded image


C25H30N4O2
418.24
419





1005


embedded image


C26H31FN4O2
450.24
451





1006


embedded image


C25H34N4O2
422.27
423





1007


embedded image


C24H30N4O2
406.24
407





1008


embedded image


C27H30N4O2
442.24
443





1009


embedded image


C27H29FN4O2
460.23
461





1010


embedded image


C26H34N4O2
434.27
435





1011


embedded image


C26H26ClFN4O2
480.17
481





1012


embedded image


C26H27FN4O2
446.21
447





1013


embedded image


C25H27N5O2
429.22
430





1014


embedded image


C27H36N4O2
448.28
449





1015


embedded image


C25H29N5O3
447.23
448





1016


embedded image


C29H32N4O2
468.25
469





1017


embedded image


C26H27FN4O2
446.21
447





1018


embedded image


C23H30N4O3
410.23
411





1019


embedded image


C23H30N4O3
410.23
411





1020


embedded image


C24H30N4O2
406.24
407





1021


embedded image


C24H28N6O2
432.23
433





1022


embedded image


C25H27N5O2
429.22
430





1023


embedded image


C25H34N4O2
422.27
423





1024


embedded image


C25H28N4O2S
448.19
449





1025


embedded image


C25H29N5O2
431.23
432





1026


embedded image


C26H26F2N4O2
464.20
465





1027


embedded image


C24H27N5O2
417.22
418





1028


embedded image


C29H38N4O2
474.30
475





1029


embedded image


C27H36N4O3
464.28
465





1030


embedded image


C24H27N5O2
417.22
418





1031


embedded image


C27H36N4O2
448.28
449





1032


embedded image


C27H36N4O2
448.28
449





1033


embedded image


C27H38N4O2
450.30
451





1034


embedded image


C29H32N4O2
468.25
469





1035


embedded image


C27H34N4O2
446.27
447





1036


embedded image


C26H27ClN4O2
462.18
463





1037


embedded image


C22H24N6O2S
436.17
437





1038


embedded image


C23H25N5O3
419.20
420





1039


embedded image


C25H32N4O2
420.25
421





1040


embedded image


C26H27ClN4O2
462.18
463





1041


embedded image


C27H30N4O2
442.24
443





1042


embedded image


C24H30N4O3
422.23
423





1043


embedded image


C27H30N4O2
442.24
443





1044


embedded image


C30H38N4O2
486.30
487





1045


embedded image


C29H34N4O3
486.26
487





1046


embedded image


C27H28F2N4O3
494.21
495





1047


embedded image


C25H32N4O3
436.25
437





1048


embedded image


C27H36N4O2
448.28
449





1049


embedded image


C23H27F3N4O2
448.21
449





1050


embedded image


C26H32N4O2
432.25
433





1051


embedded image


C26H36N4O2
436.28
437





1052


embedded image


C22H28FN3O2
385.22
386





1053


embedded image


C27H30N4O2
442.24
443





1054


embedded image


C21H24N6O
376.20
377





1055


embedded image


C25H27N5OS
445.19
446





1056


embedded image


C24H26N4O
386.21
387





1057


embedded image


C22H24N4O2
376.19
377





1058


embedded image


C27H30N4O
426.24
427





1059


embedded image


C24H32N4O
392.26
393





1060


embedded image


C22H26N6O
390.22
391





1061


embedded image


C24H27N5O2
417.22
418





1062


embedded image


C23H26ClN5O
423.18
424





1063


embedded image


C24H26ClN3O2
423.17
424





1064


embedded image


C24H25ClN6O2
464.17
465





1065


embedded image


C24H27N3OS
405.19
406





1066


embedded image


C20H21ClN4O2S
416.11
417





1067


embedded image


C25H26N4O3S
462.17
463





1068


embedded image


C26H28N4O4
460.21
461





1069


embedded image


C30H42FN3O4
527.32
528





1070


embedded image


C31H42FN3O4
539.32
540





1071


embedded image


C27H30N4O2
442.24
443





1072


embedded image


C28H32N4O3
472.25
473





1073


embedded image


C25H32FN3O2
425.25
426





1074


embedded image


C27H30FN3O2
447.23
448





1075


embedded image


C27H30FN3O
431.24
432





1076


embedded image


C28H27FN4O3
486.21
487





1077


embedded image


C28H28BrFN4O2
550.14
551





1078


embedded image


C28H31FN4O2
474.24
475





1079


embedded image


C26H31FN4O
434.25
435





1080


embedded image


C26H29FN4O2
448.23
449





1081


embedded image


C28H30FN5O
471.24
472





1082


embedded image


C29H31FN4O
470.25
471





1083


embedded image


C27H30FN3OS
463.21
464





1084


embedded image


C25H28FN5OS
465.20
466





1085


embedded image


C26H29FN4OS
464.20
465





1086


embedded image


C28H29FN4O2
472.23
473





1087


embedded image


C27H30FN3O2
447.23
448





1088


embedded image


C27H29ClFN3O2
481.19
482





1089


embedded image


C25H34FN3O
411.27
412





1090


embedded image


C25H34FN3O2
427.26
428





1091


embedded image


C23H30FN3O2
399.23
400





1092


embedded image


C24H32FN3O2
413.25
414





1093

C26H32FN3O2
437.25
438





1094

C30H36N4O4
516.27
517





1095


embedded image


C25H31F2N3O2
443.24
444





1096


embedded image


C25H31F2N3O2
443.24
444





1097


embedded image


C26H27F2N3O2
451.21
452





1098


embedded image


C26H34F2N4O
456.27
457





1099


embedded image


C27H27FN4O2
458.21
459





1100


embedded image


C27H27FN4O2
458.21
459





1101


embedded image


C24H30FN3O2
411.23
412





1102


embedded image


C23H25FN4OS
424.17
425





1103


embedded image


C28H29FN4O2
472.23
473





1104


embedded image


C25H32FN3O2
425.25
426





1105


embedded image


C24H27FN4OS
438.19
439





1106


embedded image


C25H34FN3O3
443.26
444





1107


embedded image


C26H27F2N3O2
451.21
452





1108


embedded image


C27H36FN3O2
453.28
454





1109


embedded image


C26H26F3N3O2
469.20
470





1110


embedded image


C25H27FN4O2
434.21
435





1111


embedded image


C25H34FN3O2
427.26
428





1112


embedded image


C26H34FN3O2
439.26
440





1113


embedded image


C27H36FN3O2
453.28
454





1114


embedded image


C25H34FN3O2
427.26
428





1115


embedded image


C25H33ClFN3O3
477.22
478





1116


embedded image


C24H31F2N3O2
431.24
432





1117


embedded image


C25H32FN3O2
425.25
426





1118


embedded image


C27H30FN3O3S
495.62
496





1119


embedded image


C23H27F4N3O
437.21
438





1120


embedded image


C26H36FN3O2
441.28
442





1121


embedded image


C25H27FN4O2
434.21
435





1122


embedded image


C25H33N3O2
407.26
408





1123


embedded image


C24H31N3O2
393.24
394





1124


embedded image


C25H34FN3O2
427.26
428





1125


embedded image


C23H30FN3O2
399.23
400





1126


embedded image


C27H29ClFN3O2
481.19
482





1127


embedded image


C22H25F4N3OS
455.17
456





1128


embedded image


C25H32FN3O2
425.25
426





1129


embedded image


C25H32F2N4O
442.25
443





1130


embedded image


C26H29FN4O2
448.23
449




















TABLE 8





Ex.

Molecular
Monoisotopic
M +


No.
Structure
formula
molecular wt.
H+



















1131


embedded image


C23H23Cl2N3O2
443.12
444





1132


embedded image


C23H23ClFN3O2
427.15
428





1133


embedded image


C24H26FN3O2
407.20
408





1134


embedded image


C28H33N3O4
475.25
476





1135


embedded image


C29H34N4O5
518.25
519





1136


embedded image


C33H41N3O4
543.31
544





1137


embedded image


C29H36N4O4
504.27
505





1138


embedded image


C29H32N4O4
500.24
501





1139


embedded image


C28H30F3N3O4
529.22
530





1140


embedded image


C22H22Cl2N4OS
460.09
461





1141


embedded image


C22H23ClN4OS
426.13
427





1142


embedded image


C22H23FN4OS
410.16
411





1143


embedded image


C23H25FN4OS
424.17
425





1144


embedded image


C23H22ClF3N4OS
494.12
495





1145


embedded image


C26H26N4OS
442.18
443





1146


embedded image


C25H25Cl2N3O
453.14
454





1147


embedded image


C23H25N3OS
391.17
392





1148


embedded image


C23H23F3N4OS
460.15
461





1149


embedded image


C22H23N5O3S
437.15
438





1150


embedded image


C22H24N4OS
392.17
393





1151


embedded image


C22H22Cl2N4OS
460.09
461





1152


embedded image


C22H22ClFN4OS
444.12
445





1153


embedded image


C20H22N4OS2
398.12
399





1154


embedded image


C23H26N4O2S
422.18
423





1155


embedded image


C23H23F3N4OS
460.15
461





1156


embedded image


C23H26N4OS
406.18
407





1157


embedded image


C23H26N4O2S
422.18
423





1158


embedded image


C24H27N5O2S
449.19
450





1159


embedded image


C22H23ClN4OS
426.13
427





1160


embedded image


C22H23FN4OS
410.16
411





1161


embedded image


C26H26N4OS
442.18
443





1162


embedded image


C23H26N4OS2
438.15
439





1163


embedded image


C22H22Cl2N4OS
460.09
461





1164


embedded image


C24H28N4O2S
436.19
437





1165


embedded image


C24H28N4O2S
436.19
437





1166


embedded image


C26H32N4OS
448.23
449





1167


embedded image


C23H23N5OS
417.16
418





1168


embedded image


C28H28N4OS
468.20
469





1169


embedded image


C24H28N4O2S
436.19
437





1170


embedded image


C23H24N4O3S
436.16
437





1171


embedded image


C26H32N4O2S
464.23
465





1172


embedded image


C23H26N4OS2
438.15
439





1173


embedded image


C24H28N4OS2
452.17
453





1174


embedded image


C24H28N4OS
420.20
421





1175


embedded image


C23H23F3N4O2S
476.15
477





1176


embedded image


C24H28N4O3S
452.19
453





1177


embedded image


C25H30N4OS
434.21
435





1178


embedded image


C25H30N4OS
434.21
435





1179


embedded image


C23H26N4O2S
422.18
423





1180


embedded image


C22H25N5O2S
423.17
424





1181


embedded image


C24H24N4OS2
448.14
449





1182


embedded image


C23H23F3N4O2S
476.15
477





1183


embedded image


C24H22F6N4OS
528.14
529





1184


embedded image


C23H25FN4OS
424.17
425





1185


embedded image


C24H28N4OS
420.20
421





1186


embedded image


C24H28N4OS
420.20
421





1187


embedded image


C25H26N4O3
430.20
431





1188


embedded image


C27H31N3O2
429.24
430





1189


embedded image


C25H25ClFN3O
437.17
438





1190


embedded image


C25H25Cl2N3O
453.14
454





1191


embedded image


C26H26N4O
410.21
411





1192


embedded image


C27H29N3O2
427.23
428





1193


embedded image


C27H29N3O2
427.23
428





1194


embedded image


C25H25F2N3O
421.20
422





1195


embedded image


C25H25F2N3O
421.20
422





1196


embedded image


C26H28N4O3
444.22
445





1197


embedded image


C27H32N4O
428.26
429





1198


embedded image


C25H28N4O2
416.22
417





1199


embedded image


C27H29N3O3
443.22
444





1200


embedded image


C24H28N4O2
404.22
405





1201


embedded image


C23H25N3O2
375.20
376





1202


embedded image


C24H25FN4O
404.20
405





1203


embedded image


C22H25N5O
375.21
376





1204


embedded image


C26H28FN3O
417.22
418





1205


embedded image


C26H28FN3O
417.22
418





1206


embedded image


C24H25ClN4O
420.17
421





1207


embedded image


C24H25FN4O
404.20
405





1208


embedded image


C24H25FN4O
404.20
405





1209


embedded image


C26H28FN3O2
433.22
434





1210


embedded image


C27H30N4O2
442.24
443





1211


embedded image


C25H26N4O3
430.20
431





1212


embedded image


C26H25FN4O
428.20
429





1213


embedded image


C24H25FN4O
404.20
405





1214


embedded image


C24H25FN4O
404.20
405





1215


embedded image


C26H28FN3O3S
481.18
482





1216


embedded image


C27H29FN4O2
460.23
461





1217


embedded image


C28H31FN4O2
474.24
475





1218


embedded image


C26H25F4N3O2
487.19
488





1219


embedded image


C26H28FN3O3S
481.18
482





1220


embedded image


C26H25F4N3O2
487.19
488





1221


embedded image


C26H25FN4O
428.20
429





1222


embedded image


C27H29FN4O2
460.23
461





1223


embedded image


C26H25F4N3O2
487.19
488





1224


embedded image


C25H25F2N3O
421.20
422





1225


embedded image


C25H32N4O3S
468.22
469





1226


embedded image


C24H31N5O
405.25
406





1227


embedded image


C24H31N5O2
421.25
422





1228


embedded image


C23H28FN5O
409.23
410





1229


embedded image


C26H31N5O
429.25
430





1230


embedded image


C25H29N5OS
447.21
448





1231


embedded image


C26H34N4O
418.27
419





1232


embedded image


C26H32N4O2
432.25
433




















TABLE 9





Ex.

Molecular
Monoisotopic
M +


No.
Structure
formula
molecular wt.
H+



















1233


embedded image


C31H29N3O2
475.23
476





1234


embedded image


C30H35N3O2
469.27
470





1235


embedded image


C28H30N4O3S
502.20
503





1236


embedded image


C29H30FN3O3S
519.20
520





1237


embedded image


C28H30N4O3S
502.20
503




















TABLE 10





Ex.

Molecular
Monoisotopic
M +


No.
Structure
formula
molecular wt.
H+



















1238


embedded image


C26H35N3O2
421.27
422





1239


embedded image


C26H35N3O2
421.27
422





1240


embedded image


C25H31F2N3O2
443.24
444





1241


embedded image


C27H35N3O2
433.27
434





1242


embedded image


C26H35N3O2
421.27
422





1243


embedded image


C25H36N4O2
424.28
425





1244


embedded image


C24H33N3O3
411.25
412





1245


embedded image


C26H37N3O3
439.28
440





1246


embedded image


C27H37N3O2
435.29
436





1247


embedded image


C27H37N3O2
435.29
436





1248


embedded image


C27H33N5O2
459.26
460





1249


embedded image


C26H35N3O3
437.27
438





1250


embedded image


C29H34FN3O2
475.26
476





1251


embedded image


C27H32N4O2
444.25
445





1252


embedded image


C24H33N3O2
395.26
396





1253


embedded image


C23H31N3O2
381.24
382





1254


embedded image


C25H33N3O3
423.25
424





1255


embedded image


C23H28F3N3O2
435.21
436





1256


embedded image


C23H30FN3O2
399.23
400





1257


embedded image


C27H37N3O3
451.28
452





1258


embedded image


C24H33N3O3
411.25
412





1259


embedded image


C25H33N3O2
407.26
408





1260


embedded image


C25H33N3O2
407.26
408





1261


embedded image


C25H35N3O2
409.27
410





1262


embedded image


C25H35N3O2
409.27
410





1263


embedded image


C25H35N3O2
409.27
410





1264


embedded image


C25H35N3O2
409.27
410





1265


embedded image


C27H35N5O2
461.28
462





1266


embedded image


C28H38N4O3
478.29
479





1267


embedded image


C26H36N4O2
436.28
437





1268


embedded image


C26H38N4O2
438.30
439





1269


embedded image


C30H35N3O2
469.27
470





1270


embedded image


C27H32N4O2
444.25
445





1271


embedded image


C27H36N4O3
464.28
465





1272


embedded image


C27H37N3O2
435.29
436





1273


embedded image


C30H35N3O2
469.27
470





1274


embedded image


C26H35N3O2
421.27
422





1275


embedded image


C29H39N3O2
461.30
462





1276


embedded image


C29H43N3O2
465.34
466





1277


embedded image


C28H39N3O2
449.30
450





1278


embedded image


C28H37N3O2
447.29
448





1279


embedded image


C28H40N4O2
464.32
465





1280


embedded image


C30H35N3O2
469.27
470





1281


embedded image


C30H34N4O2
482.27
483





1282


embedded image


C30H35N3O3
485.27
486





1283


embedded image


C25H33N3O4S
471.22
472





1284


embedded image


C29H39N3O2
461.30
462





1285


embedded image


C26H33N3O3
435.25
436





1286


embedded image


C27H35N5O2
461.28
462





1287


embedded image


C25H35N3O2
409.27
410





1288


embedded image


C26H35N3O4S
485.23
486





1289


embedded image


C27H38N4O2
450.30
451





1290


embedded image


C26H31N3O2S
449.21
450





1291


embedded image


C29H41N3O2
463.32
464





1292


embedded image


C25H32N4O3
436.25
437





1293


embedded image


C26H35N3O3
437.27
438





1294


embedded image


C25H30N4O2S
450.21
451





1295


embedded image


C24H31N3O2
393.24
394





1296


embedded image


C25H35N5O2
437.28
438





1297


embedded image


C27H37N5O2
463.30
464





1298


embedded image


C26H32N6O2S
492.23
493





1299


embedded image


C24H33N5O3
439.26
440





1300


embedded image


C28H40FN3O3
485.30
486





1301


embedded image


C27H36FN3O2
453.28
454





1302


embedded image


C31H37N5O2
511.30
512





1303


embedded image


C28H39N5O2
477.31
478





1304


embedded image


C27H39N5O2
465.31
466





1305


embedded image


C27H39N5O2
465.31
466





1306


embedded image


C26H35N5O2S
481.25
482





1307


embedded image


C26H33N7O2
475.27
476





1308


embedded image


C26H35N5O2
449.28
450





1309


embedded image


C26H37N5O3
467.29
468





1310


embedded image


C26H37N5O3
467.29
468





1311


embedded image


C26H37N5O3
467.29
468





1312


embedded image


C27H37N5O3
479.29
480





1313


embedded image


C27H39N5O3
481.30
482





1314


embedded image


C28H38N6O2
490.31
491





1315


embedded image


C28H39N5O4
509.30
510





1316


embedded image


C28H39N5O2
477.31
478





1317


embedded image


C29H40N6O3
520.32
521





1318


embedded image


C30H44N6O2
520.35
521





1319


embedded image


C30H44N6O3
536.35
537





1320


embedded image


C30H34N6O2
510.27
511





1321


embedded image


C33H42N6O2
554.34
555





1322


embedded image


C27H35N7O2
489.29
490





1323


embedded image


C29H38F3N5O2
545.30
546





1324


embedded image


C29H39N7O2
517.32
518





1325


embedded image


C31H37N7O2
539.30
540





1326


embedded image


C26H33N7O2
475.27
476





1327


embedded image


C26H37N5O2S
483.27
484





1328


embedded image


C26H35N5O2
449.28
450





1329


embedded image


C27H35N7O2
489.29
490





1330


embedded image


C28H41N5O3
495.32
496





1331


embedded image


C25H31N7O2S
493.23
494





1332


embedded image


C31H39N5O3
529.30
530





1333


embedded image


C30H42N6O4
550.33
551





1334


embedded image


C28H41N5O2
479.33
480





1335


embedded image


C29H30F2N4O2
504.58
505





1336


embedded image


C25H32FN3O2
425.25
426





1337


embedded image


C25H34FN3O2
427.26
428





1338


embedded image


C24H32FN3O3
429.24
430





1339


embedded image


C26H34FN3O2
439.26
440





1340


embedded image


C26H34FN3O2
439.26
440





1341


embedded image


C25H34FN3O3
443.26
444





1342


embedded image


C25H34FN3O3
443.26
444





1343


embedded image


C25H34FN3O3
443.26
444





1344


embedded image


C27H36FN3O2
453.28
454





1345


embedded image


C27H38FN3O2
455.30
456





1346


embedded image


C27H38FN3O2
455.30
456





1347


embedded image


C27H38FN3O2
455.30
456





1348


embedded image


C26H36FN3O3
457.27
458





1349


embedded image


C26H36FN3O3
457.27
458





1350


embedded image


C25H34FN3O4
459.25
460





1351


embedded image


C25H34FN3O4
459.25
460





1352


embedded image


C28H38FN3O2
467.30
468





1353


embedded image


C27H38FN3O3
471.29
472





1354


embedded image


C27H38FN3O3
471.29
472





1355


embedded image


C27H34FN5O2
479.27
480





1356


embedded image


C29H40FN3O2
481.31
482





1357


embedded image


C29H40FN3O2
481.31
482





1358


embedded image


C28H39FN4O2
482.31
483





1359


embedded image


C28H38FN3O3
483.29
484





1360


embedded image


C28H38FN3O3
483.29
484





1361


embedded image


C28H36FN5O2
493.29
494





1362


embedded image


C27H35FN6O2
494.28
495





1363


embedded image


C28H37FN4O3
496.29
497





1364


embedded image


C29H41FN4O2
496.32
497





1365


embedded image


C28H39FN4O3
498.30
499





1366


embedded image


C26H32FN3O4
469.24
470





1367


embedded image


C29H40FN3O3
497.30
498





1368


embedded image


C25H31FN4O2
438.24
439





1369


embedded image


C26H34FN3O2
439.26
440





1370


embedded image


C26H36FN3O2
441.28
442





1371


embedded image


C25H34FN3O3
443.26
444





1372


embedded image


C27H36FN3O2
453.28
454





1373


embedded image


C26H34FN3O3
455.26
456





1374


embedded image


C28H38FN3O2
467.30
468





1375


embedded image


C27H37FN4O2
468.29
469





1376


embedded image


C26H34FN3O2S
471.24
472





1377


embedded image


C26H36FN3O4
473.27
474





1378


embedded image


C28H41FN4O2
484.32
485





1379


embedded image


C28H37FN4O3
496.29
497





1380


embedded image


C28H37FN4O3
496.29
497





1381


embedded image


C32H38FN3O2
515.29
516





1382


embedded image


C31H38FN3O3
519.29
520





1383


embedded image


C31H43FN4O2
522.34
523





1384


embedded image


C27H36FN3O3
469.27
470





1385


embedded image


C27H36FN3O3
469.27
470





1386


embedded image


C28H34F3N3O3
517.26
518





1387


embedded image


C27H36FN3O4S
517.24
518





1388


embedded image


C30H41FN4O3
524.32
525





1389


embedded image


C27H36FN3O3
469.27
470





1390


embedded image


C22H28FN3O2
385.22
386





1391


embedded image


C29H38FN3O4
511.29
512





1392


embedded image


C26H36FN3O3
457.27
458





1393


embedded image


C25H34FN3O3
443.26
444





1394


embedded image


C27H36FN3O3
469.27
470





1395


embedded image


C26H34FN3O3
455.26
456





1396


embedded image


C28H38FN3O3
483.29
484





1397


embedded image


C26H36FN3O3
457.27
458





1398


embedded image


C26H34FN3O4
471.25
472





1399


embedded image


C28H38FN3O4
499.29
500





1400


embedded image


C27H38FN3O3
471.29
472





1401


embedded image


C28H40FN3O3
485.30
486





1402


embedded image


C27H36FN3O4
485.27
486





1403


embedded image


C27H36FN3O3
469.27
470




















TABLE 11








Mono-






isotopic


Ex.

Molecular
molecular


No.
Structure
formula
wt.
M + H+







1404


embedded image


C22H30N4O2
382.24
383





1405


embedded image


C24H31ClN4O
426.22
427





1406


embedded image


C23H32N4O2
396.25
397





1407


embedded image


C25H27FN4O
418.22
410





1408


embedded image


C23H32N4O2
396.25
397





1409


embedded image


C22H30N4O2
382.24
383





1410


embedded image


C23H25N5O2
403.20
404





1411


embedded image


C24H33N3O2
395.26
396





1412


embedded image


C23H31N3O2(S)-Konfiguration
381.24
382





1413


embedded image


C23H31N3O2
381.24
382





1414


embedded image


C23H30FN3O2
399.23
400





1415


embedded image


C24H32FN3O2
413.25
414





1416


embedded image


C24H32N4O
392.26
393





1417


embedded image


C24H32FN3O2
413.25
414





1418


embedded image


C24H32FN3O2(S)-configuration
413.25
414





1419


embedded image


C25H34FN3O2
427.26
428





1420


embedded image


C26H36FN3O2
441.28
442





1421


embedded image


C26H36FN3O2
441.28
442





1422


embedded image


C27H36FN3O2
453.28
454





1423


embedded image


C27H38FN3O3
471.29
472




















TABLE 12








Mono-






isotopic


Ex.

Molecular
molecular


No.
Structure
formula
wt.
M + H+







1424


embedded image


C27H35N3O2
433.27
434





1425


embedded image


C28H39N3O4
481.29
482





1426


embedded image


C27H38N4O4
482.29
483





1427


embedded image


C24H32N4O3
424.25
425





1428


embedded image


C24H33N3O2
395.26
396





1429


embedded image


C24H31N3O3
409.24
410





1430


embedded image


C29H33FN4O3
504.25
505





1431


embedded image


C27H38N4O4
482.29
483





1432


embedded image


C30H43N3O5
525.32
526





1433


embedded image


C25H33N3O3
423.25
424





1434


embedded image


C29H41N3O5
511.30
512





1435


embedded image


C26H28FN3O
417.22
418





1436


embedded image


C27H30FN3O
431.24
432





1437


embedded image


C28H38FN3O4
499.29
500





1438


embedded image


C28H38FN3O4
499.29
500





1439


embedded image


C28H38FN3O4(S)-Konfiguration
499.29
500





1440


embedded image


C25H32N4O2
420.25
421





1441


embedded image


C24H32C1N3O2
429.22
430





1442


embedded image


C29H40FN3O4
513.30
514





1443


embedded image


C30H42FN3O4
527.32
528




















TABLE 13








Mono-






isotopic


Ex.

Molecular
molecular


No.
Structure
formula
wt.
M + H+







1444


embedded image


C23H30N4O
378.24
379





1445


embedded image


C23H30N4O
378.24
379





1446


embedded image


C21H28N4O2
368.22
369





1447


embedded image


C27H38N4O
434.30
435





1448


embedded image


C26H36N4O
420.29
421





1449


embedded image


C29H42N4O
462.34
463





1450


embedded image


C28H38N4O
446.30
447





1451


embedded image


C24H32N4O
392.26
393





1452


embedded image


C26H36N4O
420.29
421





1453


embedded image


C26H32N4O
416.26
417





1454


embedded image


C23H31N3O2
381.24
382





1455


embedded image


C24H31N3O
377.25
378





1456


embedded image


C22H29N3O2
367.23
368





1457


embedded image


C22H21FN4O
376.17
377





1458


embedded image


C20H26N4O2
354.21
355





1459


embedded image


C23H24N4O2
388.19
389





1460


embedded image


C22H27ClN4O
398.19
399





1461


embedded image


C22H30N4O2
382.24
383





1462


embedded image


C21H21N5O2
375.17
376





1463


embedded image


C22H27F2N3O2
403.21
404





1464


embedded image


C22H28FN3O2
385.22
386





1465


embedded image


C22H28ClN3O2
401.19
402





1466


embedded image


C23H31N3O2
381.24
382





1467


embedded image


C23H28F3N3O2
435.21
436





1468


embedded image


C23H28F3N3O2
435.21
436





1469


embedded image


C22H27F2N3O2
403.21
404





1470


embedded image


C22H27ClFN3O2
419.18
420





1471


embedded image


C23H28N4O2
392.22
393





1472


embedded image


C23H27C1N4O2
426.18
427





1473


embedded image


C22H28BrN3O2
445.14
446





1474


embedded image


C26H31N3O2
417.24
418





1475


embedded image


C22H27F2N3O2
403.21
404





1476


embedded image


C22H28BrN3O2
445.14
446





1477


embedded image


C23H30ClN3O2
415.20
416





1478


embedded image


C21H27ClN4O2
402.18
403





1479


embedded image


C22H30N4O2
382.24
383





1480


embedded image


C22H30N4O2
382.24
383





1481


embedded image


C22H30N4O2
382.24
383





1482


embedded image


C24H25FN4O
404.20
405





1483


embedded image


C22H29N3O3
383.22
384





1484


embedded image


C20H26N4O2
354.21
355





1485


embedded image


C22H28FN3O2
385.22
386





1486


embedded image


C22H29N3O2
367.23
368





1487


embedded image


C22H28N4O
364.23
365





1488


embedded image


C25H35N3O3
425.27
426





1489


embedded image


C24H33N3O3
411.25
412





1490


embedded image


C22H29N5O2
395.23
396





1491


embedded image


C23H25N5O2
403.20
404





1492


embedded image


C23H25N5O2
403.20
404





1493


embedded image


C20H22N6O
362.19
363





1494


embedded image


C25H25N5O2
427.20
428





1495


embedded image


C23H25N3O2
375.20
376





1496


embedded image


C19H21N5O2
351.17
352





1497


embedded image


C20H22N4OS2
398.12
399





1498


embedded image


C21H23N5O
361.19
362





1499


embedded image


C20H22N6O
362.19
363





1500


embedded image


C22H28FN3O2
385.22
386





1501


embedded image


C23H29FN4O2
412.23
413





1502


embedded image


C22H34FN3O2
391.26
392





1503


embedded image


C23H30FN3O2
399.23
400





1504


embedded image


C22H28FN5O2
413.22
414





1505


embedded image


C23H24FN5O2
421.19
422





1506


embedded image


C23H22F3N3O2
429.17
430





1507


embedded image


C24H28N4O2
404.22
405





1508


embedded image


C28H33N3O2
443.26
444





1509


embedded image


C24H24N4O2
400.19
401





1510


embedded image


C24H26N4O3
418.20
419





1511


embedded image


C23H30FN3O2
399.23
400





1512


embedded image


C22H27FN4O4
430.20
431





1513


embedded image


C22H29FN4O2
400.23
401





1514


embedded image


C24H26N4O3
418.20
419





1515


embedded image


C23H30FN3O2
399.23
400





1516


embedded image


C24H29FN4O
408.23
409





1517


embedded image


C25H26FN3O2
419.20
420





1518


embedded image


C25H26FN3O2
419.20
420





1519


embedded image


C24H26FN3O2S
439.17
440





1520


embedded image


C24H30FN3O
395.24
396





1521


embedded image


C25H32FN3O
409.25
410





1522


embedded image


C26H27F2N3O
435.21
436





1523


embedded image


C22H21ClFN3O2
413.13
414





1524


embedded image


C22H22FN3O2
379.17
380





1525


embedded image


C23H25N3O3
391.19
392





1526


embedded image


C23H25N3O3
391.19
392





1527


embedded image


C22H22FN3O2
379.17
380





1528


embedded image


C23H25N3O2S
407.17
408





1529


embedded image


C23H25N3O2
375.20
376





1530


embedded image


C24H27N3O3
405.20
406





1531


embedded image


C23H30FN3O2
399.23
400





1532


embedded image


C25H31ClFN3O
443.21
444





1533


embedded image


C24H25ClFN3O3
457.16
458





1534


embedded image


C24H30FN3O2
411.23
412





1535


embedded image


C24H27N3O3
405.20
406





1536


embedded image


C23H22N4O2
386.17
387





1537


embedded image


C24H25N3O3
403.19
404





1538


embedded image


C24H27N3O4
421.20
422





1539


embedded image


C24H25N3O3
403.19
404





1540


embedded image


C24H25FN4O4
452.19
453





1541


embedded image


C23H3OFN3O2
399.23
400





1542


embedded image


C25H26FN3O
403.21
404





1543


embedded image


C26H28FN3O2
433.22
434





1544


embedded image


C28H29FN4O2
472.23
473





1545


embedded image


C26H28FN3O
417.22
418





1546


embedded image


C24H32FN3O2
413.25
414





1547


embedded image


C22H18F5N3O2
451.13
452





1548


embedded image


C24H25N3O3
403.19
404





1549


embedded image


C22H21F2N3O2
397.16
398





1550


embedded image


C22H21F2N3O2
397.16
398





1551


embedded image


C22H21F2N3O2
397.16
398





1552


embedded image


C23H23N3O4
405.17
406





1553


embedded image


C28H26FN3O2
455.20
456





1554


embedded image


C26H31N3O3
433.24
434





1555


embedded image


C25H25F2N3O
421.20
422





1556


embedded image


NC23H25N3O2S
407.17
408





1557


embedded image


C24H27N3O2S
421.18
422





1558


embedded image


C24H27N3O2
389.21
390





1559


embedded image


C24H27N3O2
389.21
390





1560


embedded image


C23H22F3N3O3
445.16
446





1561


embedded image


C25H29N3O2
403.23
404





1562


embedded image


C25H29N3O2
403.23
404





1563


embedded image


C21H22N4O2
362.17
363





1564


embedded image


C22H21F2N3O2
397.16
398





1565


embedded image


C22H24N4O3
392.18
393





1566


embedded image


C23H25N3O4S
439.16
440





1567


embedded image


C22H21F2N3O2
397.16
398





1568


embedded image


C23H22F3N3O3
445.16
446





1569


embedded image


C23H24FN3O2
393.18
394





1570


embedded image


C20H21N5O2
363.17
364





1571


embedded image


C21H21FN4O2
380.17
381





1572


embedded image


C23H30FN3O2
399.23
400





1573


embedded image


C22H22N4O3S
422.14
423





1574


embedded image


C23H25N3O2S
407.17
408





1575


embedded image


C23H25N3O2S
407.17
408





1576


embedded image


C23H25N3OS2
423.14
424





1577


embedded image


C24H27N3O2S
421.18
422





1578


embedded image


C24H27N3O2S
421.18
422





1579


embedded image


C23H22N4OS
402.15
403





1580


embedded image


C24H27N3O3S
437.18
438





1581


embedded image


C24H25N3O2S
419.17
420





1582


embedded image


C24H25N3O2S
419.17
420





1583


embedded image


C23H23N3O3S
421.15
422





1584


embedded image


C23H25N3OS2
423.14
424





1585


embedded image


C24H27N3OS2
437.16
438





1586


embedded image


C24H27N3OS
405.19
406





1587


embedded image


C24H27N3OS
405.19
406





1588


embedded image


C23H22F3N3O2S
461.14
462





1589


embedded image


C25H29N3OS
419.20
420





1590


embedded image


C25H29N3OS
419.20
420





1591


embedded image


C24H25N3O3S
435.16
436





1592


embedded image


C22H24N4O2S
408.16
409





1593


embedded image


C23H22F3N302S
461.14
462





1594


embedded image


C24H26N4O2S
434.18
435





1595


embedded image


C21H24N4O2S
396.16
397





1596


embedded image


C21H21FN4OS
396.14
397





1597


embedded image


C25H27N3O3S
449.18
450





1598


embedded image


C28H33N3OS
459.23
460





1599


embedded image


C24H26N4O2S
434.18
435





1600


embedded image


C25H28N4O2S
448.19
449





1601


embedded image


C25H28N4O2S
448.19
449





1602


embedded image


C24H28N4OS
420.20
421





1603


embedded image


C24H26N4O2S
434.18
435





1604


embedded image


C24H25N3O2S
419.17
420





1605


embedded image


C20H21N3OS2
383.11
384





1606


embedded image


C26H28FN3O2
433.22
434





1607


embedded image


C26H27ClFN3O2
467.18
468





1608


embedded image


C21H21FN4OS
396.14
397





1609


embedded image


C24H32FN3O2
413.25
414





1610


embedded image


C25H34FN3O2
427.26
428





1611


embedded image


C25H34FN3O2
427.26
428





1612


embedded image


C26H34FN3O2
439.26
440





1613


embedded image


C25H25N3OS
415.17
416





1614


embedded image


C23H22N4OS
402.15
403





1615


embedded image


C24H22FN3OS
419.15
420





1616


embedded image


C23H22N4OS
402.15
403





1617


embedded image


C21H27N5O3
397.21
398





1618


embedded image


C25H28N4O2
416.22
417









Synthesis of Pyrrolidinylanilines Required as Intermediates
[1-Amino-2-chlorophenyl)pyrrolidin-3-yl]dimethylamine

Method C-a


3-Dimethylaminopyrrolidine (0.34 g) was slowly added to a solution of 2-chloro-1 fluoro-4-nitrobenzene (0.52 g) in DMF (5 ml). After 1 hour, ethyl acetate (30 ml) was added to the reaction mixture, and it was extracted with 10% hydrochloric acid (2×20 ml). The aqueous phase was washed with ethyl acetate (2×20 ml), adjusted to pH>10 with 10% ammonia and extracted with ethyl acetate. The yellow solution was dried with sodium sulfate, filtered and concentrated in a rotary evaporator. The residue was then dissolved in dichloromethane (50 ml), zinc (10 g) was added, and glacial acetic acid (5 ml) was slowly added dropwise while cooling in ice. The suspension was stirred for 15 minutes, filtered, washed with 10% ammonia (2×20 ml) and concentrated. This resulted in the product with the molecular weight of 239.75 (C12H18ClN3); MS (ESI): 239 (M+H+), 240 (M+H+),


5-Amino-2-(3-dimethylaminopyrrolidin-1-yl)benzonitrile

Dimethylaminopyrrolidine was treated with 2-fluoro-5-nitrobenzonitrile and subsequently reduced by method C-a. This resulted in the product with the molecular weight of 230.32 (C13H18N4); MS (ESI): 231 (M+H+),


[1-(4-Amino-3-chlorophenyl)pyrrolidin-3-yl]dimethylamine

Dimethylaminopyrrolidine was treated with 3-chloro-1-fluoro-4-nitrobenzene and subsequently reduced by method C-a. This resulted in the product with the molecular weight of 239.75 (C12H18ClN3); MS (ESI): 239 (M+H+), 240 (M+H+),


[1-(4-Amino-3-methylphenyl)pyrrolidin-3-yl]dimethylamine

Dimethylaminopyrrolidine was treated with 4-fluoro-2-methyl-1-nitrobenzene and subsequently reduced by method C-a. This resulted in the product with the molecular weight of 219.33 (C13H21N3); MS (ESI): 220 (M+H+).


tert-Butyl (R)-[1-(4-amino-2-fluorophenyl)pyrrolidin-3-yl]methylcarbamate

Method C-b


tert-Butyl (R)-(+)-pyrrolidin-3-ylcarbamate (1.86 g) was slowly added to a suspension of 3,4-difluoronitrobenzene (1.59 g) and potassium carbonate (2.8 g) in DMF (10 ml). After 10 minutes, ethyl acetate (50 ml) was added, and the mixture was washed with water (3×50 ml) in a separating funnel, dried with sodium sulfate, filtered and concentrated. The residue was dissolved in DMF (10 ml), and sodium hydride (0.48 g) was added. After 15 minutes, methyl iodide (1.41 g) was then added while cooling in ice. After 30 minutes, ethyl acetate (50 ml) was added, and the mixture was washed with water (3×50 ml) in a separating funnel, dried with sodium sulfate, filtered and concentrated. The substance was then treated as described for method B. This resulted in the product with the molecular weight of 309.39 (C16H24FN3O2); MS (ESI): 310 (M+H+).


tert-Butyl (S)-[1-(4-amino-2-fluorophenyl)pyrrolidin-3-yl]methylcarbamate was obtained analogously.


tert-Butyl (R)-[1-(2-fluoro-4-isopropylaminophenyl)pyrrolidin-3-yl]methylcarbamate

tert-Butyl (R)-[1-(4-amino-2-fluorophenyl)pyrrolidin-3-yl]methylcarbamate was alkylated with acetone using triacetoxyborohydride as reducing agent by method N. This resulted in the product with the molecular weight of 351.47 (C19H30FN3O2); MS (ESI): 352 (M+H+).


tert-Butyl (R)-[1-(2-Fluoro-4-cyclobutylaminophenyl)pyrrolidin-3-yl]methylcarbamate

tert-Butyl (R)-[1-(4-amino-2-fluorophenyl)pyrrolidin-3-yl]methylcarbamate was alkylated with cyclobutanone using triacetoxyborohydride as reducing agent by method N. This resulted in the product with the molecular weight of 363.48 (C20H30FN3O2); MS (ESI): 364 (M+H+).


tert-Butyl (R)-[1-(2-fluoro-4-methylaminophenyl)pyrrolidin-3-yl]methylcarbamate

tert-Butyl (R)-{1-[4-(benzyloxycarbonylmethylamino)-2-fluorophenyl]pyrrolidin-3-yl}-methylcarbamate was treated as described for method B. This resulted in the product with the molecular weight of 323.41 (C17H26FN3O2); MS (ESI): 324 (M+H+).


tert-Butyl (R)-{1-[4-(benzyloxycarbonylmethylamino)-2-fluorophenyl]pyrrolidin-3-yl}-methylcarbamate

tert-Butyl (R)-(+)-[1-(4-amino-2-fluorophenyl)pyrrolidin-3-yl]methylcarbamate (0.93 g) was added to a solution of N-(benzyloxycarbonyloxy)succinimide (2.49 g) in dichloromethane (30 ml). After 12 hours, the mixture was washed with water (2×30 ml), dried sodium sulfate, filtered and concentrated. The residue was recrystallized from acetonitrile. The product obtained in this way was dissolved in DMF (10 ml), and sodium hydride (0.24 g) was added. After 15 minutes, methyl iodide (0.71 g) was added while cooling in ice. After 15 minutes, ethyl acetate (50 ml) was added, and the mixture was washed with water (3×30 ml), dried sodium sulfate, filtered and concentrated. This resulted in the product with the molecular weight of 457.55 (C25H32FN3O4); MS (ESI): 458 (M+H+).


(R)-[1-(2-Fluoro-4-methylaminophenyl)pyrrolidin-3-yl]dimethylamine

(R)-{1-[4-(Benzyloxycarbonylmethylamino)-2-fluorophenyl]pyrrolidin-3-yl}methylcarbamic acid tert-butyl ester was treated by method G, and the resulting amine was methylated by method M. Finally, hydrogenation was carried out by method B. This resulted in the product with the molecular weight of 237.32 (C13H20FN3); MS (ESI): 238 (M+H+).


Dimethyl-[1-(4-methylaminophenyl)pyrrolidin-3-yl]amine can be prepared analogously.


2-Dimethylamino-N-[1-(2-fluoro-4-methylaminophenyl)pyrrolidin-3-yl]-N-methylacetamide

(R)-{1-[4-(Benzyloxycarbonylmethylamino)-2-fluorophenyl]pyrrolidin-3-yl}methylcarbamic acid tert-butyl ester was treated by method G, and the resulting amine was reacted with N,N-dimethylglycine by method E. Finally, hydrogenation was carried out by method B. This resulted in the product with the molecular weight of 308.40 (C16H25FN4O); MS (ESI): 309 (M+H+).


tert-Butyl (R)-[1-(4-amino-3-fluorophenyl)pyrrolidin-3-yl]methylcarbamate

2,4-Difluoronitrobenzene was treated with tert-butyl (R)-(+)-pyrrolidin-3-ylcarbamate, methylated and subsequently hydrogenated by method C-b. This resulted in the product with the molecular weight of 309.39 (C16H24FN3O2); MS (ESI): 310 (M+H+).


tert-Butyl [1-(4-aminonaphthalen-1-yl)pyrrolidin-3-yl]methylcarbamate

Method C-c


tert-Butyl methylpyrrolidin-3-ylcarbamate (1.86 g) was slowly added to a suspension of 4-fluoro-1-nitronaphthalene (1.91 g) and potassium carbonate (2.8 g) in DMF (10 ml). After 10 minutes, ethyl acetate (50 ml) was added, and the mixture was washed with water (3×50 ml) in a separating funnel, dried with sodium sulfate, filtered and concentrated. The substance was then treated as described for method B. This resulted in the product with the molecular weight of 341.46 (C20H27N3O2); MS (ESI): 342 (M+H+).


tert-Butyl [1-(4-amino-3-bromophenyl)pyrrolidin-3-yl]methylcarbamate

2-Bromo-4-fluoro-1-nitrobenzene was treated with tert-butyl methylpyrrolidin-3-ylcarbamate and subsequently reduced by method C-a. This resulted in the product with the molecular weight of 370.29 (C16H24BrN3O2); MS (ESI): 370 (M+H+), 372 (M+H+).


Tert-butyl [1-(4-amino-3-cyanophenyl)pyrrolidin-3-yl]methylcarbamate

2-Cyano-4-fluoro-1-nitrobenzene was treated with tert-butyl methylpyrrolidin-3-yl-carbamate and subsequently reduced by method C-a. This resulted in the product with the molecular weight of 316.41 (C17H24N4O2); MS (ESI): 317 (M+H+).


tert-Butyl [1-(5-amino-6-chloropyridin-2-yl)pyrrolidin-3-yl]methylcarbamate

2-Chloro-6-fluoro-3-nitropyridine was treated with tert-butyl methylpyrrolidin-3-ylcarbamate and subsequently reduced by method C-c. This resulted in the product with the molecular weight of 326.83 (C15H23ClN4O2); MS (ESI): 326 (M+H+), 327 (M+H+).


tert-Butyl [1-(4-amino-2,3-difluorophenyl)pyrrolidin-3-yl]methylcarbamate

2,3,4-Trifluoronitrobenzene was treated with tert-butyl methylpyrrolidin-3-ylcarbamate and subsequently reduced by method C-c. This resulted in the product with the molecular weight of 327.38 (C16H23F2N3O2); MS (ESI): 328 (M+H+).


tert-Butyl [1-(4-amino-2-bromophenyl)pyrrolidin-3-yl]methylcarbamate

3-Bromo-4-fluoro-1-nitrobenzene was treated with tert-butyl methylpyrrolidin-3-ylcarbamate and subsequently reduced by method C-a. This resulted in the product with the molecular weight of 370.29 (C16H24BrN3O2); MS (ESI): 370 (M+H+), 372 (M+H+).


tert-Butyl [1-(4-amino-2,6-difluorophenyl)pyrrolidin-3-yl]methylcarbamate

3,4,5-Trifluoronitrobenzene was treated with tert-butyl methylpyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 327.38 (C16H23F2N3O2); MS (ESI): 328 (M+H+).


tert-Butyl (R)-[1-(4-amino-2-hydroxymethylphenyl)pyrrolidin-3-yl]carbamate

(2-Fluoro-5-nitrophenyl)methanol was treated with tert-butyl (R)-(+)-pyrrolidin-3-ylcarbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 307.40 (C16H25N3O3); MS (ESI): 308 (M+H+).


tert-Butyl [1-(4-amino-2-chlorophenyl)pyrrolidin-3-yl]methylcarbamate

2-Chloro-1-fluoro-4-nitrobenzene was treated with tert-butyl methylpyrrolidin-3-ylcarbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 311.81 (C15H22ClN3O2); MS (ESI): 311 (M+H+), 312 (M+H+).


tert-Butyl [1-(4-amino-2,5-difluorophenyl)pyrrolidin-3-yl]methylcarbamate

3,4,6-Trifluoronitrobenzene was treated with tert-butyl methylpyrrolidin-3-ylcarbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 327.38 (C16H23F2N3O2); MS (ESI): 328 (M+H+).


tert-Butyl [1-(4-amino-2-methylphenyl)pyrrolidin-3-yl]methylcarbamate

tert-Butyl 4-fluoro-3-methylnitrobenzene was treated with tert-butyl methylpyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 291.40 (C16H25N3O2); MS (ESI): 292 (M+H+).


tert-Butyl [1-(4-amino-3-trifluoromethylphenyl)pyrrolidin-3-yl]methylcarbamate

4-Fluoro-2-trifluoromethyinitrobenzene was treated with tert-butyl methylpyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 345.37 (C16H22F3N3O2); MS (ESI): 346 (M+H+).


tert-Butyl [1-(4-amino-2-chloro-3-fluorophenyl)pyrrolidin-3-yl]methylcarbamate

2,4-Difluoro-3-chloronitrobenzene was treated with tert-butyl methylpyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 329.80 (C15H21ClN3O2); MS (ESI): 329 (M+H+), 330 (M+H+).


tert-Butyl [1-(4-amino-2-cyanophenyl)pyrrolidin-3-yl]methylcarbamate

3-Cyano-4-fluoronitrobenzene was treated with tert-butyl methylpyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 302.38 (C16H22N4O2); MS (ESI): 303 (M+H+).


tert-Butyl [1-(4-amino-5-chloro-2-methylphenyl)pyrrolidin-3-yl]methylcarbamate

1-Chloro-5-fluoro-4-methyl-2-nitrobenzene was treated with tert-butyl methylpyrrolidin-3-ylcarbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 325.84 (C16H24ClN3O2); MS (ESI): 325 (M+H+), 326 (M+H+).


tert-Butyl (R)-[1-(5-aminopyridin-2-yl)pyrrolidin-3-yl]methylcarbamate

2-Chloro-5-nitropyridine was treated with tert-butyl (R)-(+)-pyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-b. This resulted in the product with the molecular weight of 322.37 (C16H24FN3O2); MS (ESI): 323 (M+H+).


tert-Butyl [1-(5-aminopyridin-2-yl)pyrrolidin-3-yl]methylcarbamate

2-Chloro-5-nitropyridine was treated with tert-butyl methylpyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 322.37 (C16H24FN3O2); MS (ESI): 323 (M+H+).


tert-Butyl (R)-[1-(4-aminophenyl)pyrrolidin-3-yl]methylcarbamate

4-Fluoronitrobenzene was treated with tert-butyl (R)-(+)-pyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-b. This resulted in the product with the molecular weight of 291.40 (C16H25N3O2); MS (ESI): 292 (M+H+).


tert-Butyl [1-(4-amino-2-trifluoromethylphenyl)pyrrolidin-3-yl]methylcarbamate

4-Fluoro-3-trifluoromethylnitrobenzene was treated with tert-butyl methylpyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 345.37 (C16H22F3N3O2); MS (ESI): 346 (M+H+).


tert-Butyl [1-(5-amino-4-methylpyridin-2-yl)pyrrolidin-3-yl]methylcarbamate

2-Chloro-4-methyl-5-nitropyridine was treated with tert-butyl methylpyrrolidin-3-ylcarbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 306.419 (C16H26N4O2); MS (ESI): 306 (M+H+), 307 (M+H+).


tert-Butyl [1-(5-amino-3-methylpyridin-2-yl)pyrrolidin-3-yl]methylcarbamate

2-Chloro-3-methyl-5-nitropyridine was treated with tert-butyl methylpyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 306.419 (C16H26N4O2); MS (ESI): 306 (M+H+), 307 (M+H+).


tert-Butyl [1-(4-amino-2-hydroxymethylphenyl)pyrrolidin-3-yl]methylcarbamate

(2-Fluoro-5-nitrophenyl)methanol was treated with tert-butyl methylpyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 321.42 (C17H27N3O3); MS (ESI): 322 (M+H+).


tert-Butyl [1-(4-amino-3-chloro-2-cyanophenyl)pyrrolidin-3-yl]methylcarbamate

2-Chloro-6-fluoro-3-nitrobenzonitrile was treated with tert-butyl methylpyrrolidin-3-yl-carbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 350.5 (C17H23ClN4O2); MS (ESI): 350 (M+H+), 351 (M+H+).


tert-Butyl [1-(4-amino-3-methylphenyl)pyrrolidin-3-yl]methylcarbamate

4-Fluoro-2-methylnitrobenzene was treated with tert-butyl methylpyrrolidin-3-ylcarbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 291.40 (C16H25N3O2); MS (ESI): 292 (M+H+).


tert-Butyl [1-(5-aminopyridin-2-yl)pyrrolidin-3-yl]carbamate

2-Chloro-5-nitropyridine was treated with tert-butyl (R)-(+)-pyrrolidin-3-ylcarbamate and subsequently hydrogenated by method C-c. This resulted in the product with the molecular weight of 278.36 (C14H22N4O2); MS (ESI): 279 (M+H+).


5-(3-Dimethylaminopyrrolidin-1-yl)pyridin-2-ylamine

A suspension of 5-bromo-2-nitropyridine (2 g), 3-(dimethylamino)pyrrolidine (1.14 g), (R)-(+)2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (0.5 g), palladium(II) acetate (0.09 g), cesium carbonate (4.5 g) in toluene (20 ml) was heated at 100° C. for 3 hours. Cooling to room temperature was followed by extraction with 1N hydrochloric acid (2×100 ml). The aqueous phase was adjusted to pH>10 with ammonia, extracted with ethyl acetate (2×100 ml), dried with sodium sulfate, filtered and concentrated. The substance was then treated as described for method B. This resulted in the product with the molecular weight of 206.29 (C11H18FN4); MS (ESI): 207 (M+H+).


N-[1-(4-Aminophenyl)-4-hydroxypyrrolidin-3-yl]-N-methylacetamide

trans-N-(4-Hydroxypyrrolidin-3-yl)-N-methylacetamide was reacted with 4-fluoronitrobenzene by method C, and the product was subsequently hydrogenated by method B. This resulted in the product with the molecular weight of 249.32 (C13H19N3O2); MS (ESI): 250 (M+H+).


trans-N-(4-Hydroxypyrrolidin-3-yl)-N-methylacetamide

tert-Butyl trans-3-hydroxy-4-methylaminopyrrolidin-1-carboxylate (1.0 g, tetrahedron: Asymmetry 2001, 12, 2989) was mixed with pyridine (1.5 g) and acetic anhydride (0.567 g). After 3 hours, volatile fractions were removed under high vacuum. The residue was treated by method G. This resulted in the product with the molecular weight of 158.20 (C7H14N2O2); MS (ESI): 159 (M+H+).


trans-1-(4-Aminophenyl)-4-dimethylaminopyrrolidin-3-ol

tert-Butyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate (2.0 g, tetrahedron: Asymmetry 2001, 12, 2989) was stirred with dimethylamine (40% aq., 10 ml) for 12 hours. The mixture was concentrated and partitioned between water and ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. The crude product was treated by method G. The resulting amine was reacted with 4-fluoronitrobenzene by method C. The resulting nitro compound was hydrogenated by method B. This resulted in the product with the molecular weight of 221 (C12H19N3O); MS (ESI): 222 (M+H+).


[1-(4-Aminophenyl)-4-methoxypyrrolidin-3-yl]dimethylamine

An alternative possibility is for the nitro compound prepared in the preceding method to be alkylated with methyl iodide by method F and then hydrogenated by method B. This resulted in the product with the molecular weight of 235 (C13H21N3O); MS (ESI): 236 (M+H+).


[1-(4-Aminophenyl)pyrrolidin-3-yl]dimethylamine

Dimethylpyrrolidin-3-ylamine was reacted with 4-fluoronitrobenzene by method C, and the product was subsequently hydrogenated by method B. This resulted in the product with the molecular weight of 205.31 (C12H19N3); MS (ESI): 206 (M+H+).


1-(4-Aminophenyl)-3-dimethylaminopyrrolidin-2-one

Trisodium phosphate (3.56 g) was added to a solution of 4-nitroaniline (5.0 g) in acetonitrile (30 ml) and, at 0° C., 2-bromo-4-chlorobutyryl bromide (11 g) was added. After one hour, a solution of sodium hydroxide (3.2 g) in water (10 ml) was added, and the mixture was vigorously stirred at room temperature. After 6 hours, the same amount of sodium hydroxide solution was again added, and the mixture was left to stand overnight. The reaction solution was diluted with water and extracted with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. The crude product (0.5 g) was heated with dimethylamine (160 mg) in toluene (20 ml) at 80° C. for 3 hours. The reaction solution was diluted with water and extracted with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. The crude product was hydrogenated by method B. This resulted in the product with the molecular weight of 219.29 (C12H17N3O); MS (ESI): 220 (M+H+).


1-(4-Aminophenyl)-3-(7-azabicyclo[2.2.1]hept-7-yl)pyrrolidin-2-one was obtained in an analogous manner.


4-[3-(7-Azabicyclo[2.2.1 ]hept-7-yl)pyrrolidin-1-yl]phenylamine

1-(4-Nitrophenyl)-3-(7-azabicyclo[2.2.1]hept-7-yl)pyrrolidin-2-one (0.25 g) in THF (10 ml) was mixed with borane-THF complex (1M in THF, 0.83 ml) and boiled under reflux for 3 hours. After the reaction was complete, the mixture was diluted with water and adjusted to pH 9-10 with hydrochloric acid (4N). Extraction in ethyl acetate, drying and concentration of the organic phase afforded a crude product that was hydrogenated by method B. This resulted in the product with the molecular weight of 257.38 (C16H23N3); MS (ESI): 258 (M+H+).


(R)-1′-(4-Aminophenyl)-[1,3′]bipyrrolidinyl-2-one

tert-Butyl [1-(4-Nitrophenyl)pyrrolidin-3-yl]carbamate was treated by method G. The crude product (1.4 g) was dissolved in acetonitrile (20 ml) and mixed with trisodium phosphate (0.67 g) and 4-chlorobutyryl chloride (1.1 g). After 2 hours, sodium hydroxide (0.6 g) in water (10 ml) was added and the mixture was vigorously stirred. After 12 hours, the same amount of sodium hydroxide solution was again added, and the mixture was stirred for a further 24 hours. The concentrated reaction solution was partitioned between water and-ethyl acetate, and the organic phase was dried and concentrated. The residue was hydrogenated by method B. This resulted in the product with the molecular weight of 245.33 (C14H19N3O); MS (ESI): 246 (M+H+).


1-Methylpiperidine-3-carboxylic acid [(R)-1-(4-aminophenyl)pyrrolidin-3-yl]methylamide

tert-Butyl (R)-[1-(4-nitrophenyl)pyrrolidin-3-yl]methylcarbamate was treated by method G and reacted with 1-methylpiperidine-3-carboxylic acid by method E. Finally, hydrogenation was also carried out by method E. This resulted in the product with the molecular weight of 316.45 (C18H28N4O); MS (ESI): 317 (M+H+).


(R)-N-[1-(4-Aminophenyl)pyrrolidin-3-yl]-2-dimethylamino-N-methylacetamide was obtained in an analogous manner using N,N-dimethylglycine.


N-[(R)-1-(4-Aminophenyl)pyrrolidin-3-yl]-N-(2-diethylaminoethyl)acetamide

N-(2-Diethylaminoethyl)-N-[(R)-1-(4-nitrophenyl)pyrrolidin-3-yl]acetamide was hydrogenated by method B. This resulted in the product with the molecular weight of 318.47 (C18H30N4O); MS (ESI): 319 (M+H+).


N-(2-Diethylaminoethyl)-N-[(R)-1-(4-nitrophenyl)pyrrolidin-3-yl]acetamide

Acetyl chloride (2.9 g) was dissolved in 50 ml of dry dichloromethane, mixed with 5.3 ml of triethylamine, and after addition of N,N-diethyl-N′-[(R)-1-(4-nitrophenyl)pyrrolidin-3-yl]-ethane-1,2-diamine (5.8 g), stirred at room temperature for 30 minutes. Subsequently, (LCMS check), water (10 ml) was added to the reaction, and the mixture was extracted with dichloromethane (2×10 ml). The combined organic phases were dried over magnesium sulfate, the solvent was removed, and the crude product was separated by chromatography on silica gel (dichloromethane/methanol 10:1). This resulted in the product with the molecular weight of 348.45 (C18H28N4O3); MS (ESI): 349 (M+H+).


N,N-Diethyl-N′-[(R)-1-(4-nitrophenyl)pyrrolidin-3-yl]ethane-1,2-diamine

tert-Butyl (2-diethylaminoethyl)-[(R)-1-(4-nitrophenyl)pyrrolidin-3-yl]carbamate (7.9 g) was reacted with trifluoroacetic acid by method G. This resulted in the product with the molecular weight of 306.41 (C16H26N4O2); MS (ESI): 307 (M+H+).


tert-Butyl (2-diethylaminoethyl)-[(R)-1-(4-nitrophenyl)pyrrolidin-3-yl]carbamate

tert-Butyl [(R)-1-(4-nitrophenyl)pyrrolidin-3-yl]carbamate (6.0 g) was dissolved in 50 ml of N,N-dimethylformamide and, after addition of sodium hydride (1.1 g), stirred at room temperature for 30 minutes, and subsequently chlorethyldiethylamine hydrochloride (4.1 g) was added. The mixture was subsequently stirred at room temperature with exclusion of moisture for 4 hours. The reaction was stopped by adding water (50 ml), and this was followed by extraction with ethyl acetate (3×50 ml) and drying of the combined organic phases over magnesium sulfate, and removal of the solvent. This resulted in the product with the molecular weight of 406.53 (C21H34N4O4); MS (ESI): 407 (M+H+).


Piperidine-4-carboxylic acid [4-(3-dimethylaminopyrrolidin-1-yl)phenyl]amide

Piperidine-1,4-dicarboxylic acid mono-tert-butyl ester was reacted with [1-(4-aminophenyl)pyrrolidin-3-yl]dimethylamine by method E, and the product was then treated by method G. This resulted in the product with the molecular weight of 316.45 (C18H28N4O); MS (ESI): 317 (M+H+).


Synthesis of Amines Required as Intermediates
Spiro[1,3-benzodioxol-2,1′-cyclopentane]-5-amine

A solution of spiro[5-nitro-1,3-benzodioxol-2,1′-cyclopentane] (8.8 g) in methanol (90 ml) was hydrogenated under 6 bar in the presence of palladium on carbon (10%, 0.1 g). After 30 minutes at room temperature, the mixture was filtered and concentrated. This resulted in the product with the molecular weight of 191.23 (C11H13NO2); MS(ESI): 192 (M+H+).


Spiro[5-nitro-1,3-benzodioxol-2,1′-cyclopentane]

A solution of spiro[1,3-benzodioxol-2,1′-cyclopentane] (8.5 g) in 20 ml of dichloromethane was added dropwise at 10° C. to 65% strength nitric acid (65 ml). After 2 hours at 5-10° C., the mixture was diluted with water, the organic phase was separated off, and the aqueous phase was extracted twice with dichloromethane. The combined organic phases were washed with water until neutral, dried over sodium sulfate, concentrated and crystallized from heptane. This resulted in the product with the molecular weight of 221.21 (C11H11NO4); MS(ESI): 222 (M+H+).


Spiro[1,3-benzodioxol-2,1′-cyclopentane]

Catechol (11 g) and cyclopentanone (9 ml) were heated under reflux in toluene (150 ml) with p-toluenesulfonic acid (0.18 g) with a water trap. After 18 hours, the mixture was concentrated and purified by chromatography (silica gel, heptane/ethyl acetate 4:1). This resulted in the product with the molecular weight of 176.22 (C11H12O2); MS(ESI): 177 (M+H+).


5-Chloro-2′,3′,5′,6′-tetrahydro-1′H-[2,4′]bipyridinyl-4′-ol

Butyllithium (15% in hexane; 7.6 ml) was added dropwise to a solution of 2-bromo-5-chloropyridine (2.0 g) in diethyl ether (50 ml) at −78° C. and, after one hour, a solution of N-tert-butoxycarbonyl-4-piperidinone (2.1 g) in diethyl ether (10 ml) was added dropwise. After 30 minutes, water was cautiously added, and the mixture was extracted with ethyl acetate. The organic phase was dried over sodium sulfate, filtered and concentrated. The residue was treated by method G. This resulted in the product with the molecular weight of 212.68 (C10H13ClN2O); MS(ESI): 213 (M+H+).


The following were obtained analogously:

  • 5-Fluoro-2′,3′,5′,6′-tetrahydro-1′H-[2,4′]bipyridinyl-4′-ol
  • 6-Chloro-2′,3′,5′,6′-tetrahydro-1′H-[3,4′]bipyridinyl-4′-ol.


6-Cyclopentyloxypyridin-3-ylamine

A mixture of 2-hydroxy-5-nitropyridine (1.4 g), cyclopentyl bromide (1.5 g) and potassium carbonate (3 g) was heated in DMF (20 ml) at 80° C. for 6 hours. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. The residue was purified by chromatography on silica gel (mobile phase ethyl acetate/heptane 1:2). The nitro compound obtained in this way was hydrogenated by method B. This resulted in the product with the molecular weight of 178.24 (C10H14N2O2); MS(ESI): 179 (M+H+).


6-(4-Fluorophenyl)-3-azabicyclo[4.1.0]heptane

Diethylzinc (1M in hexane, 19 ml) in dichloromethane (100 ml) was mixed with trifluoroacetic acid (3 ml) at 0° C. After 20 minutes, diiodomethane (3 ml) in dichloromethane (10 ml) was added. Then 4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine (3.0 g) in dichloromethane (10 ml) was added, and the mixture was stirred at room temperature overnight. After addition of hydrochloric acid (1N), the phases were separated and the organic phase was washed with water, dried over magnesium sulfate and concentrated. This resulted in the product with the molecular weight of 191.25 (C12H14FN); MS(ESI): 192 (M+H+).


Synthesis of Carboxylic Acids Required as Intermediates
4-(4-Methylpiperidin-1-yl)benzoic acid

4-(4-Methylpiperidin1-yl)benzonitrile (1.2 g) was heated to reflux with potassium hydroxide (0.7 g) in water (2 ml) and ethylene glycol (8 ml) for 3 hours. The mixture was diluted with water, washed with ethyl acetate and acidified with 2N hydrochloric acid. The precipitated product was filtered off with suction, dissolved in dichloromethane, dried over sodium sulfate, concentrated and crystallized from diethyl ether. This resulted in the product with the molecular weight of 219.29 (C13H17NO2); MS(ESI): 220 (M+H+).


4-(4-Methylpiperidin1-yl)benzonitrile

4-Fluorobenzonitrile (1.21 g) was heated with 4-methylpiperidine (1.00 g) at 180° C. for 1 hour. The mixture was then taken up in ethyl acetate, washed with water, 2N sodium hydroxide solution and saturated sodium bicarbonate solution, dried over sodium sulfate, concentrated and crystallized from n-pentane. This resulted in the product with the molecular weight of 200.29 (C13H16N2); MS(ESI): 201 (M+H+).


4-Butoxycyclohexanecarboxylic acid

Sodium hydride (2.78 g) was added to a solution of ethyl 4-hydroxycyclocarboxylate (10 g) and butyl iodide (10.6 g) in DMF while cooling in ice under argon. After 12 hours, the mixture was poured onto ice (200 g), extracted with ethyl acetate (100 ml) and then washed with water (3×50 ml). The organic phase was concentrated and mixed with ethanol (50 ml) and 5N sodium hydroxide (30 ml). The solution was heated at 60° C. for 4 hours. Cooling to room temperature was followed by adjustment to pH<2 with 2N hydrochloric acid, extraction with ethyl acetate (3×50 ml), drying with magnesium sulfate, filtration and concentration. This resulted in the product with the molecular weight of 200.28 (C11H20O3); MS (ESI): 201 (M+H+).


1-Benzyl-1H-[1,2,3]triazole-4-carboxylic acid

Methyl 1-benzyl-1H-[1,2,3]triazol-4-carboxylate (217 mg) was dissolved in 4 ml of methanol and hydrolyzed with 2 ml of 2N sodium hydroxide solution. After acidification with 4 ml of 2N hydrochloric acid, the resulting precipitate was filtered off, taken up in 5 ml of ethyl acetate and purified by preparative HPLC. This resulted in the product with the molecular weight of 203.2 (C10H9N3O2); MS (ESI): 204 (M+H+).


Methyl 1-benzyl-1H-[1,2,3]triazole-4-carboxylate

Benzyl azide (266 mg) was dissolved together with sodium ascorbate (20 mg) and copper sulfate (5 mg) in 8 ml of the solvent mixture (tert-butanol/water 3:1), and methyl propionate (336 mg) was added. The solution was stirred at room temperature for 2 hours. A white precipitate separated out and was filtered off with suction on a frit and subsequently dried. This resulted in the product with the molecular weight of 217.23 (C11H11N3O2); MS (ESI): 218 (M+H+).


1-Biphenyl-4-yl-1H-[1,2,3]triazole-4-carboxylic acid was prepared analogously from 4-Ethynylbiphenyl and ethyl azidoacetate.


1-Butyl-1H-indole-5-carboxylic acid

Sodium hydride (50% in oil, 1.4 g) was added to methyl 1H-indole-5-carboxylate (5.0 g) in DMF (100 ml) and, after gas evolution ceased, bromobutane (3.9 g) was added. After 12 hours, the reaction solution was diluted with ethyl acetate and washed three times with water. The organic phase was dried over magnesium sulfate and concentrated. The residue was purified by chromatography on silica gel (mobile phase ethyl acetate/heptane 1:6). The resulting ester was dissolved in methanol (10 ml) and boiled under reflux with sodium hydroxide (0.6 g ) in water (10 ml) for 12 hours. The mixture was diluted with water and acidified with hydrochloric acid, followed by extraction with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. This resulted in the product with the molecular weight of 217.27 (C13H15NO2); MS (ESI): 218 (M+H+).


3′-Acetylaminobiphenyl-4-carboxylic acid

3′-Aminobiphenyl-4-carboxylic acid (0.2 g) was mixed with pyridine (0.7 g) and acetic anhydride (180 mg) and, after 14 hours, volatile fractions were removed. The residue was taken up in sodium hydroxide solution (2N) and washed with diethyl ether. The aqueous phase was acidified with hydrochloric acid and extracted with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. This resulted in the product with the molecular weight of 255.28 (C15H13NO3); MS (ESI): 256 (M+H+).


3′-Isobutyrylaminobiphenyl-4-carboxylic acid

3′-Aminobiphenyl-4-carboxylic acid (0.2 g) was mixed in dichloromethane with potassium carbonate (121 mg) and isobutyryl chloride (94 mg). After 12 hours, the mixture was diluted with sodium hydroxide solution and washed with diethyl ether. The aqueous phase was acidified with hydrochloric acid and extracted with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. This resulted in the product with the molecular weight of 283.33 (C17H17NO3); MS (ESI): 284 (M+H+).


5-Butoxypyridine-2-carboxylic acid

Sodium hydride (50% in oil, 250 mg) was added to benzhydryl 5-hydroxypyridine-2-carboxylate (2.0 g) dissolved in DMF (20 ml) and, after gas evolution ceased, 1-bromobutane (0.72 g) was added. The mixture was heated at 90° C. for 6 hours. It was diluted with water and extracted with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. The residue was hydrogenated in analogy to method B. This resulted in the product with the molecular weight of 195.22 (C10H13NO3); MS (ESI): 196 (M+H+).


4-Methyl-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-6′-carboxylic acid

Benzhydryl 5-trifluoromethanesulfonyloxypyridine-2-carboxylate (3.0 g) was heated with 4-methylpiperidine (1.4 g) at 80° C. for one hour. The reaction mixture was immediately purified by preparative HPLC and then hydrogenated in analogy to method. This resulted in the product with the molecular weight of 220.27 (C12H16N2O2); MS (ESI): 221 (M+H+).


N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]terephthalamic acid

Method P-a


N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]terephthalamic acid methyl ester (1.7 g) dissolved in methanol (20 ml) was stirred with sodium hydroxide solution (2N, 15 ml) at room temperature for 24 hours. If conversion is incomplete, it is also possible to heat to reflux. The organic solvent was distilled off, and the mixture was acidified with hydrochloric acid. The precipitate which separated out was filtered off with suction and dried. This resulted in the product with the molecular weight of 353.42 (C20H23N3O3); MS (ESI): 354 (M+H+).


N-[4-(3-Dimethylaminopyrrolidin-1-yl)phenyl]terephthalamic acid methyl ester

[1-(4-Aminophenyl)pyrrolidin-3-yl]dimethylamine was reacted with terephthalic acid monomethyl ester by method E. This resulted in the product with the molecular weight of 367.45 (C21H25N3O3); MS (ESI): 368 (M+H+).


4-(Cyclopentanecarbonylmethylamino)benzoic acid

Methyl 4-methylaminobenzoate was reacted with cyclopentanecarboxylic acid by method E and then hydrolyzed by method P-a. This resulted in the product with the molecular weight of 247.30 (C14H17NO3); MS (ESI): 248 (M+H+).


The following compounds were obtained analogously:

  • 4-(Cyclopentanecarbonylamino)-3-methoxybenzoic acid
  • 2-Chloro-4-(cyclopentanecarbonylamino)benzoic acid
  • 2-Fluoro-4-(cyclopentanecarbonylamino)benzoic acid
  • 4-(Cyclopentanecarbonylamino)-3-methylbenzoic acid
  • 4-(Cyclopentanecarbonylamino)benzoic acid
  • 4-(Cyclopentanecarbonylamino)-3-trifluoromethoxybenzoic acid
  • 3-Chloro-4-(cyclopentanecarbonylamino)benzoic acid
  • 5-Chloro-4-(cyclopentanecarbonylamino)-2-methoxybenzoic acid
  • 4-[(Cyclohex-1-enecarbonyl)amino]benzoic acid
  • 4-[(Cyclopent-1-enecarbonyl)amino]benzoic acid


3-Fluoro-4-(1-methylbutoxy)benzoic Acid

A solution of 0.449 g of 1-[3-fluoro-4-(1-methylbutoxy)phenyl]ethanone in 6.8 ml of dioxane was dropped dropwise into 1.36 g of NaOH, 1.6 g of bromine in 6.8 ml of water. The mixture was stirred at room temperature for 30 minutes and then heated at 50° C. for 1 h. The excess bromide was decomposed by adding a sodium disulfite solution, and then the solution was poured into 25% strength hydrochloric acid solution and stirred for 20 minutes. The solution was extracted with ethyl acetate. The combined organic phases dried over sodium sulfate, concentrated in vacuo and purified by preparative HPLC. This resulted in the product with the molecular weight of 226.1 (C12H15FO3); MS (ESI): 227 (M+H+).


1-[3-Fluoro-4-(1-methylbutoxy)phenyl]ethanone

0.058 g of NaH was added to a solution of 0.176 g of 2-pentanol in 2 ml of DMF, and the solution was stirred at room temperature for 1 hour. Then 0.312 g of 3,4-difluoroacetophenone was added, and the mixture was stirred at room temperature overnight. The reaction solution was taken up in ethyl acetate and washed twice with water. The organic phase was dried over sodium sulfate and concentrated in vacuo. The resulting compound was reacted further without further purification.


The following compounds were obtained analogously:

  • 4-Cyclobutoxy-3-fluorobenzoic acid
  • 3-Fluoro-4-(2-methylcyclopropylmethoxy)benzoic acid
  • 4-(2-Cyclopropylethoxy)-3-fluorobenzoic acid
  • 3-Fluoro-4-(1-methylpiperidin-3-yloxy)benzoic acid
  • 4-(1-Acetylpiperidin-3-yloxy)-3-fluorobenzoic acid
  • 3-Fluoro-4-(1-methylpyrrolidin-3-yloxy)benzoic acid
  • 4-(1-Acetylpyrrolidin-3-yloxy)-3-fluorobenzoic acid
  • 3-Fluoro-4-(1-methylpiperidin-3-ylmethoxy)benzoic acid


4-(2,4-Difluorophenoxy)benzoic Acid

0.518 g of potassium hydroxide was added to a solution of 0.428 g of ethyl 4-(2,4-difluorophenoxy)benzoate in 2 ml of THF/water (1:1). The solution was heated at 110° C. for 6 hours. The THF was then removed in vacuo, and the aqueous phase was freeze dried and purified by preparative HPLC. This resulted in the product with the molecular weight of 250.04 (C13H8F2O3); MS (ESI): 251 (M+H+).


Ethyl 4-(2,4-difluorophenoxy)benzoate

0.018 g of NaH was added to a solution of 0.1 g of 2,4-difluorophenol in 0.5 ml of DMF. The reaction was stirred at room temperature for 45 minutes. Then 0.129 g of ethyl 4-fluorobenzoate in 0.5 ml of DMF was added dropwise. The reaction was heated at 110° C. overnight. After cooling concentrated in vacuo and the residue taken up in ethyl acetate/water. The ethyl acetate phase was washed three times with water, dried over sodium sulfate, concentrated in vacuo and purified by preparative HPLC. This resulted in the product with the molecular weight of 278.08 (C15H12F2O3); MS (ESI): 279 (M+H+)


4-(2,4-Difluorophenoxy)benzoic acid was reacted with [1-(4-aminophenyl)pyrrolidin-3-yl]-dimethylamine by method E-b. This resulted in the product with the molecular weight of 437.19 (C25H25F2N3O2); MS (ESI): 438 (M+H+) as hydrotrifluoroacetate.


4-Butoxy-3-methoxybenzoic acid

Methyl 4-hydroxy-3-methoxybenzoate was alkylated with bromobutane by method H and hydrolyzed by method P-a. This resulted in the product with the molecular weight of 224.26 (C12H16O4); MS (ESI): 225 (M+H+).


The following compounds were prepared analogously:

  • 4-Butoxy-3,5-dichlorobenzoic acid
  • 4-Butoxy-3-nitrobenzoic acid
  • 4-Butoxy-3-chlorobenzoic acid
  • 4-Butoxy-3,5-dimethylbenzoic acid
  • 4-Butoxy-2,3-dichloro-5-methoxybenzoic acid
  • 4-Butoxy-2,3,5,6-tetrafluorobenzoic acid
  • 4-Butoxy-3-fluorobenzoic acid
  • 3-Acetyl-4-butoxybenzoic acid
  • 2,4-Dibutoxybenzoic acid
  • 4-Butoxy-2-chlorobenzoic acid


4-Propoxymethylbenzoic Acid

Sodium hydride (50% in oil; 0.42 g) was cautiously added to a solution of propanol (0.6 g) in DMF (8 ml). After gas evolution ceased, methyl 4-bromomethylbenzoate (1.0 g) was added. After 4 hours, the mixture was partitioned between water and ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated. The residue was hydrolyzed by method P-a. This resulted in the product with the molecular weight of 194.23 (C11H14O3); MS (ESI): 195 (M+H+).


The following compounds were prepared analogously:

  • 4-Ethoxymethylbenzoic acid
  • 4-Butoxymethylbenzoic acid
  • 4-Isobutoxymethylbenzoic acid
  • 4-Phenoxymethylbenzoic acid
  • 4-(Pyridin-3-yloxymethyl)benzoic acid
  • 4-(Pyridin-2-yloxymethyl)benzoic acid
  • 4-Benzoimidazol-1-ylmethylbenzoic acid
  • 4-Indol-1-ylmethylbenzoic acid
  • 4-Phenylsulfanylmethylbenzoic acid
  • 4-(Pyrimidin-2-ylsulfanylmethyl)benzoic acid
  • 4-(Pyridin-2-ylsulfanylmethyl)benzoic acid
  • 4-(2-Cyanophenoxymethyl)benzoic acid
  • 4-(2-Chlorophenoxymethyl)benzoic acid
  • 4-Cyclobutoxymethylbenzoic acid
  • 4-Cyclopentyloxymethylbenzoic acid
  • 4-Cyclohexyloxymethylbenzoic acid
  • 4-sec-Butoxymethylbenzoic acid
  • 4-Pentoxymethylbenzoic acid


4-(3-Oxo-3a,4,5,6-tetrahydro-3H-cyclopentapyrazol-2-yl)benzoic acid

A solution of 4-hydrazinobenzoic acid (0.3 g), ethyl-2-oxocyclopentanecarboxylate (0.31 g) and p-toluenesulfonic acid (340 mg) in ethanol (12 ml) was boiled under reflux for 12 hours. The concentrated reaction solution was purified by preparative HPLC. The isolated reaction product (as ethyl ester) was hydrolyzed by method P-a. This resulted in the product with the molecular weight of 244.25 (C13H12N2O3); MS (ESI): 245 (M+H+).


4-Butoxy-2-methoxybenzoic acid

4-Hydroxy-2-methoxybenzaldehyde was alkylated with 1-bromobutane by method H. The resulting aldehyde (6.4 g) in dioxane (100 ml) was mixed with sodium dihydrogen phosphate (14.4 g) and sulfuric acid (2.4 ml), and the solution was cooled to 10° C. A solution of sodium chlorite (3.61 g) in water (100 ml) was added in such a way that the temperature did not exceed 10° C. 15 minutes after the addition was complete, sodium sulfite (4.6 g) was added. After a further 15 minutes, the pH was adjusted to 2 with hydrochloric acid and the dioxane was removed in a rotary evaporator. The aqueous phase was extracted with ethyl acetate. The organic phase was dried over magnesium sulfate, filtered and concentrated. The residue was purified by preparative HPLC. This resulted in the product with the molecular weight of 224.26 (C12H16O4); MS (ESI): 225 (M+H+). 4-Butoxy-5-chloro-2-methoxybenzoic acid was obtained as by-product.


4-(1-Propoxyethyl)benzoic acid

Methyl 4-(1-hydroxyethyl)benzoate (2.0 g) dissolved in DMF (30 ml) was mixed with propyl iodide (3.8 g), and then sodium hydride (50% in oil, 0.53 g) was added. After the end of the exothermic reaction, the mixture was stirred for 1 hour and then water was cautiously added. It was extracted with ethyl acetate, and the organic phase was dried over sodium sulfate, filtered and concentrated. The residue was hydrolyzed by method P-a. This resulted in the product with the molecular weight of 208.26 (C12H16O3); MS (ESI): 209 (M+H+).

Claims
  • 1. A compound of the formula I
  • 2. The compound of claim 1 of formula 1:
  • 3. The compound of claim 2 wherein R1, R2 are each independently H, (C1-C8)-alkyl, —(CH2)o—R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, CO—(C1-C8)-alkyl, —CO—(CH2)o—R12, COCH═CH(R13), COCC(R14), CO—(C1-C4)-alkyl-S(O)p—(C1-C4)-alkyl, CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))rCON(R21)(R22) or CO(C(R23)(R24))sO(R25); or R1 and R2, together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered mono-, bi- or spirocyclic ring which, apart from said nitrogen atom of attachment, optionally contains 1 or 2 additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, and is optionally substituted by F, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R26), CON(R27)(R28), hydroxy, COO(R29), N(R30)CO(C1-C6)-alkyl, N(R31)(R32) or SO2CH3;o 0, 1, 2, 3 or 4;p 0, 1 or 2;q, r, s are each independently 0, 1, 2 or 3;R13, R14 are each independently a 5-, 6-, 7-, 8-, 9- or 10 membered aromatic ring system optionally containing a further heteroatom selected from the group of nitrogen, oxygen and sulfur and optionally substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32 are each independently H or (C1-C6)-alkyl;R18 is H, (C1-C6)-alkyl, CO(C1-C6)-alkyl or CO(R33); or substituent pairs R17 and R18, R21 and R22, R27 and R28, and R31 and R32, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6 membered ring which, apart from said nitrogen atom of attachment, optionally contains one further heteroatom selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur;R33 is a 5-, 6-, 7-, 8-, 9- or 10 membered aromatic ring system which optionally contains a further heteroatom selected from the group of nitrogen, oxygen and sulfur and is optionally substituted by F, Cl, (C1-C6)-alkyl or O—(C1-C8)-alkyl;R12 is OH or a 3-, 4-, 5-, 6, 7-, 8-, 9-, 10-, 11- or 12 membered mono-, bi- or spirocyclic ring which optionally contains one or more heteroatoms from the group of N, O and S, and is optionally substituted by F, Cl, CF3, CN, oxo, O—(C1-C6)-alkyl, (C1-C6)-alkyl, O—(C0-C8)-alkylene-aryl, N(R34)(R35), COCH═CH(R36), (C(R37)(R38))t(R39), CO(C(R37)(R38))t(R39), CO(C1-C6)-alkyl, COCOO(C1-C6)-alkyl, COO(R40) or S(O)u(R41);t 0, 1, 2, 3 or 4;u 0, 1 or 2;R34, R35, R37, R38 are each independently H or (C1-C8)-alkyl; or R34 and R35, taken together with the nitrogen atom to which they are attached, optionally form a 5- or 6-membered ring which, apart from said nitrogen atom of attachment, optionally contains one further heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur, and is optionally substituted by 1 or 2 oxo groups;R36, R39 are each independently (C3-C8)-cycloalkyl or a 5-, 6-, 7-, 8-, 9- or 10-membered aromatic ring system wherein said aromatic ring system optionally contains a further heteroatom selected from the group of nitrogen, oxygen and sulfur, and is optionally substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;R40 is H, (C1-C8)-alkyl, (C2-C6)-alkenyl or (C0-C8)-alkylene-aryl;R41 is (C1-C6)-alkyl or a 5-, 6-, 7-, 8-, 9- or 10-membered aromatic ring system optionally containing one or two heteroatoms selected from the group of nitrogen, oxygen and sulfur, and optionally substituted by F, Cl, (C1-C6)-alkyl or O—(C1-C8)-alkyl;R3 is H or (C1-C6)-alkyl;R4, R5 are each independently H, (C1-C6)-alkyl, OH, O—(C1-C6)-alkyl or O—CO(C1-C6)-alkyl;R6, R7, R8, R9 are each independently H or (C1-C8)-alkyl; or substituent pairs R6 and R7, and R8 and R9, optionally form, independently of one another, an oxo group;n, m are each independently 0, 1 or 2;A, B, D, G are each independently N or C(R42);R42 is H, F, Cl, Br, CF3, CN, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, (C0-C2)-alkylene-aryl, O—(C0-C2)-alkylene-aryl, N(R43)(R44), SO2—CH3, COO—(C1-C6)-alkyl, CON(R45)(R46), N(R47)CO(R48), N(R49)SO2(R50) or CO(R51);R43, R44, R45, R46, R47, R49 are each independently H or (C1-C8)-alkyl; or substituent pairs R43 and R44, and R45 and R46, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5 or 6 membered ring which, apart from said nitrogen atom of attachment, optionally contains an additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur;R48, R50, R51 are each independently H, (C1-C8)-alkyl or aryl;R10 is H or (C1-C8)-alkyl;X is N(R52) or O;R52 is H or (C1-C8)-alkyl;E is a 3-, 4-, 5-, 6-, 7- or 8 membered bivalent carbo- or heterocyclic ring structure with 0, 1, 2, 3, or 4 heteroatoms from the group of N, O and S, and optionally substituted with H, F, Cl, CF3, NO2, OH, CN, O—(C1-C6)-alkyl, (C1-C6)-alkyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, N(R57)(R58), SO2—CH3, COO—(C1-C6)-alkyl, CON(R59)(R60), N(R61)CO(R62), N(R63)SO2(R64) or CO(R65), and wherein said bivalent carbo-or heterocyclic ring is mono- or bicyclic;R57, R58, R59, R60, R61, R63 are each independently H or (C1-C8)-alkyl; or substituent pairs R57 and R58, and R59 and R60, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5 or 6 membered ring which, apart from said nitrogen atom of attachment, optionally contains one further heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur;R62, R64, R65 are each independently H, (C1-C8)-alkyl or aryl;K is a bond, O, CH2O, N(R66), (C(R69)(R70))v or C≡C;v is 1 or 2;R66, R67, R68, R69, R70 are each independently H or (C1-C8)-alkyl;R11 is H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, a 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered mono-, bi- or spirocyclic ring, optionally containing 1, 2, 3 or 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, and optionally substituted by F, Cl, Br, CF3, NO2, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R71), CON(R72)(R73), hydroxy, COO(R74), N(R75)CO(C1-C6)-alkyl, N(R76)(R77) or SO2CH3;R71, R72, R73, R74, R75, R76, R77 are each independently H or (C1-C8)-alkyl; or substituent pairs R72 and R73, and R76 and R77, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5 or 6 membered ring which, apart from said nitrogen atom of attachment, optionally contain one additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur.
  • 4. The compound of claim 3, wherein A, B, D, G are each independently N or C(R42), and the total number of nitrogen atoms in said ring is 0-2.
  • 5. The compound of claim 4, wherein n is 1 andm is 1 or 2.
  • 6. The compound of claim 1 wherein R1, R2 are each independently H, (C1-C8)-alkyl, —(CR78R79)o-R12, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, CO—(C1-C8)-alkyl, —CO—(CH2)o—R12, CO-aryloxy-(C1-C4)-alkyl, COCH═CH(R13), COCC(R14), CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))rCON(R21)(R22), CO(C(R23)(R24))sO(R25); or R1 and R2, taken together with the nitrogen atom to which they are attached, optionally form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered mono-, bi- or spirocyclic ring which, apart from said nitrogen atom of attachment, optionally comprises one or two additional heteroatoms selected from the group of oxygen, nitrogen and sulfur, and is optionally substituted by F, Cl, CF3, (C1-C6)-alkyl, O—(C1-C4)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C2)-alkylene-aryl, oxo, CO(R26), CON(R27)(R28), hydroxy, COO(R29), N(R30)CO(C1-C6)-alkyl, N(R31)(R32) or SO2CH3;o is 0, 1, 2, 3, 4, 5 or 6;q, r are independently of one another 1, 2 or 3;s is 0, 1, 2, 3 or 4;R13, R14 are each independently an aryl ring optionally comprising one nitrogen atom;R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32 are each independently H or (C1-C6)-alkyl;R18 is H, (C1-C6)-alkyl, CO(C1-C6)-alkyl or CO(R33); or substituent pairs R17 and R18, R21 and R22, R27 and R28, R31 and R32,independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5 or 6 membered ring which, apart from said nitrogen atom of attachment, optionally contains 1 further heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur;R33 is a 5-, 6-, 7-, 8-, 9- or 10 membered aromatic ring system optionally comprising one additional heteroatom selected from the group of nitrogen, oxygen and sulfur and optionally substituted by F, Cl, (C1-C6)-alkyl or O—(C1-C8)-alkyl;R12 is OH, O—(C1-C6)-alkyl, O—(C0-C8)-alkylene-aryl, CN, S—(C1-C6)-alkyl, COO(R80), CON(R81)(R82), or a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10, 11- or 12 membered mono-, bi- or spirocyclic ring which optionally contains one or more heteroatoms from the group of N, O and S, and is optionally substituted by F, Cl, Br, OH, CF3, CN, oxo, O—(C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C1-C6)-alkyl, O—(C0-C8)-alkylene-aryl, (C0-C8)-alkylene-aryl, N(R34)(R35), COCH═CH(R36), (C(R37)(R38))t(R39), CO(C(R37)(R38))t(R39), CO(C1-C6)-alkyl, COCOO(C1-C6)-alkyl, COO(R40) or S(O)u(R41);t is 0, 1, 2, 3, 4, 5 or 6;u is 0, 1 or 2;R34, R35, R37, R38 are independently of one another H or (C1-C8)-alkyl; or substituent pair R34 and R35, taken together with the nitrogen atom to which they are attached, optionally form a 5 or 6 membered ring which, apart from said nitrogen atom of attachment, optionally contains one additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur, and is optionally substituted by 1 or 2 oxo groups;R36, R39 are each independently (C3-C8)-cycloalkyl or a 5-10 membered aromatic ring system which may comprise 0-2 further heteroatoms from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl or O—(C1-C8)-alkyl;R40 is H, (C1-C8)-alkyl, (C2-C6)-alkenyl or (C0-C8)-alkylene-aryl;R41 is (C1-C6)-alkyl or a 5-10 membered aromatic ring system which may comprise 0-2 further heteroatoms from the group of nitrogen, oxygen and sulfur and may be substituted by F, Cl, (C1-C6)-alkyl, O—(C1-C8)-alkyl;R78, R79 are independently of one another H, (C1-C8)-alkyl, hydroxy-(C1-C4)-alkyl, OH or (C1-C4)-alkoxy-(C1-C4)-alkyl;R80, R81 are independently of one another H or (C1-C8)-alkyl;R3 is H or (C1-C6)-alkyl;R4, R5 are independently of one another H, (C1-C6)-alkyl, OH, O—(C1-C6)-alkyl, O—CO(C1-C6)-alkyl or S—(C1-C6)-alkyl;R6, R7, R8, R9 is H; or substituent pairs R6 and R7, and R8 and R9, independently of one another, optionally form oxo;n is 1;m is 1 or 2;A, B, D, G are independently of one another N or C(R42); or the groups A and B or D and G are each C(R42) and together form an ortho-phenylene unit to result overall in a 1,4-bisubstituted naphthalene system;R42 is H, F, Cl, Br, CF3, CN, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, N(R43)(R44), SO2—CH3, CON(R45)(R46), N(R47)CO(R48), CO(R51) or —(CR84R85)x—O(R86);R43, R44, R45, R46, R47 are independently of one another H, (C1-C8)-alkyl; or substituent pairs R43 and R44, and R45 and R46, independently of one another, taken together with the nitrogen atom to which they are attached, optionally form a 5-6 membered ring which, apart from said nitrogen atom of attachment, optionally contain one additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur;R48, R50, R51 are each independently H, (C1-C8)-alkyl or aryl;R84, R85 are H;R86 is H or (C1-C6)-alkyl;x is 0, 1 or 2;R10 is H or (C1-C8)-alkyl;X is N(R52) or a bond;R52 is H or (C1-C8)-alkyl;E is a 3-8 membered bivalent carbo- or heterocyclic ring structure with 0-4 heteroatoms from the group of N, O and S, which may optionally have substituents from the group of H, F, Cl, Br, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, O—(C1-C4)-alkoxy-(C1-C4)-alkyl, S—(C1-C6)-alkyl, (C1-C6)-alkyl, (C2-C6)-alkenyl, O—(C3-C8)-cycloalkyl, (C3-C8)-cycloalkenyl, (C2-C6)-alkynyl, (C0-C8)-alkylene-aryl, O—(C0-C8)-alkylene-aryl, S-aryl, N(R57)(R58), SO2—CH3, N(R61)CO(R62), N(R63)SO2(R64) or CO(R65) and wherein said carbo- or heterocyclic ring structure may be mono- or bicyclic;R57, R58, R61, R63 are each independently H or (C1-C8)-alkyl;R62, R64, R65 are each independently H, (C1-C8)-alkyl or aryl;K is a bond, O, OCH2, CH2O, S, SO, SO2, N(R66), N(R67)CO, CON(R68), (C(R69)(R70))v, CO, C═C, C≡C, SCH2 or SO2CH2;v is 1, 2, 3 or 4;R66, R67, R68, R69, R70 are independently of one another H or (C1-C8)-alkyl;R11 is H, (C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C8)-alkenyl, (C3-C8)-alkynyl, a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may comprise 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, where the ring system may additionally be substituted by F, Cl, Br, CF3, CN, (C1-C6)-alkyl, O—(C1-C8)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl, (C0-C8)-alkylene-aryl, oxo, CO(R71), CON(R72)(R73), hydroxy, COO(R74), N(R75)CO(C1-C6)-alkyl, N(R76)(R77) or SO2CH3;R71, R72, R73, R74, R75, R76, R77 are independently of one another H or (C1-C8)-alkyl; or substituent pairs R72 and R73, and R76 and R77, independently of one another and taken together with the nitrogen atom to which they are attached, optionally form a 5-6 membered ring which, apart from said nitrogen atom of attachment, optionally contains an additional heteroatom component selected from the group of N—(C1-C6)-alkyl, oxygen and sulfur; or
  • 7. The compound of claim 6 having the formula Ia
  • 8. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
  • 9. The pharmaceutical composition of claim 8 further comprising one or more anorectic active ingredients.
  • 10. A method of treating obesity comprising administering to a patient in need thereof a compound of claim 1.
  • 11. A method of treating obesity comprising administering to a patient in need thereof a compound of claim 1 in combination with at least one further anorectic active ingredient.
  • 12. A method of treating type II diabetes comprising administering to a patient in need thereof a compound of claim 1.
  • 13. A method of treating type II diabetes comprising administering to a patient in need thereof a compound of claim 1 in combination with at least one further anorectic active ingredient.
  • 14. A method of reducing weight in mammals comprising administering to a patient in need thereof a compound of claim 1.
Priority Claims (1)
Number Date Country Kind
103 06 250 Feb 2003 DE national
Parent Case Info

This application claims priority from Provisional Application 60/488,545 filed Jul. 18, 2003.

Foreign Referenced Citations (16)
Number Date Country
1176140 Jan 2002 EP
WO 9613502 May 1996 WO
WO 9924406 May 1999 WO
WO 0035454 Jun 2000 WO
WO 0061569 Oct 2000 WO
WO 0071529 Nov 2000 WO
WO 0206232 Jan 2002 WO
WO 0206278 Jan 2002 WO
WO 0210146 Feb 2002 WO
WO 0220501 Mar 2002 WO
WO 0242271 May 2002 WO
WO 02098839 Dec 2002 WO
WO 02098871 Dec 2002 WO
WO 02099388 Dec 2002 WO
WO 03091256 Nov 2003 WO
WO 2004002948 Jan 2004 WO
Related Publications (1)
Number Date Country
20040220191 A1 Nov 2004 US
Provisional Applications (1)
Number Date Country
60488545 Jul 2003 US